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Abstract 
 
 
Background 
Fluorescent laparoscopic imaging of primary colorectal tumours and lymph node 
metastases would improve localisation of early tumours and allow intra-operative 
staging, potentially facilitating intra-operative stratification of the extent of surgical 
resections thereby improving patient outcomes. I aimed to develop and test a 
fluorescent molecular probe capable of allowing localisation of tumours in vivo. 
 
Methods 
Immunohistochemistry was used to identify the most appropriate colorectal cancer 
target from a panel of seven biomarkers in prospectively collected, matched normal 
and tumour tissue from 280 colorectal cancer patients. The availability of targets for 
antibody binding was assessed in live cells, fresh frozen tumour samples and ex vivo 
cancer specimens. Indocyanine green was conjugated to anti-CEA and control IgG 
antibodies, and CEA-specific fluorescence was quantified in live cancer cells. Dye-
doped silica nanoparticles loaded with NIR664 dye were synthesised using a water-
in-oil microemulsion technique. Anti-CEA IgGs or control IgGs were conjugated to 
nanoparticles using a variety of different chemical conjugation strategies and binding 
to cells was quantified in vitro. A murine xenograft model and live IVIS imaging were 
used to assess PAMAM-linked nanoparticles in vivo. 
 
Results 
Of the biomarkers tested, CEA showed the greatest differential expression between 
normal and tumour samples (p<0.001) and the best sensitivity (93.7%) and specificity 
(96.1%) for colorectal cancer detection. ICG-anti-CEA exhibited CEA-specific 
fluorescence in all three cell lines tested (p<0.01) with fluorescence peaking at 24-36 
 6 
hours. CEA-targeted, PAMAM dendrimer-conjugated nanoparticles allowed strong 
tumour-specific targeting, demonstrating up to 12.3-fold greater fluorescence than 
control nanoparticles when incubated with colorectal cancer cell lines (p<0.002). In 
LS174T xenografts, CEA-targeted nanoparticles demonstrated clear tumour-specific 
fluorescence from 6 to 72h after injection, as compared to only background 
fluorescence for control IgG-targeted nanoparticles at all time points (p<0.0001). 
 
Conclusions 
CEA has the greatest potential to allow highly specific tumour imaging. ICG-
conjugated anti-CEA antibodies allow CEA-specific imaging of colorectal cancer cells 
in vitro. Dye-doped silica nanoparticles conjugated to anti-CEA antibodies via 
PAMAM dendrimers have potential to allow intra-operative fluorescent visualisation 
of tumour cells. These findings are the first to demonstrate live tumour-specific 
fluorescent colorectal cancer imaging using an antibody-targeted nanoparticle in vivo. 
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Chapter One 
 
Introduction 
 
 
 
 
 
Some parts of the text in this chapter have been published in the manuscript “Intra-
operative tumour detection and staging in colorectal cancer surgery” (Colorectal 
Disease 2012;14(9):e510-20) and reproduced here with permission. 
  
 20 
1 INTRODUCTION 
 
My project has focussed on developing an intra-operative, fluorescent imaging 
system for laparoscopic colorectal cancer surgery. Here, I describe the various 
clinical factors that such a system would address and current, relevant in vivo tumour 
targeting technologies. I then describe the three principle components of my 
proposed solution: tumour-specific localisation, fluorescent visualisation and 
nanoparticle linkage. 
 
1.1 The clinical problem 
 
Colorectal cancer (CRC) is the fourth most common cancer in the UK, accounting for 
13% of all new cancer cases. In 2010 there were 22834 new cases diagnosed in 
men (56%) and 17861 in women (CRUK, 2010). Although five year survival from 
colorectal cancer has doubled in the last 30 years, from 25% for those diagnosed in 
1971-75 to over 50% for those diagnosed in 2001-06 (Office for National Statistics, 
2010), overall incidence rates have been increasing since the mid-1970s (CRUK, 
2010). The mainstay of treatment is surgical resection, although this is aided by neo-
adjuvant and adjuvant therapies, which can improve disease-free survival, 
downstage tumours and render initially unresectable tumours resectable. Surgical 
resection is a one-size-fits-all approach, with the tumour, the supplying blood vessels 
and the draining lymphatics resected in an en bloc fashion. 
 
A number of different clinical factors, some long-standing and others due to more 
recent developments have highlighted the limitations of current treatment paradigms 
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and the potential benefit of intra-operative tumour detection. Factors are listed here, 
with further detailed discussion below.  
 Current limitations in pre-operative staging; 
 The widespread use of laparoscopic resection; 
 The effect of the National Bowel Cancer Screening Programme on case mix; 
 Evidence that more radical resections improve survival; 
 The under-staging of stage II tumours. 
 
1.1.1 Current limitations in pre-operative staging 
There are explicit guidelines that dictate a common patient pathway from diagnosis of 
a colorectal cancer through to various treatment modalities depending on the 
patient’s physiological reserve, the anatomical location of the tumour and the stage of 
their disease (ACPGBI, 2007). Colorectal cancer has been shown to metastasise 
via the portal venous and lymphatic systems (Jamieson and Dobson, 1909). The 
large Wessex (George et al., 2006) and Trent/Wales (Mella et al., 1997) audits of the 
1990s and early 2000s showed that over 20% of patients have distant metastases at 
initial presentation. Patients therefore undergo detailed pre-operative staging to 
assess tumour extent, location, and both local and distant metastases. The 
Association of Coloprocotologists of Great Britain and Ireland dictate that, ideally, all 
patients undergo a colonoscopy with tissue taken for histology, a staging thoracic 
and abdominal computed tomography (CT) scan, and in the case of rectal tumours a 
magnetic resonance imaging (MRI) scan with endoanal ultrasound if necessary 
(ACPGBI, 2007). In patients with distant metastases (most commonly hepatic or 
thoracic), the appropriateness and timing of surgery for the primary and secondary 
tumours must be decided, and additionally whether neo-adjuvant chemotherapy is 
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required. If the mestastases are resectable, surgery is planned to resect both the 
primary and the secondary tumours and chemotherapy is indicated due to the 
presence of metastases. For resectable metastases, a ‘staged approach’ has 
traditionally been used, with initial resection of the primary, followed by 
chemotherapy and then by hepatectomy or pulmonectomy (de Haas et al., 2010, 
Feng et al., 2014), on the basis that locoregional control is the priority. For hepatic 
metastases, there has been a recent trend towards simultaneous resection of both 
the primary and secondary tumours during the same procedure, particularly with 
advances in peri- and post-operative care, and minimally invasive techniques (Adam 
et al., 2004, Siriwardena et al., 2014). In the case of rectal tumours, neo-adjuvant 
radiotherapy with or without chemotherapy is indicated where there is local lymph 
node metastasis or the circumferential resection margin is threatened. 
 
It is clear that the accuracy of the information gathered from histopathological 
examination and radiological investigations has a huge bearing on the treatment 
pathway and chance of recurrence. Despite this extensive pre-operative work-up, 
small metastases are often missed; a meta-analysis showed CT to have a sensitivity 
of 70% (95% confidence interval: 65-73%) and specificity of 78% (95% confidence 
interval: 73-82%) in detecting nodal disease in colonic cancer (Dighe et al., 2010) 
whilst MRI has a sensitivity of 66-85% and specificity of 41-97% in nodal staging for 
rectal cancer (Kim et al., 2000, Bipat et al., 2004, Brown et al., 2003). Positron 
emission tomography (PET) scanning combined with CT colonography has been 
shown to be significantly more accurate in detecting lymph node metastases than CT 
alone (Veit-Haibach et al., 2006, Sun et al., 2008), but is still not sensitive enough to 
detect micro-metastases (tumour deposits of 0.2 to 2mm (Hermanek et al., 1999)). 
Potentially, intra-operative tumour visulaisation would allow more accurate tumour 
staging by sensitive detection of lymph node deposits. 
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1.1.2 Laparoscopic surgery and the National Bowel Cancer 
Screening Programme 
 
Lapraroscopic or ‘keyhole’ resection for CRC has slowly gained popularity in the UK 
since its introduction in 1991 (Jacobs et al., 1991, Taylor et al., 2013) and short-term 
advantages have been demonstrated. This minimally invasive approach results in 
several small scars instead of the traditional midline laparotomy wound that is 
associated with post-operative pain and compromises respiratory function (Schwenk 
et al., 1999). As a result, randomised controlled trials have demonstrated a shorter 
hospital stay, earlier mobilisation and quicker functional recovery (Stead et al., 2000, 
van der Pas et al., 2013, COLOR Study Group, 2005, Weeks et al., 2002, Guillou et 
al., 2005, Abraham et al., 2004) following laparoscopic resection, without 
compromising oncological clearance. One important disadvantage is the loss of 
haptic feedback that is present at open surgery: the surgeon’s fingertips are an 
important and sensitive tool used to locate primary tumour margins, metastatic 
deposits and both embryological and oncological resection planes. Early tumours 
tend to be small and can be impossible to locate accurately with laparoscopic 
instruments. Colonic tattooing, where a tumour is injected with a permanent dye at 
endoscopy prior to surgery, is often used to help locate small tumours. This then 
appears as an ink stain on the colonic wall but the technique can be variable and 
unreliable (Conaghan et al., 2010). 
 
This problem has been compounded by an increasing proportion of tumours detected 
early in their natural history by the National Bowel Cancer Screening Programme 
(NBCSP), introduced in 2006. The incidence of Dukes A tumours (confined to the 
mucosa (Dukes, 1932)) in the NBCSP is 32% (Logan et al., 2011) compared to 8.7% 
in symptomatic patients (National Cancer Intelligence Network (NCIN), 2009). This 
 24 
shift towards earlier disease means that surgeons will be required to resect a higher 
proportion of small tumours that are difficult to locate intra-operatively. A sensitive 
intra-operative tumour visualisation system would allow small tumours to be located 
with ease and aid laparoscopic resection. It could also be used to exclude lymph 
node metastasis in patients who might otherwise be suitable for endoscopic resection 
of a tumour. 
 
1.1.3 Radical resections 
1.1.3.1 Current practice and rationale 
When resecting a colorectal tumour, the aim is to remove the tumour with clear 
margins and remove the surrounding lymph nodes that drain it ((Jamieson and 
Dobson, 1909)). The intra-abdominal lymph nodes lie in close proximity to the blood 
vessels that supply the colorectum; the typical lymphovascular route of colorectal 
cancer metastasis requires that the entire anatomical territory of the artery supplying 
the tumour is resected en bloc along with the tumour. The exact location of the 
tumour therefore dictates the operation. 
1.1.3.2 Complete mesocolic resection and central vascular ligation. 
There is emerging evidence that survival outcomes following colon cancer surgery 
might be improved by increasing the radicality of lymphadenectomy and meticulously 
adhering to oncological planes of resection. The technique of complete mesocolic 
excision with extended lymphadenectomy (central vascular ligation), as described by 
Hohenberger (Hohenberger et al., 2009), has reported local recurrence rates of 3.6% 
and 5-year disease free survival of 89.1%. This has been attributed to the removal of 
more tissue and lymph nodes in the correct surgical planes. These figures compare 
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favourably to local recurrence rates of 8-10% reported elsewhere (Jayne et al., 
2010). Further, West et al showed a survival advantage from mesocolic plane 
surgery in patients with lymph node involvement (West et al., 2008), an observation 
that has been corroborated in the Medical Research Council (MRC) CLASICC trial 
that compared laparoscopic to open resection. There is, however, a reluctance to 
adopt this approach for all patients due to a lack of robust survival data, with papers 
focussing on pathological specimen quality only (West et al., 2010, Bertelsen et al., 
2011). A study of 914 patients undergoing potentially curative surgery for T2-T4 
colonic tumours by Hashiguchi et al (Hashiguchi et al., 2011) found no staging 
benefit and minimal survival benefit in removing nodes greater than five centimetres 
from the tumour. 
 
It could therefore be argued that as only some 30% of colorectal cancers have 
evidence of nodal disease (CRUK, 2007), subjecting all patients to a radical 
segmental resection is over-treatment for the majority (Cahill et al., 2009). Whether 
this translates into unnecessary morbidity is a point of debate; experience would 
suggest that the close dissection of the delicate structures around the root of the 
mesentery, the increase in length of colon mobilised and excised, and an increase in 
operative time all add up to a longer and potentially more problematic peri-operative 
period. Hohenberger reported no difference in complication rates pre- and post- 
introduction of the complete mesocolic resection and central vascular ligation 
technique, but there are a number of potentially confounding issues such as the 
experience of the surgeon and the ancillary staff, a 24 year study period, and the 
limitations of extrapolating results from a single institution experience (Hogan and 
Winter, 2009). If patients with lymph node metastases could be identified accurately 
either pre- or intra-operatively, those most likely to benefit from a more radical 
resection could be selected. 
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This ‘personalised’ approach, where the operation is tailored to the individual biology 
of the tumour, offers a number of advantages. The aim is to ensure that an adequate 
oncological resection is performed whilst minimising the impact of surgical trauma on 
postoperative function. It is probably best exemplified in rectal cancer where the 
benefits of transanal endoscopic microsurgery (TEMS), with or without radiotherapy, 
for early stage disease (T1-2, N0) are beginning to be recognised, particularly in 
terms of organ preservation, restoration of normal bowel function and quality of life 
(Doornebosch et al., 2007, Doornebosch et al., 2008, Suppiah et al., 2008). The 
concept of tailored cancer surgery also fits comfortably with recent developments in 
minimally invasive surgery, including single incision laparoscopic surgery (SILS) and 
natural orifice transluminal endoscopic surgery (NOTES) (Cahill, 2010). These 
techniques aim to facilitate patient recovery by minimising surgical access trauma, 
and if they can be combined with a reduction in surgical site trauma then the 
outcomes might be appreciably better.  
 
1.1.4 Under-staging of stage II tumours 
Following surgical resection and post-operative histopathological examination of the 
specimen, patients diagnosed as having stage II disease (no evidence of lymph node 
metastasis, Table 1.1) and no evidence of ‘high risk’ features (lymphovascular 
invasion, poor differentiation) are considered to have had a curative resection and 
adjuvant chemotherapy is not offered, on the grounds that no benefit has been 
shown (Andre et al., 2009). However, some 25% of stage II patients subsequently 
develop metastatic disease (Chen and Bilchik, 2006, Weitz et al., 2005), implying that 
a proportion of these patients might have had occult lymph node metastases that 
were not detected during routine histopathological examination. 
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Stage T N M Dukes 
0 Tis N0 M0 - 
I T1 N0 M0 
A 
T2 N0 M0 
II T3 N0 M0 
B 
T4 N0 M0 
III Any T N1 M0 
C  Any T N2 M0 
IV Any T Any N M1 
     
     
Definitions 
Primary tumour (T) 
TX Primary tumour cannot be assessed 
T0 No evidence of primary 
Tis Carcinoma in-situ or invasion of lamina propria 
T1 Invades submucosa 
T2 Invades muscularis propria 
T3 Invades through muscularis propria 
T4 Tumour directly invades other organs or structures, and/or 
perforates visceral peritoneum (including colorectum) 
Regional lymph nodes (N) 
NX Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastsis 
N1 Metastasis in 1-3 regional nodes 
N2 Metastasis in ≥4 regional nodes 
Distant metastases (M) 
MX Distant metastasis cannot be assessed 
M0 No distant metastasis 
M1 Distant metastasis 
 
Table 1.1. Colon and rectum cancer staging (American Joint Committee on 
Cancer 5th Edition). 
 
1.1.4.1 The clinical significance of micrometastases 
There has been significant debate over the last two decades about whether 
histologically detected ‘micro-metastases’ (lymph node deposits 0.2 – 2 mm (AJCC, 
2002)) actually impact overall survival. A meta-analysis by Iddings et al (Iddings et 
al., 2006) reported no difference in 3-year survival when step-sectioning and 
immunohistochemistry were performed to identify micrometastases, but when 
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reverse-transcription polymerase chain reaction (RT-PCR) was used the presence of 
micro-metastases was associated with a significantly worse outcome. Bilchik et al 
(Bilchik et al., 2007) published their interim results of a prospective, multi-centre trial 
that suggested a possible survival benefit in patients with no micro-metastases in the 
sentinel lymph node. However a detailed meta-analysis by Rahbari et al (Rahbari et 
al., 2012) has shown them to be clinically significant, suggesting these patients would 
benefit from adjuvant therapy if they could be identified. 
 
This has led some to argue that histological ‘ultra-staging’, where each lymph node is 
evaluated using a combination of exhaustive step-sectioning, immunohistochemical 
staining for cytokeratins and/or polymerase chain reaction (Bilchik et al., 2002, 
Bembenek et al., 2005), would lead to higher rates of micrometastasis detection. This 
would mean a proportion of stage II patients would be ‘up-staged’ to stage III and 
therefore benefit from adjuvant chemotherapy (Bilchik et al., 2010). Currently only 
nodes that are positive either on macroscopic examination or on single section 
examination undergo further examination; ultra-staging every node would have 
significant cost and time implications (Wiese et al., 2010) that, in a resource-limited 
healthcare system such as the NHS, are difficult to justify. Sentinel lymph node 
mapping, which targets those nodes most likely to contain metastases, has been 
proposed as a compromise (discussed in section 1.2.4). 
 
  
 29 
1.2 In vivo colorectal cancer detection: current 
technologies 
 
1.2.1 Radioimmunoguided surgery 
Radioimmunoguided surgery (RIGS) is an intra-operative tumour detection system 
pioneered in the 1990s that is effectively a precursor to this project. This system has 
three components: an antibody to an antigen expressed by the tumour in question; a 
radionuclide that can be used to radiolabel the antibody; and a hand-held gamma 
detector that can be used intra-operatively to detect the antibody/radionuclide 
complex bound to the tumour cells. It was first described by Aitken et al in 1984 
(Aitken et al., 1984). This initial report has been followed by 29 clinical trials for 
colorectal cancer, using either carcinoembryonic antigen (CEA) or tumour-associated 
glycoprotein 72 (TAG-72) as the target antigen. Overall the sensitivity of RIGS in 
detecting colorectal cancer ranged from 20% (Hamy et al., 1995) to 100% (Kim et al., 
2005) for primary disease and 63% (Cohen et al., 1991) to 97% (Arnold et al., 1992) 
for recurrent disease, although in the vast majority it was over 75% and tended to be 
higher in cases of recurrence. There have been no systematic reviews or meta-
analyses due to significant heterogeneity between studies. 
 
Despite showing promise in both detection and an ability to improve outcomes (Sun 
et al., 2007), the difficulties in handling and disposing of radiolabelled material 
combined with ever-improving imaging modalities for pre-operative staging and 
management planning have meant that RIGS has become relatively redundant in the 
last decade. 
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1.2.2 Radioimmunotherapy and targeted chemotherapy 
Radioimmunotherapy uses antibodies to cancer-specific antigens to deliver cytotoxic 
radiation directly to tumour cells and minimise collateral damage to normal cells 
(Meyer et al., 2009, Meredith et al., 1996, de Jong et al., 2011). The majority of work 
has targeted CEA or TAG-72 and it has shown to be effective in small-volume 
disease (Koppe et al., 2005, Barbet et al., 2012) but has only had limited translational 
success. Similarly, targeted cytotoxic drug delivery has the potential to deliver high 
dose chemotherapy to cancer cells whilst limiting damage to normal cells, and has 
utilised a variety of biomarkers, including FRα (Zhang et al., 2012, Elias et al., 2011), 
EGFR (Kopansky et al., 2011) and CEA (Conaghan et al., 2008). 
 
1.2.3 Targeted non-invasive imaging 
Pre- and post-operative imaging is essential in the planning and follow-up of 
colorectal cancer patients. Recently Iodine-124-labelled antibodies to CEA have 
been administered to patients systemically and detected using positron emission 
tomography (PET) scanning (Carrasquillo et al., 2011, Schoffelen et al., 2012, 
O'Donoghue et al., 2011, Meller et al., 2011, Schoffelen et al., 2010, Boerman and 
Oyen, 2011); a high target-to-background ratio has the potential to add specificity 
when evaluating undetermined masses, a common clinical scenario during the 
follow-up of colorectal cancer patients. Other experimental work has used antibodies 
to CEA or EGFR to deliver MRI contrast agents to cancer-specific antigens 
(Cherukuri and Curley, 2010, Kamphuis et al., 2010, Vigor et al., 2010) to improve 
sensitivity and specificity. 
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1.2.4 Sentinel lymph node mapping 
In colorectal cancer surgery, sentinel lymph node mapping (using a dye injected 
subserosally around the tumour) can be used to allow focussed ultra-staging of one 
or more nodes most likely to contain metastases. It is used routinely in the 
management of breast cancer (Association of Breast Surgery at BASO, 2009) and 
melanoma (Marsden et al., 2010) and relies on the assumption that if a sentinel 
lymph node is tumour free, then there will be no lymphatic metastases in any 
remaining nodes (Bembenek et al., 2005, Wiese et al., 2010). This provides a 
practical means for avoiding the resource implications of ultra-staging every resected 
lymph node. Since its introduction in 1999 (Joosten et al., 1999), hundreds of studies 
have been published, including a number of systematic reviews and meta-analyses 
(Mulsow et al., 2003, Bembenek et al., 2008, Des Guetz et al., 2007, van der Pas et 
al., 2011). These have highlighted various limitations, including false negatives, 
variable sensitivity in detecting the sentinel node, technical difficulties (particularly 
with rectal tumours) and aberrant drainage patterns. However, in the most recent and 
in-depth meta-analysis, Van der Pas et al (van der Pas et al., 2011) suggest that a 
sentinel lymph node procedure should be considered in all colon cancer patients 
without clinical evidence of lymph node metastases. 
 
Although this is basically a method for intra-operatively delineating normal anatomy 
rather than tumour-specific detection, when combined with pathological ultra-staging 
it has the potential to alter post-operative management and has attracted further 
technological development. These developments have led to the emphasis of 
sentinel lymph node mapping shifting from a post-operative staging tool to a potential 
role in selective lymphadenectomy, by combining it with more cutting edge 
technologies such as near-infrared laparoscopy, optical coherence tomography or 
real time elastography. 
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1.2.4.1 Near-infrared laparoscopy 
Indocyanine green (ICG) is a photosensitive tricarbocyanine dye with a peak spectral 
absorbance at approximately 780 nm (Landsman et al., 1976, Haritoglou et al., 
2003), in the near-infrared region. Several feasibility studies have used indocyanine 
green as a substitute for patent blue V dye in sentinel lymph node mapping in 
colorectal cancer (Nagata et al., 2006, Kusano et al., 2008, Hutteman et al., 2011, 
Cahill et al., 2012). It can be injected subserosally (either lumenally via a 
colonoscope or laparoscopically) and a modified laparoscope used to detect the 
fluorescent signal. Compared to conventional blue dye mapping, it penetrates more 
deeply through living tissue and does not distort the view of the surgical field. The 
technique is not tumour-specific, but if combined with intra-operative, morphological 
sentinel node assessment, it has the potential to allow intra-operative staging and 
surgical stratification. 
 
Cahill et al recently combined the technique with intra-operative ultrasound 
assessment of the sentinel node in patients with early-stage cancer (Cahill et al., 
2012). The sensitivity of a 12 MHz probe is currently not high enough to detect micro-
metastases but it is foreseeable that the resolution will increase with further 
development of high frequency ultrasound. Optical coherence tomography and 
elastography (see sections 1.2.4.2 and 1.2.4.3) may offer a better chance of 
accurately assessing the sentinel node for small deposits and micrometastases via a 
‘virtual biopsy’. 
 
1.2.4.2 Optical coherence tomography 
Optical coherence tomography (OCT) works in a similar way to conventional 
ultrasound but uses light instead of sound waves (Huang et al., 1991, Osiac et al., 
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2011). Near-infrared light is used to penetrate a ‘scattering media’ (in this case 
human tissue) and back-scattering is detected to construct a three-dimensional, 
cross-sectional image. The properties of certain biological tissues enable OCT to act 
as a real-time, high resolution, microscopic imaging technique (Boppart et al., 1998, 
Boppart et al., 1999, Boppart et al., 2004). OCT has been used in a variety of clinical 
applications, including ophthalmology, evaluating coronary artery disease and, of 
note here, lymph node imaging (Zysk et al., 2007). When compared to conventional 
histopathology there is a strong correlation between images of lymph nodes 
(McLaughlin et al., 2010) but penetration tends to be limited to a few millimetres. The 
technique has since been applied to colorectal cancer surgery (Cahill et al., 2010) by 
passing a fibred OCT probe down the working channel of an endoscope in order to 
perform a real-time, in vivo, ‘virtual biopsy’ of peritoneal lymph nodes via a 
transgastric NOTES approach in a porcine model. OCT therefore has the potential to 
provide an intra-operative, real-time assessment of a sentinel node following near-
infrared laparoscopic mapping. 
 
1.2.4.3 Real-time elastography 
Real time elastography is a method of assessing the elasticity of tissues and exploits 
the fact that most tumours are harder or stiffer than surrounding normal tissue. When 
an external compression force is applied to the tissue, high frequency ultrasound is 
used to measure the strain in the tissue and construct elastography images. It was 
used initially to image breast (Itoh et al., 2006), thyroid (Lyshchik et al., 2005) and 
prostate tumours (Konig et al., 2005). Development of intra-operative staging 
applications is at an early stage with work focussing on liver and pancreatic tumours 
(Kato et al., 2008, Inoue et al., 2010, Elias et al., 2011) but it has also been applied to 
the detection of malignant lymph node deposits (Săftoiu et al., 2007, McCormack et 
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al., 2009). This is another technology that could be combined with sentinel lymph 
node mapping to provide a real-time virtual biopsy of the sentinel node. 
 
Intra-operative sentinel lymph node mapping with real-time virtual biopsy retains the 
limitations of conventional lymph node mapping. The assessed stage of a colorectal 
tumour would be entirely dependent on the assumption that the sentinel node is 
reflective of the true nodal status. Tan et al (Tan et al., 2010b) conducted a study to 
determine the distribution of the first metastatic lymph node in colorectal cancer by 
examining the mesentery of 93 patients who had only one involved lymph node found 
on histology. This node was not located directly below the tumour in 48% of cases 
and was found to have skipped the pericolic nodes or to be 5 cm beyond the 
longitudinal tumour margin in 18% of cases. Similarly, Park et al (Park et al., 2009) 
reported that in 6% of caecal cancers, metastasis occurred to lymph nodes along the 
right branch of the middle colic artery rather than the expected location of the sentinel 
node alongside the ileocolic artery. This suggests that however accurate the in vivo 
biopsy technology is at assessing the sentinel node, the results may not reflect the 
true disease stage. 
 
1.3 A potential solution: intra-operative fluorescent 
imaging 
 
My proposed solution to the limitations of current treatment paradigms is a tumour-
specific fluorescent probe, capable of binding to colorectal cancer tissue at a 
molecular level, which could be administered to a patient prior to undergoing 
laparoscopic surgery. A modified laparoscopic system could then be used to identify 
the fluorescent probe bound to cancer cells, enabling delineation of the primary 
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tumour margins and detection of metastatic disease. This would then allow an intra-
operative assessment of the stage of the tumour and the appropriate resection to 
take place. Such an application requires at least two components: a tumour-specific 
localisation component and a fluorescent visualisation component. A third component 
- a scaffold to chemically attach and arrange the two - could be used to optimise the 
fluorescent signal. 
 
1.3.1 Tumour-specific localisation component 
There is much interest in developing strategies for tumour-specific delivery of agents 
to increase our diagnostic capability or enhance the selectivity and effectiveness of 
therapeutics. These strategies rely on the ability to target tumour cells accurately 
using biomarkers that are differentially expressed between tumour and normal tissue. 
Antibodies to various tumour-associated antigens provide an ideal mechanism for 
this (Chester et al., 2004, Brennan et al., 2010). In colorectal cancer, the most 
commonly used biomarkers include carcinoembryonic antigen (CEA) (Muguruma et 
al., 1999, Heine et al., 2011, Sharkey et al., 2005, Yazaki et al., 2008, Kaushal et al., 
2008), tumour-associated glycoprotein 72 (TAG-72) (Tang et al., 2007, Zou et al., 
2009, Chen et al., 2008, Chen et al., 2011b), endothelial growth factor receptor 
(EGFR) (Qi et al., 2012, Goetz et al., 2010, Jeong et al., 2012), and folate receptor 
alpha (FRα) (Reddy and Low, 1998, Chen et al., 2005, Yang et al., 2010a). 
 
Carcinoembryonic antigen (CEA): 
CEA is a membrane-bound glycoprotein that is over-expressed in approximately 90% 
of colorectal cancers and is minimally expressed in normal colonic cells (Jantscheff 
et al., 2003). It is expressed less strongly in gastric, pancreatic, breast, lung and 
medullary thyroid cancer (Hammarström, 1999). CEA actually represents a family of 
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proteins encoded by 29 genes (Hammarström, 1999), meaning the actual epitope is 
not always clear. 
 
Tumour-associated glycoprotein 72 (TAG-72): 
TAG-72 is a mucin-like molecule with a similar expression to CEA in colorectal 
cancer and normal tissue. It is also over-expressed on the surface of a variety of 
adenocarcinomas including gastric, pancreatic, breast, prostrate, endometrial and 
ovarian tumours (Colcher et al., 1989, Johnson et al., 1986). Like CEA, TAG-72 is 
not encoded by a single gene.  
 
Folate receptor α (FR): 
FRα is a membrane-bound protein that binds and transports folic acid and is over-
expressed in epithelial-derived cancers, including those of the colorectum (Shia et 
al., 2008). It appears to be expressed relatively infrequently in colorectal tumours but 
is absent in the vast majority of normal tissues, hinting at a potentially high specificity 
(Shia et al., 2008). 
 
Epidermal growth factor receptor (EGFR): 
EGFR is a well-known target for anti-cancer therapies but the literature concerning 
the degree and frequency of EGFR over-expression in colorectal cancer is 
contradictory, with reported expression varying from 33% to 97% of cases (Koretz et 
al., 1990, Lee et al., 2002, Spano et al., 2005, Bhargava et al., 2006). It is also 
reported to be expressed in up to 48% of normal colorectal samples (Koretz et al., 
1990), which could compromise its specificity for cancer tissue. 
 
These four biomarkers have been targeted in the majority of diagnostic and 
therapeutic applications in colorectal cancer. A surprising feature of all the examples 
of in vivo tumour targeting described in section 0 is that the choice of biomarker used 
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is rarely justified in terms of its tumour sensitivity and specificity. The characteristics 
of suitable cancer biomarkers are that they must be highly expressed in a large 
majority of tumours and have low or no expression in normal tissue, encompassing 
the normal tissue from which the tumour is derived and – ideally – most or all normal 
adult tissues accessible to systemic delivery. Suitable molecules must also be 
located on the external facing surfaces of cancer cells so as to be accessible to 
systemically-delivered recognition molecules. To my knowledge, expression of the 
most commonly used markers for colorectal cancer has never been rigorously 
evaluated in a well-defined cohort of cancer and normal tissue. I will need to choose 
the most appropriate biomarker-specific antibody to use for my application 
 
1.3.2 Fluorescent visualisation component 
Once bound specifically to a cancer cell, the antibody must be visible to the operating 
surgeon but must not distort views of the surrounding anatomy. Fluorescence is ideal 
for this purpose as it can effectively be turned on or off on the screen of a modified 
laparoscope using selective filters of different wavelengths. Fluorescence occurs 
when a substance (a fluorophore) absorbs electromagnetic radiation, exciting 
electrons to a higher quantum state before returning to their ground state and 
emitting a photon (light) at a different wavelength to that which was absorbed. 
Normal biological tissues naturally emit non-specific auto-fluorescence when excited 
by light with wavelengths commonly used in fluorescent imaging (e.g. from 
mitochondria and lysosomes) which can potentially interfere with an imaging system 
(Monici, 2005). I require a fluorophore that absorbs electromagnetic radiation at a 
wavelength that penetrates tissues deeply without damaging them, emits light at a 
wavelength different to that of auto-fluorescing tissues, and is suitably bright. Near 
infra-red light (wavelength approximately 700 - 3000 nm) is ideal because 
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haemoglobin, lipids and water tend to absorb the least amount of light at wavelengths 
in the near-infrared range, allowing deeper tissue penetration than other wavelengths 
(Weissleder and Ntziachristos, 2003, Hilderbrand and Weissleder, 2010). Non-
specific tissue auto-fluorescence is also significantly lower at longer wavelengths, 
improving the target to background ratio (Muller et al., 2001). A fluorophore with a 
longer wavelength is therefore desirable in an in vivo imaging system. The near-
infrared cyanine (Cy) dyes (absorption wavelength 650-900 nm) have been used in 
clinical trials for anatomical delineation of lymph channels and nodes, bile ducts, 
mesenteric and anastomotic perfursion, and ureters (Ashitate et al., 2012, Soltesz et 
al., 2006, Kusano et al., 2008, Hutteman et al., 2010, Cahill et al., 2011, Matsui et al., 
2011, Cahill et al., 2012), frequently combined with modified laparoscopes. However, 
none of these applications use fluorophores targeted to specific tissues or cells - 
instead they are simply inserted into the anatomical compartment of interest. 
 
Several groups have published small studies evaluating fluorophores conjugated to 
targeting antibodies in murine models of colorectal (Kaushal et al., 2008, Zou et al., 
2009), pancreatic (Kaushal et al., 2008), breast (van Scheltinga et al., 2011, Wu et 
al., 2013) and head and neck cancers (Heath et al., 2012, van Scheltinga et al., 
2011) using near infrared dyes including Oregon Green Thermo (Thermo-Fisher, 
Massachusetts, USA), Cy7, IRDye 800CW (Li-Cor, Nebraska, USA) and rhodamine 
as the fluorophore. All studies demonstrated fluorescent labelling of the tumours but 
when the tumour-to-background ratio and non-specific fluorescence were taken into 
account the results were potentially less impressive, as detailed below. For such 
systems to be effective in laparoscopic colorectal cancer surgery, three important 
criteria must be fulfilled: the fluorescent signal must be of adequate magnitude to 
pass through the muscular bowel wall and the fatty mesentery; the tumour-to-
background ratio must be large enough to allow sensitive and specific detection; and 
the fluorophore must be relatively resistant to photobleaching, a particular issue due 
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to the sometimes extended duration of operations for colorectal cancers. The results 
of the published studies suggest that the systems used were unlikely to fulfil these 
criteria. For example, Heath et al used a IRDye800CW-conjugated anti-EGFR 
antibody in mice with head and neck xenograft tumours combined with a fluorescent 
intra-operative imaging system (Heath et al., 2012). The authors found the signal-to-
background ratio to be only 2.9 for the test particle and 1.4 for their control antibody, 
meaning the fluorescence achieved was not dramatically above background and 
exhibited only slight antibody directed targeting. Similarly, van Scheltinga et al 
achieved a tumour-to-background ratio of 2.8 using the same dye in a murine breast 
cancer model (van Scheltinga et al., 2011). It is notable that despite initial studies 
suggesting potential for translation to the operating theatre in 2008, there has been 
no progress beyond mouse models. 
 
1.3.2.1 Indocyanine green 
Unlike the dyes used in the examples above, indocyanine green (ICG) is insoluble in 
water at physiological pHs and is not easily conjugated to protein molecules 
(Landsman et al., 1976). Ito et al developed ICG-Sulfo-OSu, which has a 
succinimidyl ester available for binding to a free amine group on an IgG molecule (Ito 
et al., 1995). Following this there were limited attempts to use ICG-labelled 
antibodies for fluorescent immunohistochemistry of fixed tissues (Muguruma et al., 
1998, Muguruma et al., 1999) that received no further attention. This might be 
explained by the data published by Ogawa et al (Ogawa et al., 2009): the authors 
showed that when ICG-Sufo-OSu was conjugated to IgG antibody the fluorescence 
intensity was low and this remained the case when alternative antibodies were used. 
Furthermore, when the antibody to ICG molar ratio was increased, this ‘queching’ 
effect also increased; at 1:1 conjugation the observed quenching capacity was 6-fold, 
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whereas at 1:8 it was 58-fold. When the authors added 2% sodium dodecyl sulphate 
(SDS) and 2-mercaptoethanol (2-MEA), the fluorescence dramatically increased. The 
authors hypothesised that this was due to the covalent bond between the two being 
cleaved although this mechanism is not fully understood. They found that following 
cell membrane binding, ICG-antibody conjugates were gradually internalised into the 
cell cytoplasm and gradually became ‘activated’ over eight hours, producing 
detectable cytoplasmic fluorescence. Presumably this occurs during lysosomal 
metabolism. The authors exploited this phenomenon by conjugating ICG-Sulfo-OSu 
to anti-human epidermal growth factor receptor 2 (HER2) monoclonal antibodies and 
successfully using them for in vivo imaging in a murine xenograft model of breast 
cancer. The same group also published further similar work using a murine xenograft 
of prostate cancer (Nakajima et al., 2011). This property implies that the non-specific 
background signal in an in vivo system would be reduced, as only internalised ICG 
will be fluorescent and all other ICG-antibody conjugates that have not bound to the 
target antigen will remain quenched. In addition, the ICG appears to remain 
fluorescent within the cytoplasm for up to 10 days (Nakajima et al., 2011). The 
logistics involved in administering the drug and scheduling surgery would therefore 
be more flexible and multiple doses could be administered to increase the number of 
ICG molecules in the cell. These factors may allow improved fluorescent detection 
compared to simple surface-bound fluorescent antibody systems. 
 
Importantly, ICG is a U.S. Food and Drug Standards Agency (FDA) and UK 
Medicines and Healthcare Products Rugulatory Agency (MHRA) approved dye, so 
translation from in vitro studies to clinical trials could be rapid. Its potential as a 
medical dye was first described in 1957 (Fox et al., 1957) and it has been used in 
clinical studies for ophthalmic angiography (Holz et al., 1998), hepatosplanchnic 
blood flow estimation (Uusaro et al., 1995), intra-operative small bowel angiography 
(Matsui et al., 2011), biliary cholangiography (Ishizawa et al., 2009), anastomotic 
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perfusion estimation (Ris et al., 2014) and sentinel lymph node mapping (Cahill et al., 
2012, Kusano et al., 2008, Soltesz et al., 2006). It has been used in the majority of 
the anatomical delineation clinical trials mentioned in section 1.2.4.1 with no reported 
side effects. It also has an emission spectrum in the near-infrared range (810 nm in 
water and 830 nm in blood (Fox et al., 1957)), potentially reducing background 
autofluorescence (Vahrmeijer et al., 2013, Alander et al., 2012). 
 
1.3.3 Nanoparticle scaffold 
A nanoparticle is generally considered to be a particle with lengths in two or three 
dimensions of between one and 100 nm (ISO, 2008, ASTM, 2012). They can be 
synthesised in a vast number of shapes, sizes and materials, with a similarly variable 
chemical composition and surface chemistry. There has been great interest in their 
potential for biomedical applications ever since the field of nanotechnology was 
established and throughout its subsequent rapid expansion.  
 
A fluorescent, tumour-specific molecular probe for live in vivo colorectal cancer 
imaging must fulfil the following criteria: 
 The molecule must have pharmacokinetic properties that enable it to be 
delivered efficiently to a tumour following systemic vasculature delivery; 
 The fluorescent signal must be of adequate magnitude to pass through the 
muscular bowel wall and the mesentery; 
 The tumour-to-background ratio must be large enough to allow sensitive and 
specific detection; 
 The fluorophore must be relatively resistant to photobleaching; 
 It must have a favourable toxicity profile. 
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Nanotechnology may provide a potential solution to the limitations seen with simple 
fluorophore-antibody conjugates and improve the above criteria. If a chemical 
nanoparticle scaffold could be used to link the two components, the fluorescent 
signal could be concentrated by providing many more fluorophore molecules per 
antibody molecule. Multiple antibodies targeting different tumour-specific antigens 
could theoretically be attached to maximise sensitivity. 
 
For systemic delivery, the fluorophore-nanoparticle-antibody complex would have to 
be small enough to pass through the small capillaries in tumour tissue to reach the 
target antigen and be non-toxic. Although dependent upon many factors including 
particle shape, surface chemistry and charge, it is generally accepted that for this to 
occur, nanoparticles must have a diameter of less than 200 nm (Matsumura and 
Maeda, 1986, Moghimi et al., 2012, Perrault et al., 2009). Solid tumours display an 
inherent ‘leaky’ vasculature and deficient lymphatic drainage that allows 
intravenously delivered nanoparticles to passively accumulate, known as the 
enhanced permeation and retention effect (Peer et al., 2007, Matsumura and Maeda, 
1986). The combination of small particle size and relatively permeable tumour-
associated vasculature enables deep tumour penetration (Brannon-Peppas and 
Blanchette, 2004). They are usually rapidly sequestered by the liver, spleen and 
other parts of the reticuloendothelial system (RES) depending on their surface 
characteristics (Gabizon et al., 2003). The surface of a nanoparticle can be 
functionalised to carry a variety of chemical groups, enabling specific molecules 
(such as antibodies or fluorophores) to bind to them. By controlling these surface 
functional groups, a particle can be made to have a hydrophilic surface, reducing 
uptake and prolonging circulation time and hence affording greater targeting potential 
(Gaur et al., 2000). Incorporation of polyethylene glycol (PEG), a hydrophilic co-
polymer, to nanoparticle surfaces has been shown to effectively increase the 
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circulating half-life by preventing opsonisation by the RES (Owens Iii and Peppas, 
2006). 
 
1.3.3.1 Toxicity 
Research into the potential toxicity of nanoparticles for biomedical applications 
appears to have taken a backseat during the field’s rapid expansion (Lewinski et al., 
2008) but concerns have been raised regarding the toxic effects of exposure and 
accumulation (Li et al., 2010, Marquis et al., 2009, Soenen and De Cuyper, 2010, 
Yang et al., 2010b). This tends to affect the route of administration and the organ(s) 
responsible for their clearance - if the nanoparticle is non-biodegradable, 
accumulation in these organs can lead to toxicity (Ilium et al., 1986, Peracchia et al., 
1999) with unknown long term effects. In addition, the unique kinetic properties of 
nanoparticles in solution have led to errors when extrapolating toxicity data obtained 
in vitro experiments (Teeguarden et al., 2007). This is because nanoparticles usually 
exist as a suspension in a fluid as opposed to a true solution, therefore predicting 
their behaviour based on in vitro results can be difficult. 
 
1.3.3.2 Liposomes, polymeric and silica nanoparticles 
The variable shape, size, material and surface chemistry all impact the fate of a 
nanoparticle in a complex biological system (Alexis et al., 2008). These factors and 
the potential for toxicity has led to the majority of work concentrating on liposomes 
and polymeric nanoparticles (Petros and DeSimone, 2010), which have shown the 
greatest potential in vivo. 
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Liposomes are vesicles consisting of spherical phospholipid bilayers. They provide a 
non-toxic system for delivering drugs to target tissue and controlling their release, via 
endocytosis at the cell membrane. They have been successfully employed in 
delaying the release of local anaesthetic agents (Davidson et al., 2010) and in 
delivering chemotherapy agents (Kaasgaard and Andresen, 2010, Andresen et al., 
2010), vaccines, anti-fungals, anti-virals and gene therapeutics (Lian and Ho, 2001). 
Whilst ideal for delivery of a payload, they are less suitable for in vivo fluorescent 
imaging because of rapid endocytosis and poor specificity (Miller et al., 1998).  
 
Polymeric microspheres, synthesised using an emulsion polymerisation process, 
have tended to be the most common type of particle used in biological applications 
(Soppimath et al., 2001). Their size can be readily controlled and their surface can be 
functionalised with a variety of groups for conjugation. Mesoporous silica, containing 
multiple micropores, has been the preferred choice of material due to its relative non-
toxicity, ease of manufacture and optical transparency (allowing fluorophores to be 
incorporated) (Burns et al., 2006, Li et al., 2012, Slowing et al., 2008, Tang et al., 
2012).  
 
1.3.3.3 Dye-doped silica nanoparticles 
Dye-doped silica nanoparticles fulfil many of the criteria required for a targeted intra-
operative imaging platform and are my preferred choice. They comprise a fluorescent 
core with thousands of dye molecules embedded in silica. A silica shell that can be 
functionalised with various chemical groups for conjugation surrounds this. They 
were first described in 2001 (Qhobosheane et al., 2001) and since then a limited 
number of studies have been published in which these particles have been 
investigated as agents to allow fluorescent labelling of cancer cells in vitro (Huang et 
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al., 2009, Santra et al., 2001, Tivnan et al., 2012). They have been shown to be 
relatively non-toxic compared to many nanoparticles, with excretion via the faeces 
and urine following intravenous administration (Fu et al., 2013). 
 
There are two important limitations to the data presented: firstly, the methodology for 
manufacturing this type of particle is highly variable, with large variations between 
techniques and several different chemical conjugation strategies for linking a 
targeting antibody to the nanoparticle; secondly, in the limited number of papers that 
describe cell targeting experiments, the methodology is poor with a lack of robust 
controls or fluorescence quantification. A key concern is the high level of non-specific 
binding potentially exhibited by these particles when using some conjugations to 
antibodies, meaning that use of appropriate non-tumour targeted controls is critical. 
The vast majority of published work in this field has used either ‘bare’ nanoparticles 
as a control, with no targeting antibody attached, or no control particle at all. There 
are no reports of successful live in vivo tumour targeting in colorectal cancer.  
 
1.3.3.4 Quantum dots 
Quantum dots are fluorescent semiconductor nanocrystals that have a number of 
characteristics differentiating them from organic fluores (Michalet et al., 2005). Their 
size determines the absorption and emission spectra and can be closely controlled or 
‘tuned’ during their manufacture. Their extinction coefficients - the amount of light that 
can be absorbed - are also claimed to be longer and they are more stable than 
conventional dyes, with a high resistance to photobleaching, where the the fluore is 
damaged by the exciting light (Watson et al., 2003, Ballou et al., 2003). These 
properties make quantum dots potentially ideal fluorophores for imaging purposes 
but their toxicity remains a concern (Pelley et al., 2009), particularly as they are 
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commonly constructed from cadmium and either tellurium or selenium, all of which 
are toxic to humans. Efforts have been made to coat quantum dots with a chemical 
shell, such as zinc sulphide, to reduce toxicity without compromising their optical 
properties (Cho et al., 2010, Darbandi et al., 2010). It is also possible to conjugate 
antibodies to their surface (Gao et al., 2004, Wu et al., 2003, Ballou et al., 2003, 
Yang et al., 2009), allowing antigen-specific fluorescence. Despite early claims of 
huge advantages over traditional fluorophores for biomedical imaging, supporting 
robust and conclusive data have not been forthcoming. 
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1.4 HYPOTHESIS AND AIMS 
 
My hypothesis is that a tumour-specific, intra-operative fluorescent imaging system 
for detecting colorectal cancer would allow more accurate identification of primary 
tumour margins and more sensitive detection of metastatic disease, leading to more 
effective tumour treatment and improvement in patient outcomes. 
 
My aims are: 
i) To identify sensitive and specific antibodies for colorectal cancer cell antigens 
and examine their expression in a large cohort of tumour and normal colon 
samples; 
ii) To produce a fluorescent nanoparticle and conjugate it to the best performing 
antibody; 
iii) To examine the sensitivity and specificity of these fluorescent nanoparticles for 
colorectal cancer cells using model systems including cell lines and xenograft 
mouse models. 
Use of this intra-operative imaging system could potentially be examined in future 
clinical trials and if successful could improve outcomes for colorectal cancer 
treatment. 
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Chapter Two 
 
 
Methods 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The tissue micro-arrays described in this chapter were prepared by S Yeluri. 
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2 METHODS 
 
2.1 Immunohistochemistry 
 
2.1.1 Immunohistochemistry methods 
Blocks were sectioned (5 µm) onto SuperFrost Plus microscope slides (Menzel-
Glaser, Braunschweig, Germany), dewaxed with xylene and rehydrated through 
graded ethanol before rinsing in water for 5 minutes. Antibody-binding epitopes were 
retrieved either by heating the slides in pre-warmed 10mM citric acid buffer (pH 6.0), 
using a microwave (buffer pre-heated at 900W for 2 minutes, slides heated at 900W 
for 10 minutes), using a pressure cooker (pre-heated for 10 minutes, slides heated 
for eight minutes, 125°C, 103.4 kilopascals), or by incubating with 100 µl of 
proteinase K in 50 ml of phosphate buffered saline (PBS) at 37°C for 25 minutes. 
Endogenous peroxidase activity was blocked with 10% hydrogen peroxide (H2O2) for 
10 minutes before re-rinsing in water for 5 minutes. If non-specific stromal staining 
was present, an extra block step was then performed using casein (1:10 dilution in 
Tris-buffered saline, TBS; 60 ml 2.5 M NaCl mixed with 20 ml Tris-HCl pH 7.4 and 
920 ml distilled water) for 20 minutes. Each slide was mounted in a sequenza 
(Thermo Scientific, Massachusetts, USA) and rinsed with TBS followed by antibody 
diluent reagent solution (Invitrogen, Carlsbad, USA) to prevent non-specific binding. 
100µl of primary antibody diluted in diluent was added at a range of concentrations 
and incubated at room temperature for 1 hour or overnight at 4ºC. Slides were 
washed twice with TBS-tween (TBS-T, TBS plus 10% [v/v] Tween-20) and once with 
TBS, for five minutes each before incubating with an appropriate horseradish 
peroxidise (HRP)-conjugated polymer secondary antibody (Invitrogen) for 30 minutes 
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at room temperature. The slides were re-washed, twice with TBS-T and once with 
TBS for 5 minutes. 100µl of 3,3’-diaminobenzidene DAB (Invitrogen) solution was 
added to each slide for 10 minutes before a 5 minute wash in water. Slides were then 
stained with haematoxylin for 1 minute, washed in water for 1 minute, washed in 
Scott’s tap water for 1 minute and rewashed in water for 1 minute. They were then 
dehydrated with graded ethanol and xylene before being mounted with DPX 
Histology mountant (Sigma Aldrich, St Louis, USA). 
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2.1.2 Antibodies 
Antibodies to the eight chosen antigens were selected as detailed below: 
Antibody Type Clone 
Code & 
Manufacturer 
Publication
s 
Anti-CEA 
IgG1 monoclonal 
mouse anti-human 
II-7 
M7072, Dako, 
Denmark 
(Zoubir et 
al., 1990) 
Anti-CEA  
IgG1 monoclonal 
mouse anti-human 
- 
A5B7, 
Biotherapeutics 
Development 
Unit, Cancer 
Research UK, 
Clare Hall 
Laboratories, 
Potters Bar, UK 
(Meyer et 
al., 2009) 
(Dawson et 
al., 1991) 
(Lane et al., 
1994) 
Anti-TAG-72  
IgG1 monoclonal 
mouse anti-human 
- 
sc-20043, Santa 
Cruz, Texas, USA 
(Povoski et 
al., 2012) 
(Sun et al., 
2007) 
Anti-EGFR 
IgG1 monoclonal 
mouse anti-human 
31G7 
Invitrogen, 
Carlsbad, USA 
(Buckley 
and Kakar, 
2007) 
Anti-
VEGFR2 
IgG1 monoclonal 
mouse anti-human 
KDR/EIC 
ab9530, Abcam, 
Cambridge, UK 
(Duff et al., 
2006) 
(Schimanski 
et al., 
2010b) 
Anti-folate 
receptor α 
IgG1 monoclonal 
mouse anti-human 
BN3.2 
Leica 
Biosystems, 
Newcastle, UK 
(Smith et 
al., 2007) 
Anti-robo1 
IgG1 polyclonal goat 
anti-human 
I-20 
sc-16612, Santa 
Cruz, USA 
(Grone et 
al., 2006) 
(Wang et 
al., 2003) 
Anti-CD105 
IgG1 polyclonal 
mouse anti-human 
SN6h 
M3527, Dako, 
Denmark 
(Bellone et 
al., 2010) 
(Burrows et 
al., 1995) 
Table 2.1. Antibodies selected for the chosen panel of antigens. 
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2.1.3 Optimisation 
Thirteen specimens of formalin-fixed, paraffin-embedded colorectal cancer of various 
grades and one sample of normal colonic tissue were used to optimise antibody 
concentrations and experimental protocols. For each primary antibody, a range of 
concentrations was tested according to the manufacturers’ guidelines and relevant 
published papers. Control slides with no primary antibody were included. Duplicate 
slides were tested using different methods of antigen retrieval: no retrieval; heat 
retrieval; and proteinase K retrieval. Slides were examined by a pathologist (ETV) 
and the quality of staining assessed, specifically comparing tumour samples to the 
normal sample and looking for positive cancer cell staining with negative stromal 
fibroblasts and leukocytes. If staining was non-specific, with stromal and cancer cell 
staining present, fresh slides were incubated with 100µl of 10% casein for 20 minutes 
and reassessed by a pathologist. If staining was absent, slides were incubated with 
the primary antibody overnight at 4ºC and reassessed. 
 
2.1.4 Tissue micro-arrays 
2.1.4.1 Ethics and patient cohort 
Ethical approval was obtained from the National Research Ethics Service (London-
Dulwich Committee), reference 12/LO/1327. Formalin-fixed paraffin-embedded 
(FFPE) tissue blocks containing primary colorectal carcinoma and matched normal 
colorectal mucosa, collected prospectively for the MRC CLASICC trial (Guillou et al., 
2005), were available from 280 patients. FFPE blocks containing mesenteric lymph 
nodes (both tumour-cell positive and negative) were available for 18 of the patients. 
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2.1.4.2 Procedure 
Tissue microarrays (TMAs) were constructed from formalin-fixed samples of 
colorectal cancer and normal colonic mucosa using 0.6mm cores embedded in 
paraffin blocks by SY. For each patient, three cores selected from the most 
representative tumour area (as determined by haematoxylin and eosin (H&E) 
staining) and three cores from normal colon were included. The 280 colorectal 
tumours and matched normal tissues were sampled in seven TMAs, with three cores 
for each tumour and three cores for each matched normal tissue sample. 
Immunohistochemistry was performed on each TMA with anti-CEA (A5B7), anti-TAG-
72, anti-EGFR and anti-FRα at concentrations of 1:150000, 1:100, 1:50 and 1:25 
respectively. Microwave antigen retrieval was used for anti-CEA and anti-TAG-72, 
proteinase K retrieval was used for anti-EGFR and pressure cooker retrieval was 
used for anti-FRα. 
 
2.1.5 Scoring 
Slides were digitally scanned using Scanscope XT (Aperio, Vista, USA) at 20x 
magnification and were observed for scoring using ImageScope v11 (Aperio, 
Vista,USA). Staining was assessed semi-quantitatively using a bespoke scoring 
system developed in consultation with two pathologists (ETV and NPW). Cores were 
scored for intensity of epithelial cell staining (0, no staining; 1, mild; 2, moderate; 3, 
strong) and an estimate of the percentage of epithelial cells staining positively (0, 
<5%; 1, 5-20%; 2, 21-40%; 3, 41-60%; 4, 61-80%; 5, 81-100%). These scores were 
multiplied to give final scores of 0 to 15, as has been done previously (Lombardi et 
al., 1999, Soslow et al., 2000, Lyall et al., 2006, Leeman et al., 2002). A mean score 
was calculated from the core scores for each tumour and each matched normal 
sample. Tumour cores with no tumour cells and normal cores with no epithelial cells 
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visible were discounted. Carcinoembryonic antigen and TAG-72 were scored for 
apical membranous staining only. Folate receptor α showed mild cytoplasmic 
staining only, and was scored solely for this. EGFR showed membranous, and - 
more rarely - cytoplasmic and nuclear staining. However, following established 
literature (Buckley and Kakar, 2007, Scartozzi et al., 2004) EGFR was scored for 
membranous expression only. Two independent observers were involved in the 
scoring: I scored all cores and a pathologist (ETV) blinded to the antibodies scored a 
sample representing 15% of the cases. Scoring reproducibility was determined for 
each antibody using the intra-class correlation coefficient; the process of calculating 
the mean score for each patient led to 61 possible outcomes and therefore the data 
were treated as continuous rather than categorical. Scores for each case of tumour 
or normal tissue were means of scores allocated by me for each core from that 
tissue. If only one core score was available, for example due to lack of appropriate 
cell types or core loss (where the core is stripped from the slide during the staining 
process) this single score was used; a method that has been validated previously 
(Camp et al., 2000, Torhorst et al., 2001)). Means for normal and tumour tissue were 
compared using Wilcoxon signed-rank tests for paired non-parametric data. 
Sensitivities and specificities were calculated from the mean scores for tumour and 
normal tissue expression for each case using two different cut-off points: the 95th 
percentile of the normal tissue score distribution and optimal cut-offs identified by 
receiver operating characteristic curves (Maraqa et al., 2008). 
 
 
2.2 Tissue culture 
 
Six cell lines were used in this work, as detailed in Table 2.2. All cell lines tested 
negative for mycoplasma. Cells were grown in T75 flasks at 37°C and 5% CO2. 
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Cell line Description Supplier Media 
HT-29 
Human 
colorectal 
adenocarcinoma 
ATCC 
RPMI 1640 + 
10% fetal calf 
serum (Life 
Technologies) 
HRT-18 
Human 
colorectal 
adenocarcinoma 
ATCC 
RPMI 1640 + 
10% fetal calf 
serum (Life 
Technologies) 
CACO2 
Human 
colorectal 
adenocarcinoma 
ATCC 
RPMI 1640 + 
10% fetal calf 
serum (Life 
Technologies) 
LS174T 
Dukes’ B human 
colorectal 
adenocarcinoma 
ATCC 
Advanced MEM 
+ 10% fetal calf 
serum (ATCC) 
LoVo 
Dukes’ C human 
colorectal 
adenocarcinoma 
ATCC 
F12 Nutmix (Life 
Technologies) 
HCT116 
Human 
colorectal 
adenocarcinoma 
ATCC 
RPMI 1640 + 
10% fetal calf 
serum (Life 
Technologies) 
Table 2.2. Cell lines used for in vitro experiments. 
 
2.2.1 Cell line authentication 
The cell lines used most extensively in this work, LS174T, LoVo and HCT116, were 
authenticated using deoxyribonucleic acid (DNA) profiling. Genomic DNA was 
extracted using a Qiagen DNA extraction kit (Qiagen, Venio, Netherlands). This was 
then sent to Dr Claire Taylor of the Leeds Genomic Centre who used a PowerPlex 16 
HS system (Promega, Wisconin, USA) to profile the cellular DNA and compared the 
results to reference material for each cell line. All three were considered authentic. 
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2.3 Immunofluorescence 
 
2.3.1 Cell lines 
HT-29, HRT-18 and CACO2 colorectal cancer cells were cultured on plastic in RPMI 
1640 with L-glutamine media supplemented with 10% heat-treated foetal calf serum 
(FCS) (GIBCO, 21875, Invitrogen, UK). Human umbilical vein endothelial cells 
(HUVEC) were cultured on plastic in large vessel endothelial growth media (ZHM 
2961, TSC Cellworks, UK). All cell lines were incubated at 37°C and 5% CO2. For 
immunofluorescence, cells were seeded on to glass cover slips in six well plates at 
least 24 hours before use. 
2.3.1.1 Fixed cells 
The media was removed and the coverslips were washed in PBS before being 
incubated in 4% paraformaldehyde for 10 minutes at room temperature. The 
paraformaldehyde was removed and the cells were washed twice in PBS. The 
coverslips were washed in diluent reagent solution to prevent non-specific binding 
and incubated with each primary antibody, diluted to the appropriate concentration 
with diluent, for one hour at room temperature. Control slides with no primary 
antibody were included. They were washed twice with TBS-T and once with TBS for 
five minutes each and incubated with a fluorescent secondary antibody (Alexa Fluor 
594 or 488 goat anti-mouse, Life Technologies, Carlsbad, USA) for 30 minutes at 
room temperature in the dark. Five minute washes with TBS-T and TBS were 
repeated. The coverslips were then mounted onto SuperFrost Plus microscope slides 
(Menzel-Glaser) using Prolong Gold Anti-fade DAPI Reagent (Invitrogen) and left 
overnight in the dark to cure. Slides were viewed using a Zeiss Axiovision fluorescent 
microscope (Carl Zeiss, Oberkochen, Germany) with the appropriate filter for the 
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secondary antibody. Phase and fluorescent (DAPI and FITC or Texas Red) images 
were captured at 63X magnification. 
2.3.1.2 Live cells 
As above, except coverslips were not incubated in chilled methanol.  
 
2.3.2 Fresh frozen tissue 
Ethical approval from the National Research Ethics Service (Leeds East), reference 
15/YH/0080, was already in place for the Leeds Multidisciplinary Research Tissue 
Bank. Archived samples of freshly frozen colorectal cancer tissue and matched 
normal controls from five patients were cryosectioned (Leica LM3050, Leica 
Biosystems, Newcastle, UK) into 5 µm thick sections using and mounted directly onto 
SuperFrost Plus slides. They were left to dry at room temperature for 60 minutes and 
rehydrated with TBS. They were then incubated with each antibody, mounted, 
viewed and captured as per the live cells. 
 
 
2.4 Ex vivo model 
 
2.4.1 In vitro proof of concept 
LS174T cells were grown and seeded onto glass coverslips in a six-well plate as in 
2.2. The media was removed, the cells were washed with PBS and anti-CEA was 
then added and incubated for one hour at room temperature. The cells were washed 
twice with TBS and once with TBS-T and then fixed in formalin (one hour at room 
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temperature). They were then washed, incubated with a fluorescent secondary 
antibody and mounted as per section 2.3. The slides were analysed using a Zeiss 
Axiovision fluorescent microscope with the appropriate filter for the secondary 
antibody. The results were compared to immunfluorescence carried out on fixed cells 
where the primary antibody was added following fixation in formalin. 
 
2.4.2 Human study 
Ethical approval for this work was obtained from the National Research Ethics 
Service (Leeds), reference 12/YH/0002. Three patients undergoing elective resection 
of colorectal cancer were recruited. Immediately following resection of the specimen, 
a 21G cannula was inserted into the inferior mesenteric artery (descending/sigmoid 
colon tumour), ileocolic artery (caecal tumour) or right colic artery (ascending colon 
tumour) and secured with a vicryl ligature. Three ml of 0.48 mg/ml A5B7 anti-CEA in 
PBS was injected and the artery ligated. The specimen was fixed in formalin and 
underwent routine histopathological examination. Paraffin-embedded blocks of 
tumour tissue were then cut and mounted onto glass slides. The slides were 
subjected to routine immunohistochemisty but only a secondary antibody was used. 
 
 
2.5 Antibody-fluorophore conjugates 
 
2.5.1 Antibody-fluorescein 
A 15-fold molar excess of NHS-fluoroscein dye (Thermo Scientific) to IgG antibody 
was used. One mg of NHS-fluorescein was dissolved in 100 µl of DMSO. Five µl of 
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the NHS-fluorescein solution was added to 500 µl of 2 mg/ml IgG dissolved in borate 
buffer (0.05 M, pH 8.5) and mixed thoroughly. It was incubated for 1 hour at room 
temperature. It was then transferred to a 10 kDa cut-off spin filter (Amicon) and 
centrifuged for 2.5 minutes at 16100 g. The eluent was discarded and the chamber 
was topped up with borate buffer (0.05 M, pH 8.5) and the spin repeated. This was 
repeated a futher six times but PBS was added between spins. The flow-through was 
tested for fluorescence using a fluorometer to ensure no further unbound fluorescein 
was present. The filtrate was then collected in a fresh collection tube by inverting the 
filter chamber and centrifuging at 100 g for 30 seconds. The total volume was made 
up to 500 µl with PBS and used as a stock solution. It was stored at 4°C in the dark. 
The degree of fluorescein labelling was calculated using the following formulae: 
 
𝐶𝑜𝑟𝑟𝑒𝑐𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟, 𝐶𝐹 =
𝐴280
𝐴𝑚𝑎𝑥 𝑜𝑓 𝑓𝑙𝑢𝑜𝑟𝑜𝑠𝑐𝑒𝑖𝑛
 
 
- A280 = absorbance of the labelled antibody at 280 nm 
- Amax = maximum absorbance 
 
 
𝐴𝑛𝑡𝑖𝑏𝑜𝑑𝑦 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 (𝑚𝑜𝑙𝑒𝑠) =  
𝐴280 − (𝐴𝑚𝑎𝑥 𝑥 𝐶𝐹)
𝜀𝑎𝑛𝑡𝑖𝑏𝑜𝑑𝑦
 𝑥 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟 
- εantibody = molar extinction coefficient of IgG 
 
 
𝑀𝑜𝑙𝑒𝑠 𝑓𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑖𝑛 𝑝𝑒𝑟 𝑚𝑜𝑙𝑒 𝑎𝑛𝑡𝑖𝑏𝑜𝑑𝑦 =  
𝐴𝑚𝑎𝑥𝑜𝑓 𝑙𝑎𝑏𝑒𝑙𝑙𝑒𝑑 𝑎𝑛𝑡𝑖𝑏𝑜𝑑𝑦
𝜀𝑓𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑖𝑛 𝑥 𝑎𝑛𝑡𝑖𝑏𝑜𝑑𝑦 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛
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LS174T colorectal cancer cells were cultured on plastic in Advanced MEM (ATCC, 
Virginia, USA) media supplemented with 10% FCS and L-glutamine (1%). They were 
incubated at 37°C and 5% CO2 and grown in T75 flasks (Corning, New York, USA) 
until confluent. They were seeded onto glass coverslips and left for 48 hours for the 
cells to become confluent. 200 µg of Fluoroscein-anti-CEA was added to one well 
and 200 µg of fluorescein anti-digoxin was added to another. After one hour 
incubation at 37ºC, the media was removed, the cells washed and the coverslips 
mounted as in section 2.3. A Nikon A1R-A1 confocal microscope (Nikon, Tokyo, 
Japan) with NHS Elements software (version 4.0) was used for imaging. For each 
slide, the cells were focussed in phase mode and fluorescent images were captured 
with the appropriate wavelength filter selected. The settings (such as laser power and 
gain) remained constant for each slide.  
 
2.5.2 Antibody-indocyanine green 
ICG-Sulfo-OSu was purchased from Dojindo, USA. The conjugation method was 
adapted from Ogawa and Nakajima (Ogawa et al., 2009, Nakajima et al., 2011). An 
approximate 8-fold molar excess of ICG-Sulfo-OSu to IgG antibody was used for 
labelling. 1.1 µl of a 10 mM stock solution of ICG-sulfo-OSu in dimethylsulfoxide 
(DMSO, 10.9 nM) was added to 200 µg (1.34 nM) of IgG suspended in carbonate-
bicarbonate buffer (0.1 M, pH 9.1) and mixed thoroughly. It was left to react in the 
dark for two hours with gentle stirring. Excess dye was removed using the same spin 
filter protocol as in 2.5.1, washing first with carbonate-bicarbonate buffer and then 
PBS. The flow-through was tested for fluorescence using a fluorometer to ensure no 
further unbound ICG was present. The total volume was made up to 500 µl with PBS. 
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2.5.2.1 Pilot incubation and qualitative analysis 
LS174T colorectal cancer cells were cultured as above (section 2.5.1). Cells were 
seeded onto 35 mm glass-bottomed wells (Iwaki, Japan, two per cell line) with 2 ml of 
the appropriate media. After 24 hours the media was replaced and at 48 hours 200 
µl, 20 µl or 2 µl of 1 µg/µl ICG-anti-CEA was added to wells. As a control, I incubated 
one well of cells with free, unbound anti-CEA antibody at 480 g/ml for one hour, 
discarded the media/antibody solution, washed the cells, and replaced the media. I 
then incubated the cells with the ICG-anti-CEA conjugates at as above. The wells 
were then imaged at 1, 4, 8, 12, 16, 30 and 80 hours after the start of incubation 
using confocal microscopy and the images saved. 
2.5.2.2 Continuous incubation 
LS174T cells were grown as above. LoVo and HCT116 cells were grown in F12K 
Nutmix (Life Technologies) and RPMI1640 (Life Technologies) media respectively, 
supplemented with fetal calf serum (FCS,10%) and L-glutamine (1%) at 37°C and 
5% CO2, in T75 flasks (Corning, New York, USA) until confluent. Cells were seeded 
onto 35 mm glass-bottomed wells (Iwaki, Japan, two per cell line) with 2 ml of the 
appropriate media. After 24 hours the media was replaced and at 48 hours, for each 
cell line, 200 µl of 1 µg/µl ICG-anti-CEA was added to one well and 200 µl 1 µg/µl of 
ICG-anti-digoxin added to the other. The wells were then imaged individually at 1, 6, 
12, 24, 36 and 48 hours using confocal microscopy (maintaining 37°C and 5% CO2). 
 
For each slide, the cells were focussed in phase mode in the centre of one quadrant 
of the coverslip (Figure 2.1). The operator did not view the fluorescent image prior to 
cell selection. The Cy7 and phase filters were then selected and automatically 
calibrated for the first image capture only; the settings (such as laser power and gain) 
were then saved and used for all subsequent image capture. A phase/Cy7 z-stack 
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image (distance between stacks: 0.5 µm, 0.2 µm and 0.4 µm for LS174T, LoVo and 
HCT116 cells respectively, chosen to produce a similar number of z-stack images) 
was captured for the first quadrant. The upper and lower limits of the z-stack were set 
to ensure that the whole depth of at least one cell was included. The microscope 
stage was then moved to the next quadrant, the white light image focussed, and a z-
stack captured without the operator viewing the fluorescent image. This was 
repeated so that for each coverslip, five z-stack files were captured: an image from 
approximately the centre of each quadrant and one from the centre of the entire 
coverslip. By not examining the fluorescent image during image location selection, 
potential selection bias was removed. 
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Figure 2.1. Cell selection for fluorescence quantification. 
For each coverslip, confocal cellular images were captured from five points as 
shown. Cells were selected using white light (phase) imaging only to prevent 
selection bias. 
 
2.5.2.2.1 Image analysis 
A single slice from each z-stack was selected. This was chosen by identifying a 
distance from the base of the cells for each cell line such that the slice would always 
be approximately half way between the base and top of the cell. These distances 
were 5 µm, 1.4 µm and 4.8 µm for LS174T, LoVo and HCT116 cells respectively. 
These slices were saved as fluorescent, phase and combined ‘.tiff’ images for each 
cell analysed. LS174T cells grow as clusters so small clusters of a similar size were 
selected (mean 6 cells). Fluorescence was quantified using ImageJ software version 
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1.42q (NIH Freeware, Maryland, USA). The phases were ‘stacked’ and, using the 
phase image only (to prevent operator bias), the outer boundaries of cell membranes 
were traced using the freehand tool (Figure 2.2A). This trace was then applied to the 
fluorescent only image and the raw integrated density (RawIntDen, the sum of the 
pixel values in the selected area) and the area of the selection were recorded (Figure 
2.2 B). A background area was then selected (ie. an area with no cell fluorescence) 
and the same measurements taken (Figure 2.2 C-D). This process was repeated for 
each coverslip, for both ICG-anti-CEA and ICG-anti-digoxin, at each time point. 
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Figure 2.2. Whole cell fluorescence quantification. 
Image J was used to quantify the fluorescence seen on confocal microscopy. Phase 
and fluorescent images were stacked. The cell membrane was traced on the phase 
image (A) and measurements taken for the fluorescent image (B). A mean 
background measurement was taken (C) and subtracted from the cell measurement 
(D). 
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If the fluorescence of every cell on any given coverslip were to be measured, the 
data would most likely follow a Gaussian distribution. However, for completeness I 
treated the data as both parametric and non-parametric. The mean fluorescence was 
compared for CEA-targeted ICG and control IgG-targeted ICG in all three cell lines at 
all time points using the unpaired t-test (if the data are considered to be parametric) 
and the median fluorescence was compared using the Mann-Whitney test (if the data 
are considered to be non-parametric). 
2.5.2.3 LS174T pulse and chase incubation 
LS174T cells were grown and seeded onto two 35 mm glass-bottomed wells. The 
media was changed at 24 hours and at 48 hours 80 µl of 1 µg/µl anti-CEA-ICG was 
added to the first well and incubated for two hours. The media/antibody-ICG mixture 
was then removed and the media from the second well was added in its place. The 
well was imaged at 6, 12, 24, 36, 48 and 72 hours using the same confocal 
microscopy protocol. The same analysis as in 2.5.2.2.1 was used. 
 
 
2.6 Western Blot 
 
The three cell lines used in 2.5.2.2 have all been shown to express CEA: LS174T 
(intermediate/high expression (Fahlgren et al., 2003), LoVo (high expression (Ashraf 
et al., 2009)) and HCT116 (low expression (Wang et al., 1999)). 
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2.6.1 Protein lysate production and protein standardisation 
Protein lysate buffer was made by mixing 12.5 ml of a solution containing 5 ml of 1 M 
Tris-HCl (pH 7.4), 6 ml of 2.5 M NaCl, 1 ml of 10% NP40 (Sigma, USA) and 38 ml of 
distilled water with 12.5 ml of Complete Tabs solution (1 tablet dissolved in 12.5 ml of 
distilled water; Roche, Penzberg, Germany). LS174T, LoVo and HCT116 cells were 
grown in Advanced MEM (ATCC, Virginia, USA), F12K Nutmix (Life Technologies) 
and RPMI1640 (Life Technologies) media respectively, supplemented with FCS 
(10%) and L-glutamine (1%) at 37°C and 5% CO2 were grown in T75 flasks (Corning, 
New York, USA) until confluent. The media was removed and the cells were washed 
three times with fresh media (with no FCS added) and 2 ml of ice cold protein lysis 
buffer was added to each flask and incubated at 4°C for 10 minutes. The cells were 
then gently scraped from the plastic and each lysis buffer/cell mix was removed and 
placed in a 1.5 ml microfuge tube.  These were centrifuged at 14000 rpm for 10 
minutes at 4°C. The supernatant was then removed and stored at -80°C. 
 
The protein concentration in each supernatant was measured using the Bio-Rad DC 
protein assay (Biorad Laboratories, Hercules, USA) which is adapted from the Lowry 
assay (Lowry et al., 1951). A standard curve for bovine serum albumin (BSA) was 
prepared using concentrations of 0.1, 0.5, 1 and 2 mg/ml and 18 μl of each cell lysate 
containing equal amounts of protein was prepared for the running gel. 
 
2.6.2 Gel electrophoresis 
The LS174T, LoVo and HCT116 lysates were mixed with 6 μl of a mixture containing 
60 μl of NuPAGE LDS Sample Buffer (Invitrogen) and 12 μl of 2-mercaptoethanol. 
The samples were heated at 100˚C for five minutes and then cooled on ice prior to 
electrophoresis. A NuPage 10% Bis-Tris precast gel (1 mm, 10 lanes) was loaded 
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into a NuPage gel tank and filled with running buffer (25 ml of NuPage MOPS SDS 
running buffer + 475 ml distilled water). The gel was loaded with 20 μl of each cell 
line sample and 5 μl of SeeBlue Plus 2 molecular marker (Invitrogen). Spare lanes 
were filled with a distilled water/buffer mix. Elctrophoresis was performed at 180 V for 
90 minutes. Proteins were transferred onto a nitrocellulose membrane (Hybond P, 
G.E.Helathcare, Little Chalfont, UK). Transfer buffer was prepared by mixing 25 ml of 
NuPage 20X Transfer Buffer with 425 ml of distilled water and 50 ml of 100% 
methanol. The membrane and two pieces of 3MM filter paper (Whatman 
International, Maidstone, UK) were soaked in 100% methanol for 30 seconds, rinsed 
in running water for five minutes and soaked in transfer buffer. Sponges were soaked 
in water and then transfer buffer. The membrane was then loaded into the transfer 
module between the two pieces of filter paper with sponges placed on either side. 
Transfer buffer was added to the module so that the sponges were immersed and 
distilled water was added to the outer tank. A constant voltage of 30 V was applied 
for 1 hour. The membrane was removed and incubated with blocking buffer (5% [w/v] 
skimmed milk in TBS-T) overnight at 4˚C on a rocker. This was replaced with 1% 
[w/v] skimmed milk in TBS-T containing 1:100000 A5B7 anti-CEA antibody and 
incubated at room temperature for one hour on a rocker. The membrane was washed 
with TBS-T (3 x 10 minutes) and then incubated in 1% [w/v] skimmed milk in TBS-T 
containing 1:1000 horseradish peroxidae-conjugated goat anti-mouse secondary 
antibody (sc-2005, Santa Cruz) at room temperature for 1 hour on a rocker. 
Following further TBS-T washes (3 x 10 minutes), the membrane was covered with 3 
ml of a solution containing SuperSignal West Pico and SuperSignal West Femto 
(Thermo Scientific, Waltham, USA) mixed in a 5:1 ratio for 2 minutes. Excess fluid 
was drained from the membrane and it was then exposed to Hyperfilm (GE 
Healthcar, UK) for 1 minute. The film was developed with a Compact X2 X-Ograph 
automatic film processor (Compact, Malmesbury, UK).  
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2.7 Nanoparticles 
 
Dye-doped silica nanoparticles were manufactured using methods adapted from 
Santra et al (Santra et al., 2001), Huang et al (Huang et al., 2009) and Gubala et al 
(Gubala et al., 2010). IgG antibodies were then conjugated to the surface of the 
particles using both novel and published experimental techniques. The effectiveness 
of the linking methods was evaluated and compared in vitro by quantifying specific 
tumour cell binding using confocal microscopy. Unless otherwise stated, all 
chemicals were purchased from Sigma (Sigma Aldrich, St Louis, USA). ‘Wash’ steps 
refer to the nanoparticles being pelleted via centrifugation, resuspended in the wash 
solution using ultrasound sonication, re-pelleted with centrifugation and the 
supernatant discarded. 
 
2.7.1 Dendrimer-linked nanoparticle-IgG conjugates 
2.7.1.1 NIR664-doped silica nanoparticle manufacture 
Two batches of particles were made; one was dried overnight to calculate the yield 
for calculations in the conjugation steps. For each batch, five mg of NIR 664-
iodoacetamide dye was dissolved in 6.25 ml of 1-hexanol and 3.25 µl of (3-
mercaptopropyl) triethoxysilane, (MPTES) to give a dye:MPTES molar ratio of 1:2. 
The mixture was stirred under nitrogen gas for four hours at room temperature to 
ensure conjugation of the dye and organosilane. 
 
3.78 g (4.045 ml) of the non-ionic surfactant Triton X-100 was added to 15 ml of 
cyclohexane, 1.6 ml of 1-hexanol, 2 ml of the conjugated dye and 960 µl of distilled 
water in a plastic tube covered in aluminium foil. The mixture was stirred for five 
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minutes until a microemulsion had formed. 200 µl of tetraethyl orthosilicate (TEOS) 
was then added and the tube was stirred for 30 minutes at room temperature. 120 µl 
of ammonia hydroxide (28% [w/w]) was added as a catalyst and the mixture was 
stirred for 24 hours at room temperature. 150 µl of TEOS was then added and the 
tube contents stirred for a further 30 minutes at room temperature. 
The microemulsion was then broken by adding excess ethanol (20 ml) and the 
contents were divided into two equal volumes and added to 30 ml Corex centrifuge 
tubes (Corning). These underwent centrifugation at 11 000g for 25 minutes at room 
temperature. The liquid was discarded and the particles were resusupended in 
ethanol using sonication. The particles were washed four times in this way with 
ethanol. One of the tubes was stored at 4°C and the other left to dry out overnight so 
that the particles could be weighed and the yield calculated. 
2.7.1.2 Amination 
4 ml of 2 mg/ml nanoparticles suspended in ethanol plus 4% (3-
aminopropyl)triethoxysilane (APTES) was reacted for three hours at room 
temperature with stirring in a 15 ml Falcon tube. The contents were then transferred 
to a Corex centrifuge tube and washed twice with ethanol at 11000g for 25 minutes. 
The particles were then washed once in 2-(N-morpholino)ethanesulfonic acid (MES) 
buffer, pH 7.0 before being re-suspended in MES buffer pH 7.0 at 2 mg/ml. 
2.7.1.3 Amine quantification 
The number of free amine groups on the surface of the nanoparticles was 
determined using Fluorenylmethyloxycarbonyl chloride (Fmoc-Cl) in a method 
adapted from Chen et al (Chen and Zhang, 2011). This assay involves binding the 
fluorescent Fmoc-Cl molecule (a protecting reagent for amino groups, used in 
peptide synthesis (King et al., 1990)) to free amine groups on the silica nanoparticle 
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outer shell, cleaving them with piperidine and calculating how many amino groups 
were bound. The fluorescent core of dye-doped silica nanoparticles precludes 
common amine quantification assays (eg. 2,4,6-Trinitrobenzene sulfonic acid, 
TNBSA (Goodwin and Choi, 1970)) because it confounds the result. The 
quantification step of the Fmoc-Cl fluorescent assay takes place independently of the 
nanoparticles and therefore is ideal for particles with inherent fluorescent properties. 
A standard callibration curve of Fmoc fluorescence was created by measuring the 
fluorescence of various concentrations of Fmoc-Cl in a borate buffer (0.1 M, pH 8.0) 
containing 10% piperidine. The relationship between Fmoc-Cl and fluorescence is 
linear at concentrations below 1x10-6 mol L-1 (Chen and Zhang, 2011). The 
nanoparticles were suspended in borate buffer (0.1 M, pH 8.0) at a concentration of 
60 mg/ml. 435 µl of the particle suspension was mixed with 15 µl of Fmoc-Cl solution 
(0.01 M in acetonitrile) and incubated at room temperature for 40 minutes with 
mixing. The particles were then washed twice with 10 ml of 0.5% Tween-20 and four 
times with distilled water, until the fluorescence of the unconjugated Fmoc-Cl in the 
supernatant was approximately zero when measured on a fluorometer at an 
excitation wavelength of 267 nm. The particles were then resuspended in 450 µl of 
borate buffer and 50 µl of piperidine was added (giving a 10% piperidine solution) to 
release the Fmoc bound to the amine groups. The reaction was allowed to proceed 
for 10 minutes and then the mixture was centrifuged at 10000g for 15 minutes. The 
supernatant was removed and its fluorescence recorded at an excitation wavelength 
of 267 nm. 
2.7.1.4 Dendrimer conjugation 
41.7 mg of sulfo-NHS and 71.6 mg of N-(3-dimethylaminopropyl)-N′-
ethylcarbodiimide (EDC) were added to 1 µmol of PAMAM dendrimer generation 4.5 
(Dentritech, Midland, USA) dissolved in distilled water. The total reaction volume was 
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made up to 1 ml using MES buffer, pH 6.0. The reaction mixture was stirred at room 
temperature for 25 minutes and then added to 1 ml of 2 mg/ml nanoparticles 
suspended in MES pH 7.0. The reaction mixture was stirred at room temperature for 
25 minutes. Unbound dendrimer was removed in the supernatant after centrifugation 
(16 000g for 8 minutes) and the particles were washed twice with MES buffer pH 7.0. 
2.7.1.5 Antibody conjugation 
The reaction mixture was split into two and 10 µg of anti-CEA IgG antibody were 
added to one sample and 10 µg of anti-digoxin IgG antibody to the other. These were 
then incubated at room temperature for four hours with gentle stirring. The reaction 
was halted by the addition of 100 µl of sodium hydroxide pH 9.0. The functionalised 
nanoparticles were washed in 0.1M sodium phosphate, 0.15 M sodium chloride, pH 
7.2 (referred to hereon in as 0.1M PBS) twice (11 000g x 25 minutes) to remove 
unbound IgG antibody before being resuspended in 0.1M PBS at 2 mg/ml. 2% [w/v] 
bovine serum albumin (BSA) was added and the particles were stored at 4°C in the 
dark. 
 
2.7.2 SMCC-linked nanoparticle-IgG conjugates 
2.7.2.1 Antibody reduction 
500 µl of 4.8 mg/ml anti-CEA IgG antibody was added to 500 µl of 9.6 mg/ml 2-
mercaptoethylamine (2-MEA). The mixture was incubated at 37°C for 90 minutes and 
then cooled rapidly on ice. 2-MEA was then removed using a 100 kDa spin centrifuge 
filter (Millipore, Billerica, USA); the mixture was centrifuged in 0.1M PBS (14000g for 
2.5 minutes) and the eluent discarded. This was repeated seven times. The 
concentrated antibody solution was then retrieved by gentle centrifugation with the 
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tube inverted (1000g x 30 seconds) and 0.1M PBS was added to make the total 
volume up to 500 µl. A Dionex Ultimate 300 high pressure liguid chromatography 
system (Thermo Scientific) was used to confirm that this product contained both half 
and whole IgG molecules. The solution was reacted with the nanoparticles 
immediately. 
2.7.2.2 Nanoparticle manufacture 
Two batches of particles were made; one was dried overnight to calculate the yield. 
For each batch, 1.77 ml of triton X-100, 7.5 ml cyclohexane and 1.8 ml n-hexanol 
were added to a 50 ml Falcon tube to form a microemulsion. This was shaken until it 
was transparent. 400 µl of deionised water, 80 µl of 43 mM aqueous Ru(bpy)3
2+ 
solution and 60 µl ammonium hydroxide (28-30%) was added to the tube and it was 
stirred for 15 minutes at room temperature. 50 µl of TEOS was added and the 
reaction was stirred for a further 24 hours. Another 50 µl of TEOS was added and the 
reaction stirred for 30 minutes. 10 µl of APTES was then added and the reaction 
stirred for a further 24 hours. 10 ml of acetone was added to break the 
microemulsion. The contents were transferred to a Corex centrifugation tube and 
centrifuged at 10000g for 15 minutes. They were then resuspended in ethanol and 
washed twice with ethanol and twice with water. Finally, they were resuspended in 
0.1M PBS at a concentration of 1 mg/ml. 
2.7.2.3 SMCC reaction 
6 mg of fresh sulfo-SMCC was added to 4 ml of 1mg/ml nanoparticles and stirred at 
room temperature for 1 hour. The maleimide-activated particles were then washed 
twice in PBS (10000g x 15 minutes) to remove unbound sulfo-SMCC and 
resuspended at 2 mg/ml. The sample was split into two and 30 µg of reduced anti-
CEA or anti-digoxin was added to each tube. The reaction mixture was gently stirred 
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at room temperature for 2 hours and then washed twice with PBS (6000g x 15 
minutes). Finally, the particles were resuspended at 2 mg/ml and 0.1% [w/v] BSA 
added. The finished nanoparticles were stored in the dark at 4°C. 
 
2.7.3 Polyethylene glycol (PEG)-linked nanoparticle-IgG 
conjugates 
Antibodies were reduced as per section 2.7.2.1 and particles manufactured as per 
section 2.7.2.2. A stock solution of 250 mM NHS-PEG-Maleimide (SM(PEG))4 was 
made by dissolving 100 mg in 680 μl of dimethyl sulfoxide (DMSO). 8 µl of 250 mM 
SM(PEG)4 solution was added to 5 ml of 2 mg/ml nanoparticles and reacted for 30 
minutes at room temperature with gentle mixing. Unreacted linker was removed by 
washing the particles twice with PBS (pH 7.2, 10000g x 15 minutes) and 
resuspending them in PBS at 2mg/ml. The sample was divided into two. 30 µl of 
either anti-CEA or anti-digoxin IgG was added for each mg of nanoparticles. The 
reaction mixture was incubated at room temperature for 2 hours with gentle mixing. 
The particles were then washed twice with PBS and resuspended at 2 mg/ml. 0.1% 
[w/v] BSA was added and they were stored in the dark at 4°C. 
 
2.7.4 EDC-linked nanoparticle-IgG conjugates 
Nanoparticles were manufactured as per section 2.7.2.2. 
2.7.4.1 Carboxylation 
The nanoparticles were washed twice in DMF (10000g x 15 minutes). They were 
then resuspended at 1 mg/ml in 15 ml of 10% succinic anhydride dissolved in DMF. 
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They were reacted under argon gas at room temperature for 4 hours with gentle 
stirring. The carboxylated particles were then washed three times with distilled water. 
2.7.4.2 EDC conjugation 
10mg of carboxylated nanoparticles were suspended in 5 ml of 0.1M MES, 0.5M 
NaCl, pH 6.0 and 1.92 mg of EDC and 5.43 mg of sulfo-NHS were added. They were 
reacted for 15 minutes at room temperature with gentle mixing, after which the 
reaction was quenched by the addition of 20mM 2-MEA. Excess reactants were 
removed by washing the particles twice with PBS (6000g x 10 minutes) and 
resuspended at 2 mg/ml in 0.1M PBS. 10 µg of either anti-CEA or anti-digoxin IgG 
was added for each mg of nanoparticles. The reaction mixture was incubated at room 
temperature for 2 hours with gentle mixing. The particles were then washed twice 
with PBS and resuspended at 2 mg/ml. 0.1% [w/v] BSA was added and they were 
stored in the dark at 4°C. 
 
2.7.5 Nanoparticle in vitro assay 
2.7.5.1 Cell lines 
LS174T, LoVo and HCT116 cells were grown as described previously. Each cell line 
was seeded onto three sterile glass coverslips (Cellpath, Newtown Powys, UK) in a 
six-well plate (Corning) and grown for 24 hours. The media was then removed and 
the cells washed twice with PBS. They were fixed by adding paraformaldehyde (4%) 
and incubated at room temperature for 30 minutes. The paraformaldehyde was 
removed and they were washed thrice with PBS. Bovine serum albumin (BSA, 0.1% 
[w/v], (EMD chemicals, San Diego, USA)) was added to each well for 30 minutes at 
room temperature to block non-specific binding. The BSA was removed and the cells 
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were washed three times with PBS. Anti-CEA conjugated nanoparticles and control 
IgG nanoparticles (suspended in PBS at 1 mg/ml) were added to the wells and 
incubated at room temperature in the dark. After one hour the particle suspension 
was removed and the cells washed three times with PBS. The coverslips were then 
mounted onto glass slides using Depex (Waltham, Massachusettes, USA) and left 
overnight to cure before being stored at 4°C in the dark. 
2.7.5.2 Confocal microscopy 
A Nikon A1R-A1 confocal microscope (Nikon, Tokyo, Japan) with NHS Elements 
software (version 4.0) was used for all imaging. For each slide, the cells were 
focussed in phase mode in the centre of one quadrant of the coverslip. The Cy7 and 
phase filters were selected and automatically calibrated for the first image capture 
only; the settings (such as laser power and gain) were then saved and used for all 
subsequent image capture. A phase/Cy7 z-stack image (distance between stacks: 
0.5 µm, 0.2 µm and 0.4 µm for LS174T, LoVo and HCT116 cells respectively, chosen 
to produce a similar number of z-stack images) was captured for the first quadrant. 
The upper and lower limits of the z-stack were set to ensure that the whole depth of 
at least one cell was included. The microscope stage was then moved to the next 
quadrant, the white light image focussed, and a z-stack captured. This was repeated 
so that for each coverslip, five z-stack files were captured: an image from 
approximately the centre of each quadrant and one from the centre of the entire 
coverslip. By not examining the fluorescent image during image location selection, 
potential selection bias was removed. 
2.7.5.3 Nanoparticle image analysis: single z-stack slice 
Two analyses were employed to measure the fluorescence of the cells. Firstly, a 
single slice from each z-stack was selected. This was chosen by identifying a 
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distance from the base of the cells for each cell line such that the slice would always 
be approximately half way between the base and top of the cell. These distances 
were 5 µm, 1.4 µm and 4.8 µm for LS174T, LoVo and HCT116 cells respectively. 
These slices were saved as fluorescent, phase and combined ‘.tiff’ images for each 
cell analysed. LS174T cells grow as clusters so small clusters of a similar size were 
selected (mean 6 cells). Fluorescence was quantified using ImageJ software version 
1.42q (NIH Freeware, Maryland, USA). The distance per pixel was measured using 
the scale bar on the image to allow fluorescence measurments to be calibrated to the 
cell size. Using the phase image, the inner and outer boundaries of the cell 
membrane were traced using the freehand tool. This trace was then applied to the 
fluorescent only image and the raw integrated density (RawIntDen, the sum of the 
pixel values in the selected area) and the area of the selection were recorded (). A 
background area was then selected (ie. an area with no cell fluorescence) and the 
same measurements taken. 
 
 
Figure 2.3. Membrane fluorescence quantification. 
To quantify the fluorescence on confocal microscope images, I traced around the cell 
membrane (left) of the phase image, applied the trace to the fluorescent image only 
(middle) and took a measurement. I then subtracted the mean background 
fluorescence (right). 
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Finally, the circumference of the cell in question was measured. A fluorescence value 
per µm of membrane for the image was calculated as follows: 
 
𝑀𝑒𝑚𝑏𝑟𝑎𝑛𝑐𝑒 𝑓𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑐𝑒 𝑝𝑒𝑟 µ𝑚
= 
{
 
 𝑅𝑎𝑤𝐼𝑛𝑡𝐷𝑒𝑛𝑚𝑒𝑚𝑏𝑟𝑎𝑛𝑒 − [(
𝑅𝑎𝑤𝐼𝑛𝑡𝐷𝑒𝑛𝑏𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑
𝐴𝑟𝑒𝑎𝑏𝑎𝑐𝑔𝑟𝑜𝑢𝑛𝑑
) × 𝐴𝑟𝑒𝑎𝑚𝑒𝑚𝑏𝑟𝑎𝑛𝑒] 
𝐶𝑖𝑟𝑐𝑢𝑚𝑓𝑒𝑟𝑒𝑛𝑐𝑒
}
 
 
 
This procedure was followed for five z-stacks per cell line, in all three cell lines and 
for test and control particles in each case, yielding 30 measurements per conjugation 
method. 
2.7.5.4 Nanoparticle image analysis: maximum image projection 
The second image analysis utilised the maximum image projection (MIP) function in 
NHS Elements software. This function analyses all of the z-stack images and 
constructs a new single image by taking the brightest pixel from all of the z-stacks. It 
should be noted that this is not a true cumulative image as a saturated bright pixel 
cannot be made any brighter. It therefore dampens down the overall fluorescence but 
can be used to verify the results of the single z-stack slice analysis. To analyse the 
MIP images, the entire cell or cell cluster was traced, including the cell cytoplasm, 
and the RawIntDen and area were measured. A background measurement was 
taken as above and the following formula used to calculate the fluorescence: 
 
𝑀𝑒𝑎𝑛 𝑐𝑒𝑙𝑙 𝑓𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑐𝑒 = (
𝑅𝑎𝑤𝐼𝑛𝑡𝐷𝑒𝑛𝑐𝑒𝑙𝑙
𝐴𝑟𝑒𝑎𝑐𝑒𝑙𝑙
) − (
𝑅𝑎𝑤𝐼𝑛𝑡𝐷𝑒𝑛𝑏𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑
𝐴𝑟𝑒𝑎𝑏𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑
) 
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2.7.5.5 Image analysis: statistical methods 
The mean fluorescence and standard error was compared for CEA-targeted 
nanoparticles and control IgG-targeted nanoparticles for each conjugation method in 
all three cell lines using the both unpaired t-test (if the data are considered to be 
parametric) and the Mann-Whitney test (if the data are considered to be non-
parametric). 
 
2.7.6 Nanoparticle Characterisation 
The size of the nanoparticles was measured using a Zetasizer (Malvern Instruments, 
Malver, UK), Nanosight (Nanosight, Amesbury, UK) and field emission gun scanning 
electron microscopy (FEG-SEM, LEO 1530 Gemini FEGSEM fitted with an Oxford 
Instruments 80 mm X-Max SDD detector, Carl Zeiss). 
 
 
2.8 Animal model 
 
All procedures were approved and licensed by the Home Office and carried out in 
accordance with the local ethical review committee. All reasonable efforts were made 
to minimise any likely suffering and the animals were inspected daily by a qualified 
technician. The animals were weighed and the tumour dimensions measured twice 
per week. Nine 4 to 6 week old BALB/c nu/nu female mice were injected 
subcutaneously with 1.5 x 106 LS174T cells to the right flank. When the tumours 
reached approximately 8-10 mm in diameter (approximately 12 days), the mice were 
imaged using an IVIS small animal molecular imaging system (Perkin Elmer, 
Waltham, USA) with excitation and emission filters set at 672 and 694 nm 
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respectively). As a pilot experiment, three mice were injected with CEA-targeted 
nanoparticles via the tail vein and images taken at various time points, comparing 
them to a control mouse that had not undergone injection. Mice were sacrificed under 
anaesthesia and sample organs were imaged ex vivo. In a second experiment, four 
mice were injected with CEA-targeted nanoparticle and three were injected with 
digoxin-targeted nanoparticles via the tail vein (suspended in 100 μl of PBS, dose 50 
mg/kg). The mice were imaged at 1 minute, 1 hour, 6 hours, 24 hours, 36 hours, 48 
hours and 72 hours post injection. The animals were then sacrificed under 
anaesthesia. Fluorescence measurements were taken using Living Image (version 
4.3.1, Caliper Life Sciences, Massachusetts, USA). The tumour was traced as a 
‘region of interest’ and a mean quantum efficiency measurement taken. A second 
region of interest was drawn on the opposite flank and another mean quantum 
efficiency measurement taken (background fluorescence) and subtracted from the 
tumour measurement. 
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Chapter Three 
 
 
Carcinoembryonic antigen is the 
preferred biomarker for in vivo 
colorectal cancer targeting 
 
 
 
 
Some of the text and figures in this chapter have been published in the manuscript 
“Carcinoembryonic antigen (CEA) is the preferred biomarker for in vivo colorectal 
cancer targeting” (British Journal of Cancer 2013; 108(3):662-7) and reproduced here 
with permission. 
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3 CARCINOEMBRYONIC ANTIGEN IS THE 
PREFERRED BIOMARKER FOR IN VIVO 
COLORECTAL CANCER TARGETING 
 
 
3.1 Abstract 
 
Background 
Colorectal cancer-specific biomarkers have been used as molecular targets for 
fluorescent intra-operative imaging, targeted PET/MRI, and selective cytotoxic drug 
delivery, yet the selection of the biomarkers used is rarely evidence-based. We 
aimed to assess which of the four most commonly used potential biomarkers is most 
suitable.  
 
Methods 
Expression of carcinoembryonic antigen (CEA), tumour-associated glycoprotein-72 
(TAG-72), folate receptor alpha (FRα) and endothelial growth factor receptor 
(EGFR).was evaluated semi-quantitatively in matched mucosal and colorectal cancer 
tissues from 280 patients using immunohistochemistry (scores of 0-15). Matched 
positive and negative lymph nodes from 18 patients were also examined. 
Sensitivities and specificites in terms of colorectal cancer detection over normal 
tissue were determined for each marker. 
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Results 
Markers were more highly expressed in tumour tissue than in matched normal tissue 
in 98.8%, 79.0%, 37.1% and 32.8% of cases for CEA, TAG-72, FRα and EGFR 
respectively. CEA showed the greatest differential expression, with tumours scoring a 
mean of 10.8 points higher than normal tissues (95% CI 10.31-11.21, p<0.001). 
Similarly, CEA showed the greatest differential expression between positive and 
negative lymph nodes. Receiver operating characteristic analyses showed CEA to 
have the best sensitivity (93.7%) and specificity (96.1%) for colorectal cancer 
detection. 
 
Conclusion 
CEA has the greatest potential to allow highly specific tumour imaging and drug 
delivery; future translational research should aim to exploit this. 
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3.2 Introduction 
 
Intra-operative tumour visualisation would allow localisation of small tumours and the 
nodal status of a colorectal cancer to be determined in real-time, allowing 
stratification of resection type (as discussed in detail in section 1.1).  
 
One way of achieving intra-operative tumour detection and staging is to target a 
tumour-specific biomarker using antibodies. This biomarker target must have a 
number of specific characteristics: it must be located on the tumour cell membrane to 
allow systemic delivery; it must be highly expressed in a large majority of tumours; 
and it must have low or no expression in normal tissue, encompassing the normal 
tissue from which the tumour is derived and – ideally – most or all normal adult 
tissues accessible by systemic delivery. Experimental work to date has relied mainly 
on antibodies directed at the cell membrane proteins carcinoembryonic antigen 
(CEA), tumour-associated glycoprotein 72 (TAG-72), folate receptor  (FRα) or 
epithelial growth receptor (EGFR): Mugurama et al conjugated anti-CEA antibodies 
to a near-infrared dye and used it to label colonic cancer cells in paraffin sections 
with the aim of developing an endoscopic visualisation system (Muguruma et al., 
1999); Zou et al conjugated anti-TAG-72 antibodies to a near-infrared dye and 
injected them into tumour-bearing mice (Zou et al., 2009); Goetz et al and Chen et al 
used fluorescently labelled anti-EGFR and anti-folate receptor antibodes respectively 
for endoscopic adenoma detection in mouse models (Goetz et al., 2010, Chen et al., 
2005). Surprisingly, given the dependency on accurate biomarker localisation, the 
selection of the markers used for tumour-targeting is rarely justified based on their 
sensitivity or specificity. One would not contemplate using a marker giving poor 
specificity and sensitivity in routine laboratory analysis, and the same stringent 
criteria should therefore apply to in vivo tumour identification. In order to determine 
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the suitability of each of my potential antigens for use as tumour-specific markers I 
first aimed to determine the expression frequency and levels of each antigen in a 
large set of colorectal tumours and matched normal tissues. Only antigens expressed 
in a relatively large proportion of tumours, and expressed infrequently or at low levels 
in normal tissues would be suitable. 
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3.3 Results 
 
3.3.1 Selection of potential colorectal cancer-specific 
biomarkers and optimisation of antibodies for their 
analysis 
Initially I performed a detailed literature search to identify potential suitable 
biomarkers with the characteristic outlined above. I established a panel of seven 
potential target antigens: carcinoembryonic antigen (CEA), tumour-associated 
glycoprotein 72 (TAG-72), folate receptor alpha (FR), epidermal growth factor 
receptor (EGFR), VEGFR-2, roundabout protein 1 (ROBO1) and endoglin (CD105). 
CEA, TAG-72, FR and EGFR were all described in Chapter 1. VEGFR-2 is a 
tyrosine kinase receptor for VEGF-A, C, D and E, which are signalling proteins 
produced in response to hypoxia and that stimulate angiogenesis. Some 40-100% of 
colorectal cancers are thought to express VEGFR-2 (Duff et al., 2006, Hanrahan et 
al., 2003, Schimanski et al., 2010a, Amaya et al., 1997). Roundabout protein 1 
(ROBO1) is a transmembrane receptor involved in tumour angiogenesis (Wang et al., 
2003) that is upregulated in colorectal tumour cells and endothelial cells of tumour 
vessels compared with normal cells (Grone et al., 2006). Endoglin (CD105) is a 
protein expressed by angiogenic endothelial cells and is up-regulated in response to 
hypoxia (Sánchez-Elsner et al., 2002). It is also up-regulated in a range of tumour 
endothelial cells including those of the colon (Burrows et al., 1995, Bellone et al., 
2010). 
 
Antibodies to each antigen were selected by ensuring that they had been used in 
peer-reviewed publications for colorectal cancer cell recognition. I had access to an 
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anti-CEA antibody produced in-house by a Cancer Research UK-funded research 
group in London that had been used in clinical trials for CEA targeting. To check its 
performance I also used a commercially available anti-CEA antibody.  
 
I used 13 specimens of formalin-fixed, paraffin-embedded colorectal cancer of 
various grades and one sample of normal colonic tissue to optimise antibody 
concentrations and experimental conditions for definitive immunohistochemical 
analysis. I varied antibody concentration, antigen retrieval method and primary 
antibody incubation conditions for each biomarker target to give a broad range of 
epithelial staining intensities with minimal background staining (Table 3.1).  A5B7 
anti-CEA performed equally well as a commercially available, validated anti-CEA 
antibody (Figure 3.1) and I therefore chose to use this for future work because it is 
humanised and has been successfully used in both animal models and clinical trials 
(Dearling et al., 2009, Meyer et al., 2009, Rajkumar et al., 2012). Antibodies to 
VEGFR2 and robo1 produced no tumour-specific staining on colorectal cancer 
specimens despite employing extensive optimisation techniques and were therefore 
not evaluated further. Antibodies to CEA, TAG-72, EGFR and FR produced tumour-
specific staining with little or no stromal or non-cancerous epithelial cell staining. Anti-
CD105 strongly stained vessels adjacent to tumour samples with some mild tumour 
staining. However, the vascular density in the tumour specimens and the epithelial 
cell staining were markedly variable between specimens (Figure 3.2). Although a 
nanoparticle delivered systemically would potentially bind to the endothelium of neo-
vascularised regions of a tumour, this wide variability limits the potential of CD105 as 
the sole target of a tumour-specific imaging system. Furthermore, to ascertain the 
true endothelial and epithelial expression profile of CD105 in colorectal cancer, I 
would require whole tumour blocks and dual staining for endothelial cells. I intended 
to use tissue micro-arrays of colorectal cancer and matched normal samples, which 
would not be suitable for this.  
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I concluded that the biomarker targets most likely to allow differentiation of tumour 
from normal tissue were CEA, TAG-72, EGFR and FR, and selected these for 
evaluation using a large cohort of matched tumour and normal tissue samples. 
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Antibody 
Concentrations 
tested 
Optimised 
concentration 
Antigen 
retrieval 
methods 
Chosen 
antigen 
retrieval 
method 
Antibody 
incubation 
Anti-CEA 
(Dako) 
1:50, 1:100, 
1:200 
1:100 
Heat retrieval 
No retrieval 
No retrieval 1 hour room temp 
Anti-CEA 
(A5B7) 
1:1, 1:100, 
1:200, 1:400, 
1:800, 1:1200, 
1:1600, 1:2000, 
1:5000, 
1:20000, 
1:100000, 
1:150000, 
1:200000 
1:150 000 
Heat retrieval 
No retrieval 
No retrieval 1 hour room temp 
Anti-TAG-
72 
1:100, 1:125, 
1:150, 1:200, 
1:400 
1:100 
Heat retrieval 
No retrival 
No retrieval 1 hour room temp 
Anti-
VEGR2 
1:50, 1:150, 
1:300 
N/A 
Heat retrieval 
No retrieval 
Proteinase K 
Casein block 
N/A N/A 
Anti-folate 
receptor α 
1:25, 1:50, 1:75 1:50 
Heat retrieval 
No retrieval 
Proteinase K 1 hour room temp 
Anti-robo1 
1:50, 1:250, 
1:500 
N/A 
Heat retrieval 
No retrieval 
Proteinase K 
Casein block 
N/A N/A 
Anti-
CD105 
1:20, 1:50, 
1:100 
1:20 
Heat retrieval 
No retrieval 
Proteinase K 
Proteinase K Overnight 4ºC 
Table 3.1. Antibody optimisation. 
Antibodies to each antigen were optimised for immunohistochemistry using 
specimens of formalin-fixed, paraffin-embedded colorectal cancer and normal tissue. 
Concentration, retrieval method and antibody incubation conditions were 
independently varied for each. 
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Figure 3.1. Anti-CEA antibody comparison. 
A5B7 anti-CEA produced immunostaining of a similar intensity and distribution to that 
of a commercially available, validated anti-CEA antibody (Dako, USA). Formalin-
fixed, paraffin-embedded colorectal cancer were stained for CEA using each 
antibody under optimised immunohistochemistry conditions. The staining observed 
was diffuse with marked luminal accentuation in both. T = tumour, S = stroma. 
Concentrations 1:100 (Dako) and 1:200000 (A5B7), magnification X20. Scale bar = 
100 m. 
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Figure 3.2. CD105 staining. 
CD105 endothelial cell and malignant epithelial cell immunostaining varies between 
specimens. Slides were stained for CD105 expression using immunohistochemistry. 
1: mild endothelial (E) and tumour cell (T) staining. 2: Moderate endothelial cell (E) 
and mild tumour cell (T) staining. 3: Strong endothelial cell (E) and tumour cell (T) 
staining. Concentration 1:25, magnification X10 (1&2) and x40 (3).  
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3.3.2 Expression of selected biomarkers in 280 matched 
normal and tumour tissue samples 
Having selected four biomarker targets with the potential to allow tumour-specific 
targeting, I aimed to use a large cohort of matched normal and tumour tissue 
samples to examine the expression of each. To do this I used the optimised 
immunohistochemistry protocols from 3.3.1 and pre-existing tissue micro-arrays 
containing three tumour samples and three matched normal colonic mucosa samples 
from 280 patients with colorectal cancer. Clinicopathological data for this cohort are 
shown in Table 3.2. Carcinoembryonic antigen, TAG-72 and EGFR showed 
predominantly membranous staining with mild cytoplasmic staining while FR 
showed cytoplasmic staining only. Representative images of staining for each 
antigen in both normal and tumour tissues are shown in Figure 3.3. 
Carcinoembryonic antigen and TAG-72 were scored for apical membranous staining 
only. Folate receptor α showed mild cytoplasmic staining only, and was scored solely 
for this. EGFR showed membranous, and – more rarely - cytoplasmic and nuclear 
staining. However, following established literature (Buckley and Kakar, 2007, 
Scartozzi et al., 2004) EGFR was scored for membranous expression only. 
Immunostaining was assessed semi-quantitatively using a bespoke scoring system 
that assessed both the intensity of staining and the number of cells stained. I initially 
tested two scoring systems using TMAs stained for CEA: a system based on that 
described by Allred et al (Allred et al., 1993), where scores for staining intensity and 
number of cells stained are added, and one based on the Histoscore system 
(McCarty et al., 1986), where they are multiplied (Figure 3.4). No staining for any 
marker was noted in blood cells within the sections, suggesting that expression in 
this compartment is negligible. A pathologist scored a sample representing 15% of 
cases. The intraclass correlation coefficient was 0.89, demonstrating good 
agreement between scorers.  
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Characteristic 
 
Number of cases (%) 
n=280 
 
 
Age range: 33-93 years  
Mean age: 68.9 years 
 
 
Male 144 (51.4) 
Female 136 (48.6) 
pT stage 1 10 (3.6) 
  2 54 (19.3) 
  3 161 (57.5) 
  4 52 (18.6) 
  Unknown 3 (1.1) 
Table 3.2. Clinico-pathological details of patient cohort. 
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Figure 3.3. CEA, TAG-72, EGFR and FR expression in tumour and normal 
tissue. 
Representative tumour tissue microarray (TMA) cores of normal colorectal tissue (top 
row) or colorectal tumours (bottom row) showing immunoreactivity as labelled. Tissue 
microarrays containing tumour and matched normal tissue from 280 colorectal 
cancer patients were stained using immunohistochemistry for CEA, TAG-72, EGFR 
and FR. The normal tissue cores shown demonstrate the median score for that 
antigen in normal colorectal tissues (CEA = 1; TAG-72: = 2; EGFR: = 0; FRα: = 0). 
The tumour cores shown demonstrate the median positive score for that antigen in 
colorectal tumours (CEA = 15; TAG-72 = 10; EGFR = 2; FRα = 1). Nikon Eclipse 
E1000, Japan, 20X magnification. Scale bar = 100 µm. 
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Figure 3.4. Allred versus modified Histoscore scoring results. 
Comparison of two semi-quantitative scoring systems for assessing CEA expression 
in matched normal and colorectal tumour tissue. The Allred method produces a 
higher proportion of ‘high’ scoring tumours. ‘Low’ = lower third of scoring range, 
‘moderate’ = middle third and ‘high’ = upper third. 
 
 
Both the proportion of epithelial cells staining positively and the intensity of staining 
varied widely throughout the cohort in normal and tumour tissues (Figure 3.5). 
Strongly positive staining in normal tissues was relatively uncommon for all antigens, 
especially for FRα (negative in over 99% at the concentrations used). In the tumours, 
by contrast, strongly positive staining was prevalent for CEA and TAG-72, and was 
more common for FRα than in normal tissue although tumours were also mostly 
negative (61%). EGFR staining in tumours showed a similar range of scores to those 
in normal tissues. CEA, TAG-72 and FR, but not EGFR, were significantly more 
highly expressed in colorectal tumour tissues than in the normal tissues (p<0.001; 
Table 3.3). 
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Figure 3.5. Biomarker expression in matched tumour and normal tissue. 
Expression levels of CEA TAG-72, EGFR and FRα in normal colorectal tissue (left) 
and in colorectal tumours (right). Expression levels were determined by 
immunohistochemistry using a score of 0 to 15 in 280 matched normal and tumour 
tissues. The scores for each marker are arranged independently in ascending order 
to demonstrate the distributions across the cohort. 
 
 
Antigen 
Mean normal 
score 
Mean tumour 
score 
p value 
CEA 1.7 12.4 <0.001 
TAG-72 2.7 7.8 <0.001 
FRα 0.0 0.7 <0.001 
EGFR 0.9 1.3 0.08 
Table 3.3. CEA, TAG-72 and FR are significantly more highly expressed in 
colorectal tumour tissue than matched normal tissue. 
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3.3.2.1 Differential expression between matched normal and tumour tissue 
If markers are to be used for tumour-specific imaging, the frequency and the 
magnitude of increased expression in tumours are key parameters. The frequency of 
increased expression compared to normal tissue dictates the sensitivity of a 
biomarker-dependent, tumour-specific imaging system. Expression scores were 
higher in tumours as compared to matched normal tissues in 98.8%, 79.0%, 37.1% 
and 32.8% of cases for CEA, TAG-72, FRα and EGFR respectively. Although this 
percentage is relatively low for FRα it should be noted that expression was higher in 
tumours as compared to matched normal tissue in almost all cases where positive 
staining was detected in either tissue. However in the case of EGFR, expression was 
higher in normal tissue (34% of cases) more frequently than in tumours (33% of 
cases) indicating little or no bias for tumour-specific expression. I have estimated the 
magnitude of the differences in expression between matched tumour and normal 
tissues as the tumour expression score minus the normal expression score (Figure 
3.6). CEA demonstrated the greatest difference in expression, with tumours scoring 
on average 10.8 (95% confidence interval 10.31-11.21) points higher than normal 
tissues. This difference was more than twice that of the next best marker, TAG-72, 
which showed tumour expression to be 5.1 (95% CI 4.35-5.77) points higher than 
normal tissue. Epithelial growth factor receptor and FRα showed a much smaller 
difference of 0.4 (95% CI 0.09-0.79) and 0.7 points (95% CI 0.49-.086) respectively. 
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Figure 3.6. Differential expression for each biomarker.. 
CEA shows the most consistent over-expression in tumour tissues and the greatest 
differential expression between matched normal and tumour tissues. Expression 
scores for normal tissues were subtracted from those for matched tumour tissues to 
quantify the degree of tumour over-expression for each case. Over-expression 
scores for each marker are arranged in ascending order to demonstrate the 
distributions across the cohort (left). Minus scores reflect cases where tumour 
expression was lower than expression in the matched normal tissue. Mean over-
expression scores (central marker) with 95% confidence intervals (error bars) are 
also shown (right). 
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3.3.3 Specificity and sensitivity of selected biomarkers for 
tumour detection 
Accurate imaging of tumours based on the expression of any marker is heavily 
influenced by the limit of detection of the imaging system for marker expression. In a 
fluorescent imaging system, I foresee the gain being adjusted to calibrate the lowest 
limit of detection and prevent normal tissues producing a signal. I modelled this 
influence for each marker by examining what proportion of tumours would be 
successfully visualised when different expression scores were defined as the limit of 
detection; this is the sensitivity. I also tested what proportion of normal tissues would 
be “invisible”, as required for tumour-specific imaging, using the same limits; this is 
the specificity. First, I arbitrarily set this cut-off point as the 95th percentile of the 
normal score distribution, thereby tolerating a 5% chance of incorrectly detecting 
normal tissue as positive (a specificity of 95%). This cut-off gave sensitivities of 
93.7%, 45.4%, 39.3% and 11.8% for CEA, TAG-72, FRα and EGFR respectively. An 
alternative approach is to use statistical techniques to identify a cut-off for each 
marker that allows the maximum sensitivity and specificity. A receiver operating 
characteristics (ROC) graph allows a visual and numerical assessment of the 
performance of a classifier (Fawcett, 2006, Zweig and Campbell, 1993), in my case 
the ability of a biomarker expression score to discriminate between tumour and 
normal tissue. I produced ROC curves for each biomarker and calculated the ‘area 
under the curve’ for each (Figure 3.7 and Table 3.4). CEA performed particularly well, 
with the AUC approaching 1, whereas EGFR was little better than chance alone, with 
an AUC approaching 0.5. The second best performing biomarker was TAG-72 with 
an AUC of 0.795 followed by FR with 0.695. 
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Figure 3.7. Receiver operating characteristic curve for CEA, TAG-72, EGFR and 
FR. 
CEA performs well in discriminating between tumour and normal tissue (greatest 
area under the curve, AUC); EGFR performs poorly. 
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Biomarker 
Area under the 
curve 
Sensitivity Specificity 
CEA 0.988 93.7 96.1 
TAG-72 0.795 70.3 78.5 
EGFR 0.527 39.3 99.2 
FR 0.695 21.7 90.5 
Table 3.4. Peak sensitivity and specificity for each biomarker. 
CEA out-performed other markers, with a superior area under the curve on receiver 
operator characteristic analysis, sensitivity and specificity. 
 
 
In addition to AUC values, I was interested in the sensitivity and specificity of each 
biomarker. Using the data outputs of the ROC analysis, I added the sensitivity and 
specificity for each cut-off point and plotted the results (Figure 3.8). The calculated 
optimal cut-off values were: CEA, 6.42; TAG-72, 4.42; EGFR, 2.17; and FRα, 0. 
These cut-offs gave sensitivities and specificities of 93.7% and 96.1% for CEA, 
70.3% and 78.5% for TAG-72, 39.3% and 99.2% for FRα, and 21.7% and 90.5% for 
EGFR. 
 
I concluded that, of the biomarkers tested, CEA is the best performing for tumour 
discrimination in formalin-fixed, paraffin-embedded tissue: it shows the most 
consistent over-expression in colorectal cancer; it shows the greatest differential 
expression between normal and matched tumour tissue; and it has the greatest AUC 
and sensitivity and specificity on ROC analysis.  
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Figure 3.8. Optimum cut-off scores. 
Optimum cut-off values were calculated for each marker by testing multiple cut-off 
points and selecting the value with the greatest combined sensitivity and specificity. 
Calculated optimal cut-off values: CEA, 6.42; TAG-72, 4.42; EGFR, 2.17; FRα, 0. 
 
 
3.3.4 Expression of selected biomarkers in 18 matched 
normal and metastatic mesenteric lymph nodes. 
For intra-operative staging of colorectal cancer to be possible, the status of 
mesenteric lymph nodes adjacent to primary tumours must be determined. Therefore 
biomarker expression of both tumour cells in positive lymph nodes and of normal 
lymph node cells are critical. I aimed to evaluate whether the biomarker expression 
patterns I observed in primary tumours is similar in lymph node metastases. To do 
 103 
this I examined the expression of each biomarker in lymph nodes taken during 
resection from patients from my cohort, using the same immunohistochemistry 
protocols as above. I had access to the tissue from 18 patients. In each case, I 
examined a node found to contain metastatic tumour cells (“positive”) and a node 
that was clear of metastatic deposits (“negative”) (Figure 3.9). Expression of all 
markers followed the same pattern as in primary tumours, and was uncommon in 
negative nodes; TAG-72 showed the most staining in negative nodes, being 
expressed at low levels by cells in the germinal centres in 5 out of 18 cases (Figure 
3.10), a feature previously described (Marianicostantini et al., 1991). 
Carcinoembryonic antigen also showed very slight germinal centre expression in two 
of 18 cases, also previously described (Potomski et al., 1979). Carcinoembryonic 
antigen was expressed in all positive nodes, with high scores in the majority (Figure 
3.11). The distributions of expression in positive nodes were similar to the patterns 
seen in primary tumours, with prevalent and strong expression of CEA and TAG-72 
and less frequent and weaker expression of FRα and EGFR. 
 
I concluded that, in this small cohort of samples, the expression of all four biomarkers 
in metastatic and normal lymph nodes appears similar to the patterns seen in primary 
tumours and normal colorectal mucosa. 
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Figure 3.9. Biomaker expression in lymph nodes. 
Biomarker expression is similar in lymph nodes to primary tumours. Expression 
levels of CEA, TAG-72, EGFR or FRα in lymph nodes containing colorectal tumour 
deposits (“positive”; right) and in matched lymph nodes lacking tumour cells 
(“negative”; left). Expression levels were determined by immunohistochemistry using 
scores of 0 to 15 in 18 cases. The scores for each marker are arranged 
independently in ascending order to demonstrate the distributions across the cohort 
(note: data points are linked by lines to aid interpretation of the distributions not to 
imply adjacent data points are directly related). 
 
  
 105 
 
Figure 3.10. Non-specific staining in normal lymph nodes. 
Lymph nodes containing no metastases showed moderate positive staining in the 
germinal centres when incubated with anti-TAG-72 antibodies. Concentration 1:100, 
magnification X20. 
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Figure 3.11. Tumour specific expression in lymph nodes. 
Metastatic deposits in lymph nodes stained heavily when incubated with anti-CEA 
antibodies. Tumour-specific staining was present in all 18 positive lymph nodes 
examined and showed a similar pattern of luminal accentuation to that seen in 
corresponding primary tumours. Concentration 1:200000, magnification X20. 
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3.4 Discussion 
 
I have shown that CEA is the best performing biomarker for colorectal cancer-specific 
targeting, with consistent over-expression in tumour tissue, a high differential 
expression between normal and matched tumour tissue, and very high sensitivity and 
specificity values on ROC analysis. 
 
I sought to examine the expression of a panel of membrane-bound colorectal cancer 
biomarkers in a large cohort of matched normal and tumour tissue using 
immunohistochemistry to determine their potential for use in my project. My first step 
was to use a small sample of formalin-fixed, paraffin-embedded colorectal cancer 
samples and one normal colonic sample to test for tumour-specific immunostaining 
and to optimise immunohistochemistry experimental conditions. CEA, TAG-72, 
EGFR and FR have all been used in experimental colorectal cancer targeting 
studies (section 3.2) and were therefore obvious choices for inclusion in this work. 
Antibodies to these biomarkers all showed tumour-specific immunostaining and were 
selected for evaluation using TMAs. I also included three further biomarkers in this 
initial phase: VEGFR-2, robo1 and CD105. VEGFR- 2 is an established therapeutic 
target for metastatic colorectal cancer (Winder and Lenz, 2010, Duff et al., 2006, 
Tonra et al., 2006, Giantonio et al., 2007) and has been used for in vivo imaging of 
gastrointestinal tract tumours in murine models (Foersch et al., 2010). Most work has 
concentrated on its expression by endothelial cells but there is some evidence that it 
is also expressed by colorectal cancer cells (Hanrahan et al., 2003). Despite varying 
the antibody concentration, incubation conditions and antigen retrieval methods, I 
failed to demonstrate any tumour cell specific staining during my optimisation 
process. The evidence for epithelial cell expression is limited to a few studies with 
small sample sizes that have focussed on endothelial cell expression (Amaya et al., 
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1997, Duff et al., 2006, Hanrahan et al., 2003). Similarly, robo1 is thought to be 
upregulated in both colorectal tumour cells and endothelial cells of tumour vessels 
compared with normal cells (Wang et al., 2003, Grone et al., 2006), potentially 
allowing specific binding in two compartments. The evidence for expression in either 
compartment is limited and, as with VEGFR-2, I failed to demonstrate any tumour-
specific staining. Endoglin, also known as CD105, is up regulated in colon cancer 
endothelial cells and one study has also reported upregulation in colorectal cancer 
nodal metastases (Clasper et al., 2008). It showed marked variability in expression in 
both malignant epithelial cells and endothelial cells. I considered this unsuitable as 
the sole targeting component of a nanoparticle-based imaging system but it holds 
promise as a secondary targeting antibody; it is conceivable that it could improve the 
cancer-recognition performance of a nanoparticle with a more appropriate principle 
targeting antibody such as anti-CEA. Although my antibody optimisation experiments 
utilised just 14 colorectal cancer samples, the other four biomarkers all showed far 
greater potential and I therefore decided to concentrate on them for the TMA work. 
 
Immunohistochemistry is a relatively simple, established technique for examining the 
expression of various antigens in human tissue. However, measuring and comparing 
this expression is challenging due to the subjective assessment of the staining it 
produces. Investigators have used a variety of subtly different scoring systems when 
assessing protein expression in TMAs. These range from simple descriptive 
measurements such as ‘weak’, ‘moderate’ and ‘strong’ (Adams et al., 1999), to fully 
automated scoring using software packages (Rizzardi et al., 2012). Consensus 
reports have been published (van Diest et al., 1997) advising that the staining pattern 
and area of lesion of interest should first be defined, before scoring taking into 
account intensity and number of cells. The staining observed in three of my four 
biomarkers was predominantly membranous with varying degrees of mild 
cytoplasmic staining. My project requires a membrane-bound target, and it was this 
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expression that was of most interest. I therefore did not explore an automated 
scoring method as the results would have potentially been skewed by co-existing 
mild cytoplasmic staining. I tested two semi-quantitative scoring systems, based on 
the two most common methods in similar published studies: the Allred method (Allred 
et al., 1993) and a variation on the Histoscore method (McCarty et al., 1986). The 
Allred method tended to produce a higher proportion of ‘high’ scores (defined as 
being in the top third of the score range for each method) in tumour tissue, potentially 
reducing the potential for discriminating between two high scoring biomarker targets. 
Although the modified Histoscore tended to produce a higher proportion of ‘low’ 
scores in normal tissue, it allowed greater discrimination of high scores and I 
therefore elected to use this system for my analysis so that I could compare 
biomarker performance. The scoring system also appears to be reproducible, with 
good agreement between observers (intraclass correlation 0.89). 
   
Using this scoring system, I was able to investigate three key criteria: i) the 
proportion of the cohort in which tumours stained positively for markers; ii) the 
proportion of the cohort in which tumours stained more strongly for markers than the 
matched normal tissues; and iii) the magnitude of over-expression in tumours. CEA 
out-performed other markers dramatically in all three measures, showing the most 
frequent tumour expression, and the most frequent and greatest tumour over-
expression. In particular, differential CEA expression within normal/tumour pairs was 
notably greater as compared to other markers, providing evidence that CEA is the 
most reliable marker for differentiating between normal and tumour tissue. 
 
When I repeated the experiments using positive and matched normal lymph nodes, 
CEA was again the superior target, with high levels and frequency of expression 
within positive nodes. Although the sample of nodes used was small, the expression 
pattern was identical to that seen in primary tumour epithelial cells and of a similar 
 110 
level. There was some low level staining seen in matched normal lymph node tissue 
for CEA and TAG-72, but this occurred at the germinal centres and has been 
described previously for both markers (Marianicostantini et al., 1991, Potomski et al., 
1979). In the context of my overall project, intra-operative staging relies on the 
accurate assessment of the mesenteric lymph nodes; these findings suggest an anti-
CEA antibody would be suitable as the tumour-recognition component of my imaging 
probe. 
 
In practical imaging situations, the threshold, or cut-off, used to differentiate between 
normal and tumour would be determined by the user, by adjusting the signal gain. 
This could be altered to favour either sensitivity (lowering the cut-off to detect 
tumours more easily at the risk of detecting normal tissue erroneously) or specificity 
(raising the cut-off to avoid detection of normal tissue at the risk of missing tumour 
cells). I quantified the abilities of the markers to be used in tumour cell detection 
using their optimal cut-offs, as determined using ROC analyses, in terms of 
sensitivity (proportion of tumours correctly detected) and specificity (proportion of 
normal tissues correctly not detected). CEA was the most sensitive marker by a 
considerable margin (93.7%, as compared to the nearest alternative TAG-72 at 
70.3%), and was also highly specific (96.1%). FRα was the most specific marker 
(99.2%), however its utility is limited by the fact that it was not detectable in the 
majority of tumours, as previously reported (Shia et al., 2008), resulting in a poor 
sensitivity (39.3%). In addition, the magnitude of differential expression between 
normal and tumour was relatively narrow, providing less security in determining 
tumour or normal identities. Most notably, EGFR was a surprisingly poor marker, 
being detected in less than half the tumours and being commonly more highly 
expressed in normal tissues than in tumours. Cetuximab, a monoclonal antibody 
directed against EGFR, has been used in patients with tumours that show 
immunohistochemical expression of this antigen (Jonker et al., 2007, Van Cutsem et 
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al., 2009). My findings have no direct relevance to this therapy but the prevalence of 
EGFR expression I have shown is lower than most published studies, some of which 
claim up to 97% (Koretz et al., 1990, Lee et al., 2002, Spano et al., 2005, Bhargava 
et al., 2006). There are a number of different antibodies available and this may be 
due to differences between them. There is also controversy regarding the 
relationship between EGFR expression (as assessed by immunohistochemistry) and 
response to monoclonal antibody therapy (Cunningham et al., 2004) with EGFR-
negative patients responding to treatment (Chung et al., 2005). 
 
I therefore concluded that of the four biomarkers tested, and on the basis of 
immunohistochemical expression, CEA is the most suitable for intra-operative tumour 
targeting with a fluorescent nanoparticle. However, these results apply to formalin-
fixed, paraffin-embedded tissue only; as part of a systemically delivered imaging 
probe, the antibody will be required to perform in a far more complex biological 
system. In the next chapter I describe experiments designed to model these 
conditions. 
 
This is the first immunohistochemistry study to compare commonly used biomarker 
targets for in vivo targeting of colorectal cancer and these results are also relevant to 
investigators in the fields of non-invasive targeted imaging and targeted therapeutics. 
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4 CEA AND TAG-72 ARE AVAILABLE FOR ANTIBODY 
BINDING IN LIVE CELLS 
 
4.1 Abstract 
 
Background 
Expression studies of CEA and TAG-72 using immunohistochemistry on formalin 
fixed paraffin embedded tissue have demonstrated that these markers have potential 
for use in vivo colorectal cancer targeting. I now aimed to ascertain whether these 
antigens are available for antibody binding in live cancer cells and fresh frozen 
tumour samples, as would be required in an in vivo setting. I also aimed to test 
whether systemically delivered antibodies were able to reach tumour cells in an ex 
vivo model. 
 
Methods 
I used three colorectal cancer cell lines and suitable controls for immunofluorescent 
evaluation of anti-CEA and anti-TAG-72 antibody binding in both fixed cells and live 
cells. I also examined binding in fresh frozen tumour tissue. Finally, I injected anti-
CEA antibodies into the supplying artery of three freshly resected CEA-expressing 
human colorectal cancer specimens prior to fixation, and evaluated the tumour cells 
for evidence of antibody binding using immunohistochemistry. 
 
Results 
Incubation with both anti-CEA and anti-TAG-72 antibodies produced staining in live 
cells, but only anti-CEA produced staining in fixed cells. The staining tended to be 
stronger and more diffuse with anti-CEA. Only non-specific staining was evident with 
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both antibodies in fresh frozen tissue. No tumour-bound anti-CEA antibodies were 
detected following arterial injection in ex vivo tumours. 
 
Conclusion 
CEA and TAG-72 are available for binding in live colorectal cancer cells but delivery 
to a tumour in vivo may represent a challenge. 
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4.2 Introduction 
 
The key criteria for markers that are suitable for targeting colorectal cancer cells with 
fluorescent particles have been described previously (see section 1.3). I have already 
determined which of a range of candidates display suitable differential expression in 
Chapter 3. The two best performing biomarkers from these experiments were TAG-
72 and CEA, both of which showed high levels of expression in the majority of 
tumours, relatively low expression in matched normal tissue and a large differential in 
expression levels between tumour and normal tissues. In this chapter, my aim was to 
determine which of these antigens was available for antibody-binding in live cells.  
Previously published work from other laboratories has demonstrated that some 
antigens from these molecules are apparently available for binding following systemic 
delivery; iodine125-labelled anti-TAG-72 antibodies were used to locate occult tumour 
cells intra-operatively in radio-immunoguided surgery (Povoski et al., 2012) and 
iodine131-labelled anti-CEA antibodies have been used for targeted cytotoxic delivery 
in radioimmunotherapy applications (Meyer et al., 2009). However in some cases, 
controls were relatively poor with no non-targeted antibody control to prove that the 
apparent tumour specificity was due to antibody binding rather than an alternative 
mechanism such as the EPR phenomenon (Matsumura and Maeda, 1986). Formally, 
it remains unclear whether these antigens are truly available in a live biological 
system and to what degree. I used three colorectal cancer cell lines for this work: HT-
29 cells, derived from grade II human colonic adenocarcinoma (Fogh J, 1975); 
CACO2 cells, derived from a human colonic adenocarcinoma (Koivisto and 
Salaspuro, 1997); and HRT-18 cells, derived from a human rectal adenocarcinoma 
(Tompkins et al., 1974).   
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4.3 Results 
 
I aimed to assess the availability of CEA and TAG-72 in various cellular systems in 
order to assess whether they are available for binding in a live biological system. I 
used three system models to assess antigen availability: fixed and live cell lines; 
freshly frozen human colorectal cancer tissue samples; and freshly resected, ex vivo 
colorectal cancer specimens in situ within the resected colon. To evaluate antigen 
availability and antigen binding in cell lines and in fresh frozen tissue I used 
immunofluorescence or, for ex vivo samples, immunohistochemistry.  
 
4.3.1 CEA, but not TAG-72, is available for antibody binding 
in fixed cells 
First, I aimed to assess whether CEA and TAG-72 antigens were available in fixed 
colorectal cancer cell lines – this was to validate these lines as suitable CEA- and 
TAG-72-epxressing models to use subsequently as live cell models. I used three 
widely available colorectal cancer cell lines for this: HT-29, CACO2 and HRT18 cells. 
Having demonstrated antigen availability in FFPE treated colorectal tissue, I 
hypothesised that fixed colorectal tissue culture cells would show similar antigen 
availability. I therefore fixed cells from each cell line with paraformaldehyde prior to 
incubating them with the primary anti-CEA or anti-TAG-72 antibody followed by an 
appropriate fluorescent secondary antibody. Control conditions involved incubating 
cells with the fluorescent secondary antibody only, omitting the primary antibodies. 
Staining was assessed subjectively in terms of whether the membranous staining 
was present (mild, moderate or strong) or absent, and whether it was diffuse across 
all cells or focal. 
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Whilst staining was present in fixed cells in all three cell lines when incubated with 
anti-CEA antibodies, staining was not present in fixed cells with anti-TAG-72 
antibodies (Figure 4.1). When no primary antibody was used, no staining was 
apparent in any cell line. The lack of staining with anti-TAG-72 antibodies was 
surprising given the results obtained with FFPE tissue. I concluded that, in this fixed 
cell in vitro model of colorectal cancer, CEA is available for immunostaining but TAG-
72 is not. 
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Figure 4.1. Immunostaining in fixed cells. 
Fixed HT29, CACO2 and HRT18 cells show colorectal cancer cell specific 
immunostaining when incubated with anti-CEA but not anti-TAG-72 antibodies and a 
suitable fluorescent antibody. Four images are shown for each: DAPI staining (top 
left), CEA/TAG-72 staining (top right), phase contrast (bottom left) and merged image 
(bottom right), X63 magnification. Although different fluorescent secondary antibodies 
were used due to availability, gain and exposure settings were consistent. Scale bar 
= 40 µm. 
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4.3.2 CEA and TAG-72 are available for antibody binding in 
live cells 
Next, I aimed to assess whether CEA and TAG-72 antigens were available in live 
cells from the same three colorectal cancer cell lines. I used the same test and 
control conditions (but with paraformaldehyde fixation omitted). In addition, human 
endothelial cells (HUVECs) were used as a negative control cell line, since the 
colorectal markers CEA and TAG-72 would not be expressed in these cells. In order 
to demonstrate the specificity of any binding further, I used anti-CD105 antibodies as 
negative control antibodies; CD105 is an endothelial cell marker that should not be 
detectable on colorectal epithelial cells but should be detected on HUVEC cells (Li et 
al., 2000). 
 
4.3.2.1 Unfixed (live) cell immunofluorescence allows appropriate imaging of 
cell surface markers 
When live HUVEC cells were incubated with anti-CD105 antibodies, strong 
fluorescent staining was observed (Figure 4.2). When anti-CD105 antibodies were 
incubated with live colorectal cancer cell lines there was no evidence of any staining, 
validating its use as a negative control. When live HUVEC cells were incubated with 
anti-CEA and anti-TAG-72 antibodies, no fluorescent staining was observed (Figure 
4.3). I concluded that live cell immunofluorescence allows appropriate imaging of cell 
surface markers and that HUVEC cells and anti-CD105 antibodies are appropriate 
controls for this work. 
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Figure 4.2. Anti-CD105 antibodies as a negative control. 
Anti-CD105 antibodies act as a suitable negative control to demonstrate the 
specificity of anti-colorectal cell antigen/colorectal cancer cell binding. Four different 
cell types, as labelled, were seeded on glass coverslips and incubated in live culture 
with anti-CD105 antibodies (1h), before treatment to allow IF visualisation of 
antibody:antigen binding. Magnification = 63X. 
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Figure 4.3. HUVECs as a negative control cell line. 
HUVECs act as a suitable negative control cell line to demonstrate the specificity of 
anti-colorectal cell antigen/colorectal cancer cell binding. HUVEC cells were seeded 
on glass coverslips and incubated in live culture with anti-CD105, anti-CEA and anti-
TAG-72 antibodies (1h), before treatment to allow IF visualisation of antibody:antigen 
binding. Magnification = 63X. 
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4.3.2.2 CEA and TAG-72 are available for immune-recognition in live 
colorectal cancer cells 
Both CEA- and TAG-72-specific staining was demonstrated in live cells from all three 
colorectal cancer cell lines (Figure 4.4). When no primary antibody was used, no 
staining was apparent in any cell line. 
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Figure 4.4. Immunostaining in live cells. 
Live HT29, CACO2 and HRT18 cells show colorectal cancer cell specific 
immunostaining when incubated with anti-CEA and anti-TAG-72 antibodies and a 
suitable fluorescent antibody. Four images are shown for each: DAPI staining (top 
left), CEA/TAG-72 staining (top right), phase contrast (bottom left) and merged image 
(bottom right), X63 magnification. CEA-targeted staining appears to be stronger and 
more diffuse than TAG-72. Scale bar = 40 m. 
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Whilst staining was present in both fixed and live cells in all three cell lines when 
incubated with anti-CEA antibodies, staining was only present in live cells with anti-
TAG-72 antibodies. The results are summarised in Table 4.1. 
 
 
 
Cell line 
 
No primary CEA TAG-72 
HT-29 
 
Fixed 
 
No staining Focal, strong Nil 
 
Live 
 
No staining Diffuse, strong Focal, moderate 
CACO2 
 
Fixed 
 
No staining Diffuse, mild Nil 
 
Live 
 
No staining Diffuse, mild Focal, mild 
HRT-18 
 
Fixed 
 
No staining Diffuse, moderate Nil 
 
Live 
 
No staining Focal, moderate Focal, mild 
 
Table 4.1. Summary of immunostaining patterns. 
Fluorescent immunostaining patterns of fixed and live cells from three colorectal 
cancer cell lines when incubated with anti-CEA and anti-TAG-72 antibodies. 
Incubation with anti-CEA antibodies appears to produce a stronger and more diffuse 
staining pattern. 
 
 
I concluded that both CEA and TAG-72 are available for antibody binding in a live cell 
culture in vitro system. Although the results are qualitative only, incubation with anti-
CEA antibodies appears to produce a stronger and more diffuse staining pattern. 
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4.3.3 Assessment of the accessibility of CEA and TAG-72 for 
imaging in the context of tumour architecture 
Having demonstrated the availability of CEA and TAG-72 for antigen-antibody 
binding in live colorectal cancer cell lines, I aimed to investigate accessibility in fresh 
frozen tissue, as this represents a model that is one step closer to live human tissue. 
Sections of archived fresh frozen colorectal tumour and matched normal colon tissue 
(five patients) were prepared and incubated with anti-CEA and anti-TAG-72 
antibodies using the same immunofluorescence protocol as used previously. In each 
case, one slide was incubated with the secondary antibody only as a negative control 
and no staining was observed in any of these controls. 
 
Although promising fluorescent images were obtained when fresh frozen colorectal 
cancer tissue was incubated with anti-CEA and anti-TAG-72 antibodies (Figure 4.5 
and Figure 4.6), matched normal colonic tissue also yielded fluorescence. This was 
seen in all five matched patient samples. Extended TBS-Tween wash steps with 
gentle agitation were added to the method in an attempt to ensure unbound primary 
antibody was completely removed from the specimen but this had no effect (Figure 
4.7). 
 
I concluded that it was unclear if the fluorescent staining seen in fresh frozen tumour 
samples was the result of genuine antigen-specific antibody binding. 
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Figure 4.5. CEA immunostaining in fresh frozen tissue. 
Fresh frozen colorectal cancer and matched normal tissue both exhibit fluorescent 
staining when incubated with anti-CEA antibodies. Tissue samples were sectioned 
and subjected to immunofluorescence with anti-CEA antibodies and an appropriate 
fluorescent secondary antibody. Four images are shown: DAPI staining (top left), 
CEA expression (top right), phase contrast (bottom left) and merged 
DAPI/CEA/phase, X63 magnification. 
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Figure 4.6. TAG-72 immunostaining in fresh frozen tissue. 
Fresh frozen colorectal cancer and matched normal tissue both exhibit fluorescent 
staining when incubated with anti-TAG-72 antibodies. Tissue samples were 
sectioned and subjected to immunofluorescence with anti-TAG-72 antibodies and an 
appropriate fluorescent secondary antibody. Four images are shown: DAPI staining 
(top left), TAG-72 expression (top right), phase contrast (bottom left) and merged 
DAPI/TAG-72/phase, X63 magnification. 
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Figure 4.7. Immunostaining in fresh frozen tissue is not tumour-specific. 
Fresh frozen colorectal cancer and matched normal tissue both exhibit fluorescent 
staining when incubated with anti-CEA antibodies despite extended wash and 
agitation steps prior to fluorescent secondary antibody incubation. Four images are 
shown: DAPI staining (top left), CEA expression (top right), phase contrast (bottom 
left) and merged DAPI/CEA/phase, X63 magnification. 
 
 
4.3.4 Assessment of biomarker localisation in an ex vivo 
model of systemic antibody delivery 
Having shown that CEA is available for antigen-antibody binding in vitro at least in 
cell lines, I sought to design a model to test whether antibodies could reach their 
antigens on the surface of tumour cells in the context of genuine tumour architecture 
and when delivered via the arterial vasculature. For this experiment I chose to focus 
on CEA as a target biomarker because it had performed best in FFPE human tissue 
samples and most consistently in cell lines. To do this I aimed to inject anti-CEA 
antibodies into the main supplying artery of freshly resected tumour specimens in the 
operating theatre, and then use immunohistochemistry to detect bound anti-CEA 
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antibodies. However, to prove that this model had the potential for success, I needed 
to show that routine histopathological examination, specifically fixation with formalin, 
would not prevent a secondary antibody binding to the primary anti-CEA antibody-
antigen complex. I examined this by performing similar antibody-binding and 
subsequent fixation in HT-29 cells with A5B7 anti-CEA antibodies. Live HT-29 cells 
on coverslips were incubated with anti-CEA antibodies, and were then fixed with 
formalin, and subsequently incubated with fluorescent secondary antibodies. Figure 
4.8 shows HT-29 cells treated in this way, along with cells that had undergone 
routine immunofluorescence with anti-CEA antibodies and a fluorescent secondary 
antibody (ie. live cells treated in turn with primary and secondary antibodies, and 
imaged unfixed). Successful localisation of the antibody-antigen complexes appeared 
to be unaffected by formalin fixation. 
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Figure 4.8. Formalin fixation did not prevent CEA immunostaining. 
Formalin fixation of cells following incubation with anti-CEA antibodies but prior to 
incubation with fluorescent secondary antibodies does not affect staining. Left: live 
cells were incubated with anti-CEA antibodies and then fixed in formalin. Twenty-four 
hours later they were incubated with a suitable fluorescent secondary antibody. 
Right: live HT-29 cells were incubated with anti-CEA antibodies and a suitable 
fluorescent secondary antibody. Four images are shown: DAPI staining (top left), 
CEA expression (top right), phase contrast (bottom left) and merged 
DAPI/CEA/phase, X63 magnification. 
 
 
Having successfully shown that recognition of anti-CEA antibodies by secondary 
antibodies was unaffected by formalin fixation, I proceeded to attempt to deliver the 
primary antibody to tumour cells by injection into the arteries of ex vivo tumours. I 
injected a solution of A5B7 antibody into the ileocolic artery of three freshly resected 
right-sided colonic cancer specimens in the operating theatre. Following routine 
histopathological staging, I subjected sections of paraffin embedded tumour tissue to 
immunohistochemistry to identify bound A5B7 antibody. As a control I incubated 
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slides with both the primary anti-CEA antibody and a suitable secondary antibody to 
show that the tumours expressed CEA. I then incubated a separate slide with the 
secondary antibody only: if primary anti-CEA antibodies had reached the tumour, I 
would expect immunostaining to be present. Unfortunately this was not detectable in 
any of the patients (Figure 4.9). I concluded that the antibodies may not reach the 
tumour cells in this ex vivo model. 
 
 
 
Figure 4.9. Ex vivo model mmunohistochemical staining. 
Anti-CEA antibodies injected into the main supplying artery of a freshly resected 
CEA-secreting tumour specimen prior to formalin fixation and paraffin embedding did 
not allow tumour specific immunohistochemical staining. Control: formalin fixed 
paraffin embedded tumour tissue was subjected to routine immunohistochemical 
analysis with further addition of anti-CEA antibodies. Test: Immunohistochemical 
analysis was undertaken using secondary antibodies only. Magnificaiton 20X. 
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4.4 Discussion 
 
Although my immunohistochemistry biomarker study (Chapter 3) showed a 
consistently high degree of CEA/TAG-72 expression and therefore antibody-antigen 
binding, it is difficult to draw conclusions about antigen availability; it may be that a 
colorectal tumour has high antigen expression but antibodies cannot access the 
binding sites in a live biological system, rather than in formalin-fixed, paraffin 
embedded tissue where the antigens are relatively accessible. Cultured cell lines 
provide a basic system in which to test whether the results seen in Chapter 3 can be 
reproduced in a less controlled and more realistic biological environment. Some of 
the recognised limitations of immunofluorescence - background noise, 
autofluorescence, non-specific binding and photobleaching (Swedlow et al., 2002, 
Wolf et al., 2007) - are all features that a systemically-delivered molecular imaging 
probe would need to overcome in vivo. 
 
Initially I fixed the cells prior to antibody incubation, as is routinely done in 
immunofluorescence protocols, to confirm that specific antibody binding took place. 
This would be expected as the cells are in a similar state to those in the formalin-
fixed paraffin-embedded tissue samples used in Chapter 3. Using the same 
conditions and antibody concentrations, I then incubated live cells with both 
antibodies. Although the results were non-quantitative, and therefore subjective in 
part, two apparent trends emerged: incubating colorectal cancer cells with anti-CEA 
antibodies produced a stronger and more diffuse staining pattern than anti-TAG-72; 
and incubating fixed cells with anti-TAG-72 antibodies produced no staining whereas 
live cells did. I would expect the first of these observations to be true, having already 
shown that CEA is more highly expressed than TAG-72 in a large cohort of colorectal 
tumours. The second observation was more surprising, but might be due to a 
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difference in the effect of fixation on live cells in media compared to human 
specimens where the cancer cells are within the tissue architecture comprising of the 
stroma and other cell types. Paraformaldehyde causes cross-linking, where covalent 
bonds form between proteins, and tends to damage cell membranes (Puchtler and 
Meloan, 1985); it may also reduce antigen availability or the cross-linking may reduce 
the number of available antigen-binding sites. From these experiments I was able to 
conclude that both CEA and TAG-72 are available for antibody binding in a live cell 
culture in vitro system, although potentially CEA appears to be more readily available 
for antibody binding than TAG-72. 
 
Human fresh frozen tissue is frozen immediately after surgical resection, avoiding 
fixation. I aimed to assess whether I could reproduce the tumour-specific CEA and 
TAG-72 expression pattern seen in paraffin-embedded tumour samples and live cells 
by evaluating antibody binding in slices of fresh human tumour tissue and matched 
normal tissue. Although there appeared to be a high level of fluorescent staining in 
tumour samples, this was not tumour-specific; a similar pattern was observed in 
matched normal control tissue in all five patient samples. Non-specific background 
staining has been reported as being more common in frozen tissue than paraffin-
embedded tissue (Elias, 1990). It is possible that the freezing process damages the 
cell membranes or the antigen binding sites and alters them in such a way as to 
enable non-specific binding. If this is the case, these findings do not threaten the 
eventual aim of my project. However, if these findings are due to a feature of human 
normal colonocytes that causes non-specific binding by these antibodies, this could 
prevent tumour-specific imaging of cancer cells in vivo by my proposed molecular 
probe. Given that both anti-CEA and anti-TAG-72 antibodies have been used for 
colorectal cancer targeting in human studies (Mayer et al., 2000, Povoski et al., 
2012), I am optimistic that this is not the case. 
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Following the results of live cell incubation with anti-CEA and anti-TAG 72, together 
with the results from Chapter 3, I chose to focus on CEA as the biomarker target of 
choice as it had consistently out-performed TAG-72. I designed this experiment with 
the aim of showing whether systemically delivered antibodies could reach a tumour 
and bind in sufficient number to detect their presence using immunohistochemistry. 
First, I tested whether formalin fixation following primary antibody binding affected the 
detection of the primary with a secondary antibody; Figure 4.8 shows that this had no 
adverse effect on the immunofluorescent signal. I then injected an anti-CEA antibody 
solution into the ileocolic artery of three freshly resected right colonic cancer 
specimens and tested paraffin-embedded samples for CEA expression using 
immunohistochemistry. Unfortunately I was unable to demonstrate any tumour-
specific binding. A likely reason for this is that pulsatile arterial blood flow is required 
to deliver molecules to the tumour cells; the act of injecting the solution will 
undoubtedly have forced antibodies along the artery to some extent but they may not 
have reached the small calibre arterioles supplying the tumour. Alternatively, the 
antibodies may have reached these vessels but require a hydrostatic pressure 
gradient to leave the vasculature and bind to cells; this is absent in my ex vivo 
system. Finally, there is an unavoidable delay between ligating the artery supplying 
blood and removing the tumour specimen prior to antibody injection, during which the 
blood within the vessel may have coagulated, obstructing antibody delivery. Despite 
these findings, there is evidence that systemically delivered antibodies are able to 
bind specifically and measurably to colorectal cancer cells. A5B7 anti-CEA antibodies 
bound to radioisotopes were used in radioimmunoguided surgery and 
radioimmunotherapy in UK clinical trials with success (Dawson et al., 1991, Meyer et 
al., 2009), suggesting that my model for systemic delivery may have been flawed. 
Were I to design the experiment again, I would have considered using an orthotopic 
mouse model of colorectal cancer where blood flow could be maintained to the 
tumour during and after antibody injection. 
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In conclusion, cell culture immunofluorescence shows that CEA and TAG-72 are 
available for antibody-antigen binding in vitro, and expression is similar to the 
patterns observed in Chapter 3, with CEA displaying the greatest binding. Although I 
was unable to demonstrate tumour-specific binding of anti-CEA antibodies using 
fresh frozen tissue samples or arterial delivery to fresh tumour specimens, there are 
a number of plausible reasons for this and I do not believe it prevents me from 
developing the project further. 
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5 INDOCYANINE GREEN CONJUGATED ANTI-CEA 
ANTIBODIES ALLOW FLUORESCENT IMAGING OF 
COLORECTAL CANCER CELLS 
 
5.1 Abstract 
 
Background 
Indocyanine green (ICG) is a near-infrared dye approved for use in humans in both 
the UK and USA. Its fluorescence is quenched when conjugated to an antibody, but 
reportedly this quenching is halted if the molecule is internalised by a cell, 
presumably by reversal of the conjugation and release of free dye. I aimed to assess 
whether ICG-conjugated anti-CEA antibodies would allow specific fluorescent 
labelling of colorectal cancer cells. 
 
Methods 
ICG-Sulfo-Osu was conjugated to A5B7 anti-CEA antibodies or control anti-digoxin 
antibodies. Conjugates were incubated with live LS174T, LoVo or HCT116 colorectal 
cancer cells and near-infrared fluorescence was imaged using confocal microscopy. 
Cellular fluorescence was quantified using ImageJ software. 
 
Results 
ICG-anti-CEA exhibited CEA-specific fluorescence in all three cell lines (p<0.01) with 
fluorescence increasing until 24-36 hours, and reducing thereafter. The fold 
difference in fluorescence between ICG-anti-CEA and ICG-anti-digoxin treated cells 
at 36 hours was 5.2, 8.2 and 12.2 for LS174T, LoVo and HCT116 cells respectively. 
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When LS174T cells were incubated with only a 2 hour pulse of ICG-anti-CEA 
antibodies followed by subsequent incubation without the antibody, fluorescence 
accumulated with similar dynamics as before, peaking at 36 hours.  
 
Conclusion 
ICG conjugated to A5B7 anti-CEA antibodies allows CEA-specific imaging of 
colorectal cancer cells in vitro. 
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5.2 Introduction 
 
A relatively simple fluorescent molecular probe for intra-operative cancer imaging is a 
fluorophore conjugated to a tumour-specific antibody and several groups have 
published small studies evaluating this, with moderate success (section 1.3.2). 
However, use of indocyanine green (ICG) as a simple antibody-fluorophore 
conjugate has demonstrated some promise. Importantly, ICG is a U.S. Food and 
Drug Standards Agency (FDA) and UK Medicines and Healthcare Products 
Regulatory Agency (MHRA) approved dye, so there is potential for rapid translation 
to clinical studies.  
 
A slightly modified version of ICG (ICG-Sulfo-OSu, Figure 5.1) is quenched when 
bound to a protein such as an antibody (Ogawa et al., 2009) but has been shown to 
re-fluoresce when internalised by cells, a change that is thought to be due to 
cleavage of the bonds linking the dye to the antibody in lysosomes. Once 
internalised, the fluorescent signal from the ICG has been reported to remain 
detectable for up to 10 days (Nakajima et al., 2011), which in the clinical setting 
would allow a degree of flexibility in the timing an operation. As the fluorescence 
occurs in the cell cytoplasm rather than the cell membrane fluorescence seen in 
simple surface-bound fluorescent antibody systems, the signal density may be 
greater due to more target cell fluorophores.  
 
I have already shown that CEA is the most suitable target for tumour-specific imaging 
of colorectal cancers (section 3.3), and that it is available to anti-CEA antibodies in 
live cells (section 4.3).  Critically for my studies, Schmidt et al showed that anti-CEA 
antibodies are internalised by the colorectal cancer cell line LS174T (Schmidt et al., 
2008), meaning that ICG-linked anti-CEA antibodies may well be induced to 
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fluoresce after internalisation. I therefore chose to evaluate the potential of ICG-anti-
CEA antibodies for imaging of colorectal cancer cells in vitro.  
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Figure 5.1. ICG-labelled IgG antibodies. 
ICG-Sulfo-Osu is an amine-reactive derivative of ICG and can be conjugated to a 
free amine group on an IgG molecule. 
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5.3 Results 
 
My first aim was to conjugate ICG to anti-CEA antibodies and to determine whether 
this conjugate would allow time-dependent and specific accumulation of fluorescence 
in colorectal cancer cells. I used three CEA-expressing colorectal cell lines for this 
work: LoVo cells have a high expression, LS174T cells a moderate/high expression 
and HCT116 cells a low expression (Ohannesian et al., 1995, Ashraf et al., 2009, da 
Paz et al., 2012, Fahlgren et al., 2003, Wang et al., 1999). I undertook a series of cell 
culture experiments to test whether cytoplasmic fluorescence was detectable 
(implying ICG-anti-CEA internalisation), whether this was CEA-specific and the 
relationship between signal intensity and time. 
 
5.3.1 Qualitative assessment of ICG-anti-CEA fluorescence 
in LS174T cells 
5.3.1.1 ICG-anti-CEA is CEA-specific and produces time-dependent 
cytoplasmic fluorescence 
For my first experiment, I conjugated ICG-sulfo-OSu to A5B7 anti-CEA antibodies 
and incubated the conjugates with live LS174T cells . I used live cell confocal 
microscopy to assess cytoplasmic fluorescence at time points from 1 hour to  80 
hours after the beginning of the incubation (Figure 5.2). As a negative control I 
saturated the surface of cells with unlabelled anti-CEA antibody to block the antigen 
binding sites, before washing away unbound antibody and treating as before.  
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Figure 5.2. ICG-anti-CEA antibodies allow cytoplasmic fluorescence. 
Anti-CEA antibodies conjugated to ICG-Sulfo-OSu are internalised by live LS184T 
colorectal cancer cells resulting in cytoplasmic fluorescence. Cells were incubated 
with 100 µg/ml ICG-anti-CEA and imaged at the times shown using confocal 
microscopy. Microscope settings were fixed throughout to allow the fluorescence at 
different time points to be directly comparable. As a control, cells were pre-incubated 
with 480 g/ml of free anti-CEA antibody for one hour prior to incubation with the 
ICG-anti-CEA as above (image shown at 30 hours). (Magnification 100X, scale bar = 
10 µm). 
 
 
Cytoplasmic fluorescence was detectable from 4 hours and reached a peak at 30 
hours. By 60 hours it had reduced considerably.  Pre-incubation with unlabelled anti-
CEA blocked accumulation of fluorescence at any time point tested. I concluded that 
ICG-anti-CEA binds specifically to CEA and is internalised leading to ICG 
fluorescence within the cytoplasm.   
 
5.3.1.2 ICG-anti-CEA fluorescence is dose dependent 
I also investigated whether the accumulation of fluorescence was dose-dependent. 
Three different dilutions of the conjugated antibody were used and fluorescence was 
assessed at 30 hours: 100 µg/ml, 10 µg/ml and 1 µg/ml.  The highest of the three 
concentrations tested produced the greatest fluorescent signal (Figure 5.3). 
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Figure 5.3. ICG-anti-CEA cytoplasmic fluorescence is dose-dependent. 
Live LS174T cells in media were incubated with ICG-Ab suspended in PBS at 
concentrations of 1:10 (100 g/ml), 1:100 (10 g/ml) and 1:1000 (1 g/ml). Confocal 
fluorescent microscope images were taken after 30 hours, representing peak 
fluorescence in earlier experiments. (Magnification 63X, scale bar = 10 µm). 
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5.3.2 Quantitative assessment of ICG-anti-CEA vs ICG-anti-
digoxin fluorescence in colorectal cell lines 
5.3.2.1 Anti-digoxin antibodies are a suitable control for immune-mediated 
colorectal cancer cell targeting experiments 
I aimed to quantify the fluorescence produced by ICG-anti-CEA conjugates and 
compare this to that of of ICG-labelled control antibodies. To do this I required a 
suitable control IgG antibody: I selected anti-digoxin, a mouse monoclonal IgG 
antibody for this purpose. Digoxin is a glycoside not expressed by colorectal cancer 
cells. To confirm that this negative control was suitable, I aimed to examine whether 
the cells I planned to use in my experiments not expressed digoxin. To do this I 
conjugated NHS-fluorescein, a commonly used label that retains its fluorescence 
when bound to proteins, to anti-CEA and anti-digoxin antibodies. To check that each 
antibody had a similar fluorescent signal, I used the molar extinction coefficient of 
NHS-fluorescein to calculate the number of fluorescein molecules conjugated to each 
IgG molecule: 9.23 for CEA and 10.03 for digoxin. I then incubated each with fixed 
cells from all three cell lines that I planned to use in my experiments. Whilst 
incubation with fluorescein-conjugated anti-CEA antibodies allowed fluorescent cell 
labelling, anti-digoxin antibodies produced no signal in any cell line (Figure 5.4). I 
concluded that anti-digoxin antibodies are an ideal control IgG antibody for immune-
mediated colorectal cancer cell labelling experiments. 
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Figure 5.4. Anti-digoxin antibodies are a suitable negative control for colorectal 
cancer cell targeting experiments. 
Fluorescein was conjugated to IgG antibodies and unbound fluorescein removed via 
filtration. Live LS174T cells were incubated with the conjugates for one hour, 
washed, mounted on slides and imaged with confocal microscopy. Scale bar = 50 
µm. Magnification 63X. 
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5.3.2.2 ICG-anti-CEA allows tumour cell-specific imaging in a range of 
colorectal cancer cell lines. 
For my next experiment, I aimed to use three CEA-expressing colorectal cancer cell 
lines: LS174T, LoVo and HCT116. Each cell line is known to express CEA at differing 
levels: LoVo cells have a high expression, LS174T cells a moderate/high expression 
and HCT116 cells a low expression (Ohannesian et al., 1995, Ashraf et al., 2009, da 
Paz et al., 2012, Fahlgren et al., 2003, Wang et al., 1999). I attempted to compare 
the expression levels of CEA for each cell line using Western Blot analysis. My 
results reflect the expression data in the literature, with LoVo cells exhibiting the 
strongest expression, LS174T moderate expression and HCT116 cells the lowest 
expression level (Figure 5.5). 
 
 
 
Figure 5.5. Expression of CEA by colorectal cancer cells was confirmed by 
Western Blot analysis. 
LoVo cells showed the greatest CEA concentration, followed by LS174T cells and 
HCT116 cells. 
 
 
I aimed to assess ICG-anti-CEA and ICG-anti-digoxin (control) binding in each cell 
line. I incubated the conjugates with live cells cells cultured in media in glass-
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bottomed wells at a concentration of 100 µg/ml and I used confocal microscopy to 
capture comparable fluorescent images at 1, 6, 12, 24, 36 and 48 hours from the 
start of incubation. I quantified the fluorescence using ImageJ software by obtaining 
images of five cells of each cell line at each time point. I then calculated the mean 
fluorescent signal by measuring that of the cell and subtracting the mean background 
fluorescence. I plotted a graph for each cell line and compared the difference 
between test and control antibodies  (Figure 5.6). Peak fluorescence occurred at 36 
hours for LS174T and HCT116 cells and at 24 hours for LoVo cells. The fold 
difference in mean fluorescence between anti-CEA and control IgG conjugated ICG 
at 36 hours was 5.2, 8.2 and 12.2 for LS174T, LoVo and HCT117 respectively. The 
difference was significant at each time point from 6 to 36 hours for all cell lines. The 
fold increase in the fluorescent signal of the ICG anti-CEA antibodies at 1 hour and 
36 hours was significant (p<0.05) in LS174T cells (1.9) and HCT116 cells (3.5) but 
not in LoVo cells (1.5) (Figure 5.6). I concluded that continuous incubation with ICG-
anti-CEA produced significantly greater cellular fluorescence than control ICG-anti-
digoxin at each time point after 6 hours in all three cell lines. 
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Figure 5.6. ICG-anti-CEA fluorescence in LS174T, LoVo and HCT116 cells. 
ICG-anti-CEA antibodies produce significantly more cellular fluorescence than control 
ICG-anti-digoxin antibodies when incubated with colorectal cancer cells, which peaks 
at 24-36 hours. Live LS174T, LoVo and HCT116 cells were seeded onto glass 
covcerslips and continuously incubated with 100 g of ICG-antibody in 2 ml of media 
and images captured using confocal microscopy. Fluorescence was measured using 
ImageJ software. *p<0.05, **p<0.01, ***p<0.001. Whiskers represent standard error 
of the mean. a.u. = arbitrary units. 
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5.3.2.3 Cellular labelling is also achieved with only a short pulse of exposure 
to ICG-conjugated antibody 
For my last experiment, I used LS174T cells only and conducted a pulse and chase 
experiment. This represents a more realistic model of systemically delivered 
fluorescent antibodies in vivo; they would reach a tumour via the arterial system but 
would be cleared from the bloodstream and excreted relatively quickly (Pedley et al., 
1989). I incubated the cells with the same concentration of ICG-anti-CEA antibodies 
but removed unbound antibody after two hours, washed the cells, and replaced the 
media with media lacking anti-CEA antibodies. I then quantified the fluorescence at 
6, 12, 24, 36, 48 and 72 hours after the limited incubation period (Figure 5.7). The 
fold change in mean fluorescence between the six hour and 36 hour (peak) time 
points was 4.1 (p<0.01). The fluorescent signal had reduced significantly by 48 hours 
(p<0.01). I concluded that, when exposed to ICG-anti-CEA for a limited time, LS174T 
cells demonstrate time-dependent fluorescence that peaks approximately 36 hours 
after incubation. This in vitro model suggests this mechanism of tumour-specific 
fluorescent imaging holds promise in vivo. 
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Figure 5.7. Pulse and chase incubation. 
LS174T cells demonstrate increasing cytoplasmic fluorescence with time when 
incubated with ICG-anti-CEA antibodies for two hours in a pulse and chase 
experiment. Incubation took place at 0-2 h. The peak signal occurred at 36 hours and 
then reduced significantly. Mean and standard error of the mean shown. **p<0.01. 
a.u. = arbitrary units. 
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5.4 Discussion 
 
I have shown that anti-CEA antibodies conjugated to ICG-Sulfo-OSu allow significant 
CEA-specific cellular fluorescence in a variety of colorectal cancer cell lines, which 
appears to be both time and dose dependent. Fluorescence at 36 hours was up to 
12.2 fold greater than controls. When LS174T cells were exposed to ICG-anti-CEA 
for two hours only, cellular fluorescence peaked at 36 hours and then fell back to pre-
six hour levels. These findings are the first of their kind in the field of colorectal 
cancer fluorescent imaging.  
 
ICG fluorescence has been shown to quench when bound to IgG antibodies but re-
fluoresce when internalised by the target cell (Ogawa et al., 2009), leading to target-
cell specific cytoplasmic fluorescence. This is thought to be the result of cleavage of 
the covalent bond between the antibody and ICG molecule: the authors 
demonstrated re-fluorescence when sodium dodecyl sulphate (SDS) and 2-
mercaptoethanol (2-MEA) were used to cleave the bonds. However, it has not been 
demonstrated conclusively that this occurs following internalisation by a cell 
membrane. It is conceivable that the antibody is degraded inside a lysosome, either 
leaving the ICG molecule intact, or the ICG degrading more slowly. For this 
technique to be used in colorectal cancer, bound anti-CEA antibodies must be 
internalised. This was thought not to be the case (Behr et al., 2000, Bryan et al., 
2005) until Schmidt et al showed that all tested anti-CEA antibodies were internalised 
by LS174T cells with a half-life of 10-16 hours (Schmidt et al., 2008). I therefore 
tested the hypothesis that ICG-conjugated A5B7 anti-CEA antibodies allow tumour-
specific imaging of colorectal cancer cells in vitro. Ogawa et al showed that when 
ICG-Sufo-OSu was conjugated to IgG antibody the fluorescence intensity was low 
and unaffected by varying the antibody. Furthermore, when the antibody to ICG 
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molar ratio was increased, this ‘quenching’ effect also increased; at 1:1 conjugation 
the observed quenching capacity was 6-fold, whereas at 1:8 it was 58-fold. I similarly 
used a molar ratio of 1:8 when conjugating anti-CEA and antidigoxin antibodies with 
ICG-Sulfo-OSu. In all three cell lines that I tested, targeted ICG showed significantly 
greater fluorescence at each time point from six to 48 hours compared to non-
targeted control ICG (Figure 5.6). The time dependent nature of the fluorescence and 
the fact that it appeared to be cytoplasmic, suggests the fluorophore had been 
internalised by the cells. Cellular fluorescence from control IgG-conjugated ICG was 
negligible in LoVo and HCT116 cells but greater in LS174T cells. LS174T cells are 
known to express mucin to a greater degree compared to other colorectal cancer cell 
lines (Bu et al., 2011), and this difference may explain the relatively high non-specific 
binding. Peak fluorescence occurred at 24 to 36 hours post incubation and 
decreased thereafter; in all three cell lines tested, the fluorescence at 48 hours was 
greater than at six hours. Ogawa et al used this technique to target HER2 expressing 
breast cancer cells and PASM-expressing prostate cancer cells, with peak 
fluorescence occurring at eight hours, but CEA is known to be internalised relatively 
slowly (Schmidt et al., 2008). The fold difference in mean fluorescence between anti-
CEA and control IgG conjugated ICG at 36 hours was 5.2, 8.2 and 12.2 for LS174T, 
LoVo and HCT117 respectively (p<0.05). Each cell line is known to express CEA but 
at differing concentrations: LoVo cells have a high expression, LS174T cells a 
moderate/high expression and HCT116 cells a low expression (Ohannesian et al., 
1995, Ashraf et al., 2009, da Paz et al., 2012, Fahlgren et al., 2003, Wang et al., 
1999). Interestingly, my results do not reflect these expression levels. This is the 
case even when non-specific control ICG binding is ignored (to take into account the 
higher levels in LS174T cells). This is likely to be due to differing steric hindrance, 
where the antigen density at the cell membrane can affect antibody binding (Kent et 
al., 1978), occurring between cell lines. Conjugating ICG-Sulfo-OSu to the IgG 
molecules may also alter the degree of steric hindrance by changing the surface 
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chemical properties of the heavy chains. Although my results demonstrate CEA-
specific fluorescence, the relationship between cellular CEA concentration and 
fluorescence is not clear. The fate of the ICG dye is also unknown. In all three cell 
lines the cytoplasmic fluorescence reduced after 48 hours suggesting it was either 
excreted by the cell or degraded within it. This reduction in fluorescence also 
suggests that either the membrane-bound CEA molecules were recycled at a slower 
rate than they were bound and internalised, leading to a saturation effect, or the all 
the ICG-anti-CEA was processed by the cell membrane. 
 
To model my proposed application for this imaging technique more closely, I 
conducted a pulse-chase experiment, where the cells were exposed to ICG-
antibodies for a limited time only. This is analogous to pre-operative intravenous 
delivery, metabolism and excretion. A similar approach has been used in studies 
concerning imaging agents for PET (Kuang et al., 2014) and MRI (Mayer-Kuckuk et 
al., 2005) of hepatocellular cancer and bone precursor cells respectively, but not for 
intra-operative imaging. I chose LS174T cells for this experiment because although 
the fold difference between test and control antibodies at 36 hours was 5.2 compared 
to 12.2 for HCT116 cells, the overall mean peak fluorescent signal was greater (13.9 
vs 4.35 vs 7.03 for LS174T, LoVo and HCT116 respectively) and showed the 
greatest difference in signal between one hour and peak (6.56 vs 2.57 vs 5.03). 
These data suggest that these cells would be most appropriate for future in vivo 
work. They have also been a popular choice by investigators using animal models of 
colorectal cancer, particularly in xenograft models (Ahlskog et al., 2009, Buchsbaum 
et al., 1988, Zou et al., 2009). 
 
Following incubation, I removed the media, washed the cells to remove unbound 
antibodies, and replaced the media with an aliquot from an identical glass-bottomed 
well containing LS174T cells seeded at the same time and from the same cell 
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population. This was to ensure that the behaviour of the cells was not affected by 
removing the antibodies; the addition of fresh media could potentially increase 
internalisation and distort the results, precluding comparisons with the previous 
experiment where the antibodies were not removed. This is known as ‘conditioned 
media’, and contains metabolites, growth factors and extracellular matrix proteins 
secreted by the cancer cells (Michielsen et al., 2012). The fluorescent signal 
measurements followed the same pattern as the previous experiment, with a 
significant increase in fluorescence up to peak at 36 hours and then a significant 
decrease between 36 and 48 hours. Interestingly, the fold change between six and 
36 hours was greater in this pulse and chase experiment than in the previous 
continuous incubation experiment (4.1 vs 1.9). 
 
The potential of this imaging system for colorectal cancer is greatly enhanced by the 
nature of the reagents; ICG is approved for human use by both the FDA and MHRA, 
and A5B7 anti-CEA antibody has been used in a number clinical trials. If these in 
vitro results can be replicated in vivo, translation to the operating theatre will be rapid. 
My results suggest that peak fluorescence lasts for several hours, making it ideal for 
surgical resection. 
 
In conclusion, A5B7 anti-CEA antibodies conjugated to ICG allow CEA-specific 
fluorescence in vitro in a variety of colorectal cancer cell lines. These data suggest 
clear potential for tumour-specific imaging in a range of tumour types. This warrants 
further investigation. 
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Chapter Six 
 
 
CEA-targeted, dye-doped silica 
nanoparticles allow specific in vivo 
fluorescent imaging of colorectal 
cancer models 
 
 
 
 
Some of the text and figures in this chapter have been published in the manuscript 
“CEA-targeted nanoparticles allow specific in vivo fluorescent imaging of colorectal 
cancer models” (Nanomedicine 2015; 10(8):1223-31) and reproduced here with 
permission. 
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6 CEA-TARGETED, DYE-DOPED SILICA 
NANOPARTICLES ALLOW SPECIFIC IN VIVO 
FLUORESCENT IMAGING OF COLORECTAL 
CANCER MODELS 
 
 
6.1 Abstract 
 
Background 
Fluorescent laparoscopic imaging of primary colorectal tumours and lymph node 
metastases would improve localisation of early tumours and allow intra-operative 
staging, potentially facilitating intra-operative stratification of the extent of surgical 
resections thereby improving patient outcomes. I aimed to develop and test 
fluorescent nanoparticles capable of allowing localisation of tumours in vivo. 
 
Methods 
Dye-doped silica nanoparticles loaded with NIR664 dye were synthesised using a 
water-in-oil microemulsion technique. Anti-CEA IgGs or control IgGs were conjugated 
to nanoparticles using four different chemistries: sulfosuccinimidyl-4-(N-
maleimidomethyl)cyclohexane-1-carboxylate (sulfo-SMCC); polyethylene glycol 
(PEG); 1-Ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride (EDC); or 
polyamidoamine dendrimers (PAMAM). Binding of CEA-targeted or control 
nanoparticles to colorectal cancer cells (LS174T, LOVO and HCT116) was quantified 
in vitro using confocal microscopy and ImageJ. A murine xenograft model and IVIS 
imaging were used to assess PAMAM-linked nanoparticles in vivo. 
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Results 
CEA-targeted, PAMAM dendrimer-conjugated, nanoparticles allowed strong tumour-
specific targeting, demonstrating 12.3-, 8.0- and 3.2-fold greater fluorescence than 
control IgG-targeted nanoparticles when incubated with LS174T, LoVo and HCT116 
cells respectively (p<0.002). EDC-linked nanoparticles showed 1.7 fold greater 
binding of CEA-targeted nanoparticles in LoVo cells only (p=0.016). Use of sulfo-
SMCC or PEG did not allow significant tumour-specific labelling. In LS174T 
xenografts, CEA-targeted nanoparticles demonstrated clear tumour-specific 
fluorescence from 6 to 72h after injection, as compared to only background 
fluorescence for control IgG-targeted nanoparticles at all time points (median radiant 
efficiency at 48h, ηe=16 x10
7 v 0, p<0.0001). 
 
Conclusion 
These findings are the first to demonstrate live tumour-specific fluorescent colorectal 
cancer imaging using an antibody-targeted nanoparticle in vivo. Dye-doped silica 
nanoparticles conjugated to anti-CEA antibodies via PAMAM dendrimers have 
potential to allow intra-operative fluorescent visualisation of tumour cells. 
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6.2 Introduction 
 
In the previous chapter I exploited a unique feature of the near-infrared dye 
indocyanine green to improve the signal-to-background ratio of fluorescent anti-CEA 
antibodies. In an effort to further improve the required criteria for an in vivo molecular 
imaging probe (section 1.3.3), I aimed to develop a non-toxic, fluorescent 
nanoparticle capable of concentrating the fluorescent signal to allow sensitive and 
specific detection of colorectal cancer cells. Many types of nanoparticles have been 
described. The particular challenge in this application was to construct a particle that 
could simultaneously fluoresce and target tumour cells. Dye-doped silica 
nanoparticles (Santra et al., 2001) potentially meet the required criteria for in vivo 
imaging - a near-infrared fluorophore can be incorporated into their centre, there are 
multiple surface chemistry options for antibody conjugation and they are potentially 
small enough for in vivo systemic delivery. 
 
6.2.1 Aims 
The aims for this part of my project were to: 
 
i. Manufacture and characterise a dye-doped silica nanoparticle 
ii. Conjugate anti-CEA and control IgG antibodies to the surface of the particle 
using a variety of chemical linking strategies; 
iii. Assess the ability of the nanoparticles to bind to tumour cells in vitro and 
quantify the specificity and fluorescent signal magnitude for each linking 
strategy; 
iv. Test the best performing nanoparticle in a murine model of colorectal cancer 
in vivo. 
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I used two fluorescent dyes in this work to dope the silica particles: RuBpy and 
NIR664. RuBpy (Tris(bipyridine)ruthenium(II) chloride) has excitation and emission 
wavelengths of 452 nm and 640 nm respectively (Santra et al., 2001), is water-
soluble and benefits from a long excited state lifetime (Rivarola et al., 2006), meaning 
the fluorescent signal persists for longer than other fluorophores. It has been used in 
the vast majority of published studies involving targeted dye-doped silica 
nanoparticles (Chen et al., 2012, He et al., 2013, He et al., 2008, He et al., 2012, 
Heitsch et al., 2008, Santra et al., 2001, Tan et al., 2010a, Tao et al., 2013, Wang et 
al., 2005, Wu et al., 2008, Hun and Zhang, 2007). NIR664 is an iodoacetamide dye 
with excitation and emission wavelengths of 672 nm and 694 nm respectively. It is 
stable across a wide range of pH values, has a quantum efficiency (ratio of light 
emitted to light absorbed) of 23%, a molar absorptivity (how well it absorbs light) of 
187000 L mol-1 cm-1 and is relatively cheap (Mank and Yeung, 1995, Nooney et al., 
2009). This compares to a quantum efficiency of 14% and molar absorptivity of 
14600 L mol-1 cm-1 for RupBy (Kalyanasundaram, 1982, Reithmeier et al., 2012). 
 
I aimed to target dye-doped silica nanoparticles to carcinoembryonic antigen (CEA) 
using the anti-CEA antibody from previous chapters. I also aimed to use robust 
controls, a feature absent in the majority of published studies, comprising of identical 
nanoparticles conjugated to IgG antibodies specific to an antigen not found on the 
surface of colorectal cancer cells. I aimed to assess four chemical linking strategies: 
 
i. sulfo-succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC); 
ii. polyethylene glycol (PEG); 
iii. 1-Ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride (EDC); 
iv. polyamidoamine  dendrimers (PAMAM). 
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SMCC is a heterobifunctional linker that can be used to conjugate a molecule with a 
free amine group to a molecule with a free sulfhydryl group. At the time of this work, 
SMCC was a very novel linker for conjugating nanoparticles to reduced antibodies for 
cell targeting. Only one published manuscript had described linking a reduced 
antibody to a fluorescent probe but in this case a quantum dot was used rather than 
a larger nanoparticle (Tiwari et al., 2009). The theoretical advantage of using reduced 
antibodies is that their orientation at the surface of the nanoparticle is controlled, as 
the location of the sulfhydryl group is known. In contrast, when amine groups on IgG 
antibodies are used, the location of the bond, and therefore the orientation of the 
antibody, are unknown and unpredictable (Xiao et al., 2014). 
 
PEG is widely used in medicine, principally as a laxative (Dipalma et al., 1984). 
Incorporation of PEG, a hydrophilic co-polymer, to nanoparticle surfaces has been 
shown to effectively increase the circulating half-life by preventing opsonisation by 
the reticuloendothelial system (RES) (Owens Iii and Peppas, 2006). PEG molecules 
consist of repeating units and are therefore available in a range of lengths. I was 
therefore keen to test this as a potential linker for my application. I selected a short, 
bifunctional PEG linker capable of conjugating amine groups to sulfhydryl groups on 
reduced antibodies. 
 
EDC is known as a zero-length crosslinker due to the ‘leaving group’ that is formed 
when it is used to conjugate carboxyl and amine groups. It has been used to 
conjugate whole IgG antibodies to silica nanoparticles (Zhao et al., 2004b, Wu et al., 
2008) for tumour targeting in vitro but no in vivo studies have been published. 
 
The use of dendrimers to conjugate antibodies to nanoparticles is novel, having been 
described by just one group (Gubala et al., 2010). Dendrimers are branched chains 
that can be synthesised to have a specific number of branches or ‘generations’. 
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Whilst their structure inevitably increases the overall size of a nanoparticle, the 
surface density of available binding sites is increased and the inherent charge of the 
nanoparticle-antibody complex is potentially altered, which may increase 
bioreactivity. 
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6.3 Results 
 
6.3.1 Dye-doped silica nanoparticles: manufacture and 
characterisation 
I manufactured basic dye-doped silica nanoparticles using a water-in-oil 
microemulsion technique. This produced particles with a fluorescent core and a silica 
shell surrounding it. I initially used the fluorescent dye Tris(2,2′-
bipyridyl) dichlororuthenium (II) hexahydrate (RuBpy) as this had shown promise in 
the few studies that had successfully synthesised this type of nanoparticle. In later 
experiments I used NIR664, an iodo-acetamide dye, which has a longer wavelength, 
potentially reducing autofluorescence. I aimed to characterise these particles by 
measuring their size, the density of amine groups available for binding and their 
fluorescence spectra. 
6.3.1.1 Physical characterisation of ‘bare’ nanoparticles 
6.3.1.1.1 Amine group quantification 
After manufacturing the basic dye-doped silica nanoparticle, I aminated the surface 
using 3-aminopropyltriethoxysilane (APTES). The amine groups allow conjugation of 
biofunctional linkers and their availability for binding is therefore essential for my 
proposed application. To determine the number of available groups I used 
fluorenylmethyloxycarbonyl chloride (Fmoc-Cl) in a method adapted from previously 
published work (Chen and Zhang, 2011). Following nanoparticle amination, I 
conjugated fluorescent Fmoc-Cl molecules to the free amine groups on the outer 
shell and then cleaved them using piperidine. I calculated how many amino groups 
were bound by measuring the absorbance of the solution containing the cleaved 
Fmoc-Cl molecules with reference to a standard curve for Fmoc-Cl absorbance 
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(Figure 6.1). My result of 3.41 x10-7 mol/m is greater than the only other published 
study to quantify available amino groups in dye-doped silica nanoparticles (1.1 x10-8 
mol/mg), albeit using a slightly different method (Liu et al., 2007). 
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Sample 
 
Fluorescence 
Conc 
(mM)
 Dilution 
Sample 
mass (mg) 
Mol Fmoc/mg 
X Avagadro’s 
constant (amine 
groups/mg) 
 
1 
 
453.0 14.9 1:30 3.3 1.51 x10
-7
 9.09 x10
15
 
 
2 
 
425.3 13.9 1:10 4 3.48 x10
-7
 20.96 x10
15
 
 
3 
 
404.5 13.1 1:10 2.5 5.24 x10
-7
 31.56 x10
15
 
 
 
 
Mean 3.41 x10
-7
 2.054 x10
16
 
 
Figure 6.1. The availability of amine groups on the surface of the bare 
nanoparticle quantified using Fmoc-Cl. 
Dye-doped silica nanoparticles were manufactured using a water-in-oil 
microemulsion technique and aminated using APTES. Fmoc-Cl molecules were 
bound to the free amine groups on the particle surface before being cleaved and 
measured. A standard curve was plotted for Fmoc and readings taken for samples 
from three separate batches of bare nanoparticles. 
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6.3.1.1.2 Fluorescence analysis 
To assess the fluorescence of the basic nanoparticles I used a fluorometer and 
recorded excitation and emission spectra at various concentrations. The peak 
excitation and emission wavelengths for particles loaded with RuBpy dye were 458 
and 607 nm respectively (Figure 6.2) and 665 and 686 nm for NIR664-loaded 
particles. The fluorescent signal produced by particles suspended in phosphate 
buffered saline increased with increasing concentration up to approximately 1 mg/ml, 
after which the signal reduced (Figure 6.3). I used these data to plan later in vitro and 
in vivo experimental protocols. 
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Figure 6.2. Fluorescence spectra of RupBy-doped and NIR664-doped silica 
nanoparticles. 
Dye-doped silica nanoparticles were manufactured using a water-in-oil 
microemulsion technique and suspended in PBS. Peak absorption and emission 
wavelengths labelled for RupBy- and NIR664-doped particles. Relative intensities are 
not comparable due to setup differences. 
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Figure 6.3. The relationship between RupBy-doped nanoparticle concentration 
and emission fluorescence. 
Dye-doped silica nanoparticles were manufactured using a water-in-oil 
microemulsion technique and suspended in PBS at various concentrations. The 
fluorescent signal fell at concentrations in excess of 1 mg/ml. 
 
 
6.3.1.1.3 Particle size 
To measure particle size I used field emission gun scanning electron microscopy 
(FEG-SEM). I recorded images of a sample of the nanoparticles, randomly selected 
50 and measured their diameter (Figure 6.4). The mean diameter was 56.57 nm 
(standard error of the mean = 0.99; standard deviation = 6.99). 
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Figure 6.4. Size distribution of dye-doped silica nanoparticles. 
NIR664-doped silica nanoparticles were manufactured using a water-in-oil 
microemulsion technique. The particles were imaged using FEG-SEM (left) and the 
diameter of 50 randomonly-selected particles was measured using Photoshop. The 
size distribution is shown as a histogram (right). The mean diameter was 57 nm. 
 
 
6.3.2 Chemical linkage strategies for antibody conjugation 
I used a variety of chemical linkage strategies to attach antibodies to NPs.  In each 
case, the chemistry is different and the assays used to assess successful 
conjugation are different.  For example, SMCC required reduced “half” antibodies for 
conjugation as the chemistry is based on linking free amine groups to sulfhydryl 
groups, while EDC required whole antibodies conjugated via amine to carboxyl 
groups (Figure 6.5).  Assays to assess conjugation include assessment of loss of 
sulfhydryl groups after conjugation, or measurement of the physical increase in size 
of the particles after conjugation. The conjugation strategies and their 
characterisation are described below in turn. 
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Figure 6.5. Nanoparticle-antibody conjugation. 
Left: SMCC and bifunctional PEG were used to conjugate reduced antibodies to the 
nanoparticle. Right: EDC and PAMAM dendrimers were used to link whole IgG 
antibodies to the aminated surface of the dye-dopes silica nanoparticle. 1 = 
fluorescent core; 2 = silica shell; 3 = biofunctional cross linker; 4 = antibody. 
 
 
6.3.2.1 SMCC linkage to nanoparticles 
I aimed to reduce anti-CEA antibodies and then link them via a free sulfhydryl group 
(Figure 6.6 and Figure 6.7) to the aminated nanoparticle surface using SMCC. I used 
2-MEA to reduce the IgG antibodies, removed unreacted 2-MEA using spin 
centrifuge filters and examined the resultant protein species using high-pressure 
liquid chromatography (HPLC).  I found that the 2-MEA had successfully reduced the 
antibody, producing two peaks, corresponding to non-reduced IgG molecules (the 
first peak, due to the larger molecular mass) and reduced IgG molecules. 
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Figure 6.6. IgG antibody reduction. 
IgG antibodies were successfully reduced using 2-MEA. The antibodies were 
incubated with 2-MEA at 37 Celsius for one hour to selectively reduce the disulphide 
bonds between heavy chains, providing free sulfhydryl groups for conjugation to 
SMCC. The solution was then subjected to HPLC. Peak (a) corresponds to whole, 
non-reduced IgG molecules (~150 kDa) and peak (b) to reduced IgG molecules (~75 
kDa). 
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I incubated the aminated nanoparticles with SMCC and then washed them with 
ethanol to remove any unreacted biolinker. I then added the reduced antibody 
solution (containing both whole and reduced IgG molecules), incubated the mixture 
to allow conjugation and washed the particles with ethanol to remove unbound 
antibody. To confirm that the reduced antibodies had bound to the nanoparticles, I 
used Ellman’s reagent to measure available sulfhydryl groups (Sedlak and Lindsay, 
1968). Immediately after reduction with 2-MEA, 1.2 mg of A5B7 anti-CEA IgG 
antibody yielded 1.34 x 10-4 moles of sulfhydryl groups. Following incubation with the 
SMCC-conjugated nanoparticles, the reaction supernatant contained 4.21x10-7 moles 
of sulfhydryl groups. I concluded that the reduced antibodies appeared to have 
bound to the surface of the nanoparticles and, given that the residual sulfhydryl 
groups remained available despite prolonged incubation, that the available binding 
sites were likely to be saturated.  
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Figure 6.7. SMCC conjugation. 
SMCC reacts with the aminated nanoparticle surface to form a stable amide bond 
with a maleimide group that can then be conjugated to the free sulfhydryl group on a 
reduced IgG fragment. 
 
 
6.3.2.2 Bifunctional PEG linkage to nanoparticles 
I used bifunctional PEG crosslinkers to conjugate reduced antibodies in a similar 
fashion, linking free amine groups on the surface of the nanoparticles to the free 
sulfhydryl groups on reduced antibodies (Figure 6.8). Ellman’s reagent was again 
used to quantify available sulfhydryl groups before and after antibody and 
nanoparticles incubation and confirmed a reduction (1.97 x 10-4 moles versus 1.33 x 
10-6 moles). I concluded that the reduced antibodies appeared to have bound to the 
surface of the nanoparticles and, given that the residual sulfhydryl groups remained 
available despite prolonged incubation, that the available binding sites were likely to 
be saturated. 
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Figure 6.8. Bifunctional PEG conjugation. 
Bifunctional PEG crosslinker was used to conjugate reduced IgG antibodies to 
aminated nanoparticles. 
 
 
6.3.2.3 EDC linkage to nanoparticles 
I carboxylated the nanoparticle surface and then used EDC (Figure 6.9) to link whole 
IgG antibodies. To confirm that the antibodies had bound and that no unbound 
antibodies remained in the nanoparticle suspension following wash steps, I 
measured the absorbance of the reaction mixture and each discarded supernatant 
following centrifugation. In each case, the absorbance at 280 nm, corresponding to 
protein, reduced following incubation and washing (Figure 6.10). From this assay I 
was able to confirm that: i) the antibodies were immobilised onto the nanoparticles; ii) 
the available binding sites were saturated; and iii) repeated washing via 
centrifugation successfully removed unbound antibodies. 
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Figure 6.9. EDC conjugation. 
EDC and sulfo-NHS were used as a zero length crosslinker to conjugate 
carboxylated nanoparticles and whole antibodies. 
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Figure 6.10. Absorbance assay to determine effectiveness of particle washing. 
Absorbance at 280 nm of the reaction mixture (in this case sulfo-NHS, EDC and anti-
CEA antibodies) prior to the nanoparticles being added (pre-incubation), following 
incubation but with the nanoparticles removed, and of the supernatant following 
washes in ethanol.  
 
 
6.3.2.4 PAMAM linkage to nanoparticles 
I also used PAMAM dendrimers to link whole IgG antibodies to the nanoparticle 
surface (Figure 6.11). I used EDC as a zero crosslinker between the dendrimer and 
nanoparticle and between the dendrimer and whole antibodies. I repeated the 
absorbance assay used to confirm antibody immobilisation on the nanoparticles. Of 
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the four linking strategies tested, PAMAM dendrimer conjugation leads to the 
greatest change in nanoparticle diameter due to its size (approximately 50 
Angstroms). The next largest linker, PEG, is 17.6 Angstroms when conjugated. I 
therefore aimed to compare the size of ‘bare’ nanoparticles and CEA-targeted 
nanoparticles where PAMAM had been used as the linker. The mean diameter of 
PAMAM linked nanoparticles was 71 nm (standard error of the mean = 20.85, 
standard deviation 20.02 nm), compared to 57 nm (standard error of the mean = 
0.99, standard deviation = 6.99 nm) for bare nanoparticles (Figure 6.12). I concluded 
that the targeted nanoparticles were still small enough to fulfil the requirements for 
my proposed application. 
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Figure 6.11. PAMAM dendrimer conjugation. 
PAMAM dendrimers can be used to conjugate aminated nanoparticles to whole 
antibodies. PAMAM dendrimers are branched chain molecules that can be 
synthesised to contain a specified number of branches. Top: PAMAM generation 1.5 
carboxylate sodium salt dendrimer. Half generations leave an outer carboxyl group 
available for binding to amines via EDC. Each of the four ‘R’ groups has four carboxyl 
groups available for binding amines. Bottom: I used PAMAM generation 4.5 
carboxylate sodium salt dendrimers to conjugate aminated nanoparticles to whole 
IgG antibodies. Each ‘R’ group in this case has 16 available carboxyl groups, due to 
the increased number of branches (four versus one). 
 
 
 
Figure 6.12. Bare particle versus targeted particle size. 
Bare dye-doped silica nanoparticles had a mean diameter of 57 nm (standard error of 
the mean = 0.99, standard deviation = 6.99 nm) and nanoparticles conjugated to anti-
CEA antibodies via PAMAM dendrimers had a mean diameter of 71 nm (standard 
error of the mean = 20.85, standard deviation = 20.02 nm, p<0.0001, unpaired t-test). 
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6.3.3 In vitro analysis of binding of colorectal cancer cells by 
targeted nanoparticles 
I aimed to assess the potential of each of the linking strategies for directing tumour-
specific fluorescent imaging quantitatively. To do this I aimed to compare the ability 
of each conjugated NP type to direct binding of NPs to CEA-positive colorectal 
tumour cells in vitro. To assess the specificity of these interactions, in each case I 
compared binding directed by the anti-CEA antibody used previously, with a control 
IgG, specific for the glycoside digoxin. Using a control IgG antibody results in a 
control nanoparticle that is virtually identical in structure and chemical properties to 
the CEA-targeted nanoparticle. Digoxin is not expressed by colorectal cancer cells, 
as I have shown in chapter five and therefore anti-digoxin is a suitable control IgG 
molecule. The use of ‘bare’ nanoparticles as a control is inappropriate as the surface 
chemistry will be different from targeted particles, with inevitable differences in 
surface charge, size and potential for non-specific binding. 
 
Three different colorectal cell lines were used, each of which is expresses CEA at 
differing concentrations as demonstrated on Western blot analysis in section 5.3.2.2: 
LoVo cells have a high expression, LS174T cells a moderate/high expression and 
HCT116 cells a low expression. To assess nanoparticle binding, I used confocal 
microscopy to obtain fluorescent images and quantified fluorescence digitally in two 
ways: within a representative optical section through the cells, and within a  
‘maximum image projection image’ (MIP), where the signals from multiple images 
taken throughout the depth of the cell are compressed and merged into a single 
image (see section 2.7.5.4 for further details). Data are expressed as the fold 
difference in fluorescent intensity between the cells incubated with control and CEA-
directed particles. 
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PEG- and SMCC- linked nanoparticles failed to demonstrate any antibody-dependent 
tumour cell binding. A high degree of non-specific binding was observed with SMCC-
linked particles whilst PEG-linked particles produced very little signal (Figure 6.13). 
Similarly, nanoparticles conjugated using EDC showed very poor antibody-
dependent tumour cell binding, with only 1.7-fold greater binding of CEA-targeted 
nanoparticles as compared to control in only one cell line (LoVo, p=0.017). 
 
 
 
Figure 6.13. Fluorescence analysis: SMCC, PEG and EDC. 
Antibody conjugation of dye-doped silica nanoparticles using SMC, PEG or EDC 
failed to allow consistent specific fluorescent imaging in LoVo cells. LoVo cells were 
incubated with either nanoparticles conjugated to either anti-CEA, or control 
antibodies using conjugation chemistry based on SMC, PEG or EDC as shown. 
Fluorescent images were collected using confocal microscopy and fluorescence was 
quantified. Representative phase contrast and fluorescent central optical section 
images are shown (magnification, x 63). Graphs representing mean fluorescence 
(with standard deviations) are shown; significance was tested using unpaired t-tests. 
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Conjugation via PAMAM dendrimers allowed strong tumour-specific targeting, with 
CEA-targeted nanoparticles demonstrating 12.3-, 8.0- and 3.2-fold greater 
fluorescence than control in LS174T, LoVo and HCT116 cells respectively (p<0.002) 
for the single slice analysis (Figure 6.14). A similar pattern of successful CEA-
targeted fluorescence was observed in the MIP analysis, with CEA-targeted 
nanoparticles demonstrating 4.5-, 3.7- and 2.6-fold greater fluorescence than control 
particles in LS174T, LoVo and HCT116 cells respectively (p<0.0002). The results are 
summarised in Table 6.1. A three-dimensional fluorescent reconstruction image 
provided further confirmation that the nanoparticles were immobilised at the cell 
surface (Figure 6.15). 
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Figure 6.14. Fluorescence analysis: PAMAM dendrimers. 
Dye-doped silica nanoparticles conjugated to anti-CEA antibodies via PAMAM 
dendrimers allow specific fluorescent imaging of colorectal cancer cell lines in vitro. 
Three different colorectal cancer cell lines were incubated with either nanoparticles 
conjugated to anti-CEA, or to control antibodies. Images were collected using 
confocal microscopy and fluorescence was quantified. Representative images are 
shown (magnification, x 63): A) phase contrast and fluorescent central optical 
sections; B) phase contrast and maximum image projection. Graphs representing 
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mean fluorescence (with standard deviations) are shown; significance was tested 
using unpaired t-tests. 
 
 
 
Table 6.1. Summary of in vitro fluorescence quantification analysis. 
Data from control and test experiments were compared using both parametric and 
non-parametric statistical analyses. MIP = maximum intensity projection. Statistically 
significant results in bold. 
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Figure 6.15. Three dimensional reconstruction of nanoparticle-coated cells. 
Dye-doped silica nanoparticles conjugated to anti-CEA antibodies via PAMAM 
dendrimers bind to the cell membrane of LoVo cells. Nanoparticles were incubated 
with fixed cells and fluorescent images captured with confocal microscopy. A three-
dimensional reconstruction was created using NHS-Elements software version 4.0 
from z-stack images. 
 
 
I concluded that dye-doped silica nanoparticles conjugated to anti-CEA antibodies via 
PAMAM dendrimers allowed tumour cell-specific fluorescent targeting in vitro, and 
had shown sufficient promise to justify testing in an animal model of colorectal 
cancer. 
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6.3.4 In vivo analysis of binding of colorectal cancer cells by 
targeted NPs 
Having demonstrated specific targeting of colorectal cancer cells in vitro using 
PAMAM-conjugated nanoparticles, I aimed to test their potential for in vivo 
fluorescent targeting. To do this I designed a series of experiments involving 
systemic nanoparticle delivery to a murine xenograft model of colorectal cancer. 
6.3.4.1 NIR664-doped silica nanoparticles are detectable in vivo. 
First I confirmed that the IVIS small animal imaging system, which was to be used for 
all in vivo experimental imaging, was capable of detecting the fluorescent signal from 
the nanoparticles. I suspended the particles in PBS at 2 mg/ml, 200 µg/ml and 20 
µg/ml and took fluorescent images with the appropriate wavelengths selected (Figure 
6.16). I planned to use a dose of 50 mg/kg in the targeting experiments, in line with 
other silica nanoparticle mouse experiments (Meng et al., 2011, Tivnan et al., 2012), 
which equates to approximately 625 µg/ml (assuming a six week old BALB/c nu/nu 
female mouse has a weight of 25 g and circulating blood volume of 80 ml/kg 
(Doevendans et al., 1998) with uniform nanoparticle distribution throughout the 
vascular compartment). The strong fluorescent images I obtained with a 200 µg/ml 
suspension suggested that the IVIS system should be able to detect this 
concentration. 
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Figure 6.16. Fluorescent nanoparticles are detectable using an IVIS imaging 
system. 
CEA-targeted nanoparticles suspended in PBS were detected using an IVIS small 
animal imaging system. Nanoparticles were in Eppendorf Tubes and blanked out with 
black card to allow comparison. Left: 2 mg/ml. Middle: 200 µg/ml. Right: 20 µg/ml. 
 
 
Next I aimed to determine in a pilot experiment whether nanoparticles delivered 
systemically to mice were detectable, for how long, and their location. I injected CEA-
targeted nanoparticles into the tail veins of three 6 week old BALB/c nu/nu female 
mice (without xenograft tumours) and took live IVIS images one minute, one hour, 24 
hours, 48 hours and 72 hours after injection (Figure 6.17). At 24 hours post-injection, 
I sacrificed one of the mice, retrieved the liver, kidneys and spleen, and imaged the 
organs ex vivo. I did the same with a control mouse that had not been injected with 
nanoparticles. 
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Figure 6.17. Systemically delivered nanoparticles are detectable in vivo. 
Mice were injected with CEA-targeted nanoparticles and were imaged either 
individually or in groups using IVIS at various times as shown. Note that the injection 
in Mouse 1 failed to deliver successfully to the vein as evidenced by the fact that 
particles are visible in the subcutaneous tissues at one minute and one hour. At one 
hour post-injection, all three mice were imaged as normal (top picture) but also with 
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the tail fluorescence in Mouse 1 ‘blanked’ with black card (bottom picture), allowing 
the IVIS system to auto-expose and detect more sensitively the fluorescence in the 
livers of Mouse 2 and Mouse 3. Mouse 1 was subsequently imaged separately. After 
24 hours, organs were harvested from Mouse 3 and imaged ex vivo (panel B), along 
with the same organs from a mouse that had not received the nanoparticles. Only 
Mouse 2 was imaged at 48 and 72 hours.   
 
 
The tail vein nanoparticle injection failed in Mouse 1, and the fluorescent signal 
remained in the subcutaneous tissues of the tail with no apparent decrease in signal 
even at 48h hours. The other mice demonstrate systemic delivery of particles within 
one minute and accumulation in the liver within one hour, consistent with hepatic 
excretion. At 24 hours post-injection there appeared to be biliary fluorescence in 
addition to hepatic fluorescence. By 72 hours, the hepatic fluorescence had 
decreased, leaving only biliary fluorescence. This was suggestive of hepatobiliary 
excretion, a feature observed previously in systemically delivered silica nanoparticles 
(Souris et al., 2010). The mean fluorescence of the ex vivo liver from Mouse 3 at 24 
hours was 37.26x107 p/sec/cm2/sr/µW/cm2, compared to a degree of natural 
fluorescence of 0.454x107 p/sec/cm2/sr/µW/cm2 for the control mouse liver (a fold 
difference of 82). The control mouse spleen and kidney exhibited no natural 
fluorescence whilst the spleen and kidney from mouse three exhibited low level 
fluorescence (0.477 and 0.337x107 p/sec/cm2/sr/µW/cm2 respectively). 
 
I concluded that the nanoparticles were detectable in vivo, were deliverable 
systemically, and were metabolised and excreted predominately by the liver. 
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6.3.4.2 CEA-targeted fluorescent nanoparticles can be used for tumour-
specific imaging in a murine xenograft model of colorectal cancer 
For my final experiment, I aimed to test whether CEA-targeted nanoparticles were 
capable of tumour-specific labelling, as measured by fluorescence, in vivo. I injected 
seven mice bearing LS174T xenograft tumours with either CEA-targeted or control 
IgG-targeted nanoparticles and obtained fluorescent images at one minute, one hour, 
six hours, 24 hours, 48 hours and 72 hours post-injection (Figure 6.19). One of the 
tail vein injections failed, leaving three test and three control mice. Liver fluorescence 
was evident at six hours (mean 80.1x106 p/sec/cm2/sr/µW/cm2) and peaked at 24 
hours (89.8x106 p/sec/cm2/sr/µW/cm2) before reducing (48 hours: 74.2x106 
p/sec/cm2/sr/µW/cm2 and 72 hours: 48.0x106 p/sec/cm2/sr/µW/cm2) (Figure 6.18). 
 
 
 
Figure 6.18. Hepatic fluorescence is similar for control and CEA-targeted 
nanoparticles. 
Hepatic fluorescence following systemic delivery of control and CEA-targeted 
nanoparticles in vivo. Fluorescence peaked at 24 hours and reduced thereafter. 
There was no significant difference in hepatic fluorescence between mice injected 
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with control particles and those injected with CEA-targeted particles at any time point 
(p ranging from 0.3 to 0.9). 
 
 
Hepatic localisation was confirmed by ex vivo imaging of isolated organs. There was 
no significant difference in liver fluorescence between mice injected with control 
particles and those injected with CEA-targeted particles at any time point (p ranging 
from 0.3 to 0.9, Mann Whitney Test). Fluorescence in other mouse tissues was not 
seen for either control or CEA-targeted particles, demonstrating that the particles 
have negligible non-specific or antibody directed binding to host cells. Substantial 
tumour fluorescence was detected in all mice injected with CEA-targeted 
nanoparticles from six hours post-injection. Mean tumour fluorescence increased 
over the whole experiment from six hours (mean 0.62x107 p/sec/cm2/sr/µW/cm2) to 
72 hours (mean 4.74x107 p/sec/cm2/sr/µW/cm2), although increases were only small 
after 48 hours. Mice injected with control IgG-targeted nanoparticles showed no 
tumour fluorescence above background at any point (Figure 6.20). Fluorescence in 
the CEA-targeted tumours was significantly greater than controls at every time point 
after and including 6 hours (p<0.0001, Wilcoxon Signed Rank Test). The continued 
accumulation of tumour fluorescence with the CEA-targeted nanoparticles for up to 
72 hours suggests that at least a proportion of the conjugated particles are stable in 
the circulation for a minimum of 72 hours. 
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Figure 6.19. Systemic administration of CEA-targeted nanoparticles leads to 
tumour-specific fluorescence in a xenograft murine model of colorectal cancer. 
No tumour cell fluorescence was observed in mice injected with control-IgG targeted 
nanoparticles whereas in all three mice injected with CEA-targeted nanoparticles 
tumour cell fluorescence was observed. Control images at 72 hours not available. L = 
liver, T = tumour. 
 
 
 
 
Figure 6.20. CEA-targeted nanoparticles allow fluorescent tumour detection in 
vivo. 
Mean tumour fluorescence at 72 hours post-injection was 4.74x107 
p/sec/cm2/sr/µW/cm2 for mice injected with CEA-targeted nanoparticles. No tumour 
fluorescence above background was detected in control mice (p<0.0001). 
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6.4 Discussion 
 
In this chapter I sought to use nanotechnology to provide a concentrated fluorescent 
signal in an antibody-mediated, tumour specific, in vivo imaging system. 
Nanoparticles can be synthesised to be a large variety of sizes, shapes and chemical 
compositions. Polymeric microspheres, synthesised using an emulsion 
polymerisation process, have tended to be the most common type of particle used in 
biological applications (Soppimath et al., 2001). I initially focussed on polymeric 
nanoparticles as our laboratory had some prior experience with their synthesis 
(Vakurov et al., 2009). Their size can be readily controlled and their surface can be 
functionalised with a variety of groups for conjugation. However, both the fluorophore 
and antibody would need to be immobilised onto the surface using the same 
functional group: whilst theoretically possible this would require accurate and in-
depth information about the reaction kinetics of each molecule for the appropriate 
ratio of antibody:fluorophore to be predicted and achieved. Dye-doped silica 
nanoparticles (Ow et al., 2005, Santra et al., 2001) represent a better solution: they 
have an inherent fluorescent core so the surface can be used solely for targeting; 
they are sufficiently small for my purposes; they are chemically inert and 
comparatively non-toxic; and they can be functionalised for conjugation to proteins 
relatively easily. They can be synthesised by two methods: the Stober method or the 
water-in-oil reverse microemulsion method. I chose to focus on the latter because, 
compared to the former, particles tend to be monodispersed and their diameter is 
easier to control, particularly below 100 nm (Bagwe and Khilar, 2000, Bagwe et al., 
1999).  
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6.4.1 Manufacture and optimisation of dye-doped silica 
nanoparticles 
The synthesis of the basic nanoparticle can be broadly divided into three parts: 
 
i. Dye-doping a silica matrix. This is where fluorescent molecules are 
embedded in silica and this forms the fluorescent core of the particle. The 
silica matrix is hydrophilic so the choice of dye is important - polar dye 
molecules are best as the electrostatic interaction with the negatively-charged 
silica molecules leads to a stable core. In addition, the dye molecules must be 
large enough to prevent dye leakage from the pores in the silica matrix (Zhao 
et al., 2004a). Initially I used RuBpy dye, most commonly used in published 
studies, but later switched to NIR664 due to its near-infrared wavelength 
(Malik et al., 2011). 
 
ii. Formation of a water-in-oil microemulsion system. This is formed by creating 
a stable, transparent solution of water, surfactant and co-surfactant. The 
molar ratio of these compounds and the choice of surfactant determine the 
size of the particles. 
 
iii. Creation of dye-doped particles with a silica shell. This occurs through 
hydrolysis of tetraorthosilicate (TEOS), catalysed by ammonium hydroxide, 
and ‘nucleation’ of the dye-doped silica into the water pools inside the reverse 
micelles of the water-in-oil microemulsion. 
 
Having synthesised the basic dye-doped particle, the surface can be modified to 
make a functional group available for conjugation to another molecule. This group 
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determines the choice of linker for antibody conjugation. Within the remit of limiting 
the overall diameter of the particles as far as possible to allow them to pass out of the 
vasculature in vivo, three surface chemistries can be used. The basic particle has 
free -OH groups available and these were used for antibody conjugation in the 
original paper describing dye doped silica particles (Santra et al., 2001), in a study 
targeting human leukaemia cells in vitro. Cyanogen bromide was used to link the 
silica surface -OH groups to free amine groups on the leukaemia-specific cell-surface 
antibodies. The authors presented comparative images of leukaemia cells incubated 
with targeted and control nanoparticles, although fluorescence was not quantified. 
Cyanogen bromide appears not to have been repeated in any other relevant work, 
probably related to its toxicity and the associated practical implications. The surface 
free -OH groups can also be modified to make either amine or carboxyl groups 
available for conjugation. Amination occurs by the addition of 3-aminopropyl-
(triethoxyl)silane (APS). The amine groups can then be used for conjugation to free 
amine groups on whole antibodies via glutaraldehyde (Huang et al., 2009). 
Alternatively, carboxyl groups can be introduced by adding trimethoxysilyl-
propyldiethylenetriamine (DETA) (Zhao et al., 2004b, Lian et al., 2004). 
Carboxylation can also be achieved by reacting aminated particles with succinic 
anhydride and N,N-dimethylformamide (DMF) under an inert gas (Liu et al., 2007, 
Zhao et al., 2004b). Carboxyl-functionalised particles can then be conjugated to 
antibodies via streptavidin and biotin (Lian et al., 2004) or EDC (Liu et al., 2007, Wu 
et al., 2008, Zhao et al., 2004b). EDC is the most common linker used, and 
apparently the most successful conjugation method in published literature. SMCC 
has been used to conjugate whole antibodies to silica (Gubala et al., 2010) and iron 
oxide (Abdolahi et al., 2013) nanoparticles by converting free amine groups on the 
IgG antibody to sulfhydryl groups using Taut’s Reagent (2-iminothiolane). 
Conjugation using heterobifunctional PEG is a further option that can increase the 
particle circulating half-life by preventing reticulo-endothelial opsonisation (Owens Iii 
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and Peppas, 2006) and can link either a free amine or carboxyl group depending on 
the type polymer selected, all of which are available commercially. More recently 
dendrimers have also been used as novel linkers between nanoparticles and 
antibodies (Gubala et al., 2010). 
 
There are two key and recurring issues in this field: experiments have tended to be 
either non-controlled or poorly controlled with ‘bare’ nanoparticles used as opposed 
to the more appropriate choice of non-targeting antibodies; and there has been a lack 
of a robust fluorescence quantification assay to enable statistically significant 
conclusions to be drawn. These issues are of particular importance since I have 
shown non-specific binding of antibody-conjugated nanoparticles is prevalent using 
some conjugation strategies, while antigen-specific targeting is more problematic.  
 
I initially decided to focus on four linking chemistries. EDC has had the most 
promising results in published studies and was therefore a low risk strategy. Our 
laboratory has previously used reduced antibodies on nanoscale biosensor surfaces 
in an effort to control the orientation of the IgG molecule (Figure 6.6) and therefore 
increase the availability of antigen binding sites. I was keen to apply the same 
principle to my nanoparticles, using SMCC in the opposite manner to published 
studies by linking free amine groups on the nanoparticle surface to a sulfhydryl group 
made available by reducing an IgG antibody. I chose to use small length PEG linkers 
to conjugate reduced antibodies in the same way. Finally, I chose dendrimers to link 
whole antibodies. Although there was relatively little published literature relating to 
their use in this context, they potentially increase the number of available binding 
sites for the antibodies. 
 
Steps ii. and iii. above were optimised by the group who pioneered this type of 
nanoparticle (Bagwe et al., 2004). However, there is a paucity of robust data 
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available regarding the modification of the surface chemistry and conjugation to 
bioactive molecules. I designed the methodology for each surface modification 
(amination or carboxylation) and subsequent conjugation process (SMCC, PEG, 
EDC and PAMAM) by studying published work in related fields and breaking down 
each methodology into individual reaction steps so that I could optimise the reaction 
conditions for each in terms of molar ratio, temperature, pH and equipment used. 
This was very much a pragmatic process; it would theoretically be possible to 
optimise each step in great detail by systematically controlling and varying all of the 
various conditions but this would not be feasible or practical in the development of 
my novel application, where combining nanoparticles with a cellular system yields a 
huge number of further unknown variables. 
 
A major component of the manufacture process is the pelleting and re-suspending of 
the particles. This allows unreacted chemicals and/or reaction by-products to be 
removed, and for the suspension fluid to be changed so that the correct conditions 
can be achieved for the subsequent reaction step. Initially I used plastic tubes and 
relatively low centrifugation speeds, in line with the limited number of published 
studies (Liu et al., 2007), but found that this did not ‘wash’ the particles effectively. 
When I took SEM images of basic particles manufactured this way, surfactant was 
visible despite multiple wash steps. I therefore used higher centrifuge speeds but 
then found the nanoparticle pellet was difficult to re-suspend despite extensive 
sonication. I found that Corex glass centrifuge tubes overcame this problem, 
seemingly allowing much more efficient sonication of the pellet in comparison to 
plastic tubes, and allowing effective ‘washes’ (Figure 6.21). I also measured protein 
absorbance values for the supernatant produced in consecutive wash steps following 
antibody conjugation to check that the number of wash steps in my protocol was 
adequate for removing unbound IgG (Figure 6.10). 
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Figure 6.21. ‘Bare’ NIR664 doped silica nanoparticles. 
Left: dried particles; middle: pelleted particles during ethanol wash steps; right: pellet 
re-suspended in ethanol via sonication. 
 
 
Amination of the particles was required for all of my linking strategies. There are 
several established assays for quantifying the number of free amine groups in a 
substance (Habeeb, 1966) but they tend to rely on absorbance or fluorescence 
assays. This is a problem when the amine groups are located on a fluorescent 
particle as the results are distorted. A single paper has been published describing an 
optimised method for quantifying amine groups in fluorescent nanoparticles and I 
adapted this for use with my particles (Chen and Zhang, 2011), with similar results 
(approximately 2x1016 free amine groups per mg of particles, Figure 6.1). For 
conjugation using SMCC and bifunctional PEG, I used reduced antibodies. The 
antibodies were reduced using 2-MEA (Yoshitake et al., 1979). I was careful to use 
reaction conditions that resulted in cleavage of the disulphide bonds between the two 
heavy chains but preservation of the light chains and antigen binding capability. 
Typically this process produces a mixture of reduced and whole antibodies in a 2:3 
ratio. To confirm that I had successfully reduced the IgG antibodies I subjected the 
mixture to HPLC (Figure 6.6), the two peaks representing reduced and whole 
antibodies. Following incubation with sulfhydryl-reactive nanoparticles, I confirmed a 
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reduction in the number of free sulfhydryl groups present in the reaction mixture, 
suggesting that the reduced antibody fragments had bound to the nanoparticle 
surface. 
 
In order to maximise the fluorescent signal in my in vitro experiments, I measured the 
fluorescence of RuBpy-doped nanoparticles in suspension in PBS at various 
concentrations. A graph of the results increases to a plateau at 0.5 to 1 mg/ml with a 
decrease in fluorescence thereafter (Figure 6.3). This is probably due to self-
quenching, which tends to occur at higher concentrations due to the formation of 
dimers or other quenching complexes in the dye solution (Penzkofer and Lu, 1986). I 
stored my particles at 2 mg/ml in the dark and then used them at 1 mg/ml in my in 
vitro experiments. 
 
6.4.2 In vitro assays for specific antibody-directed binding 
I carefully designed my in vitro experiments to be as robust as possible, with minimal 
potential for bias. I used anti-digoxin as a control IgG antibody and conjugated it to 
nanoparticles from the same batch, and at the same time as conjugating to anti-CEA. 
I used anti-digoxin IgG as a control in Chapter 5 and showed that digoxin is not 
present in colorectal cancer cells. I selected three cell lines known to express CEA at 
differing levels to reflect the heterogeneity in expression in human colorectal cancer. 
There are a number of sources of bias when assessing and comparing fluorescent 
images of cells: 
i. Cell selection 
ii. Image acquisition 
iii. Image selection 
iv. Fluorescence measurement 
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Most published studies that have quantified fluorescent nanoparticle cell binding 
have tended to use a single cell line and a simple fluorescent measurement of whole 
cells (Blechinger et al., 2013, Jonkman et al., 2014, Torrano and Brauchle, 2014, 
Jiwaji et al., 2014). They have not described robust protocols to minimise bias. One 
paper addressed differences in cell fluorescence measurements in the z plane but 
again this was in a single cell type (Prats-Mateu et al., 2014). I have compared 
membrane-specific fluorescence in three morphologically different cell lines between 
test and control nanoparticles, and have minimised all sources of bias as far as 
possible. 
 
Cell selection: prevention of selection bias in the x-y plane 
When capturing confocal images, I positioned the microscope over five pre-
determined areas on each slide and selected cells using the phase white light image, 
blinding me to the fluorescent images and preventing selection bias in the x-y plane 
of the slide. 
 
Image acquisition 
To ensure that the confocal images for each cell line could be compared, I used the 
microscope software to select the optimum image settings (gain and intensity) for the 
first cell and then used these settings for all remaining measurements. 
 
Image selection: prevention of selection bias in the z plane 
I designed the fluorescence quantification assay taking into account that the 
nanoparticles were targeted to an antigen located at the cell membrane and cells 
from different cell lines have variable diameters. I took z-stack images for each image 
captured and then worked out the approximate diameter of cells from each cell line, 
so that I could consistently select optical slices through the cell centres for analysis, 
preventing selection bias in the z plane.  
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Fluorescence measurement 
Simply measuring the fluorescence of a whole cell would prevent a comparison 
between cell lines as the non-fluorescing cytoplasm would have a greater impact on 
the measurements in some cell lines compared to others (for example, LS174T cells 
tend to grow in colonies whilst LoVo cells are small but tend to be separate). I 
therefore used ImageJ software to measure mean fluorescence per unit length of 
membrane, corrected for background fluorescence. To ensure consistency and 
prevent a further source of selection bias, I made the membrane trace using the 
phase image only and then transferred the trace to the fluorescent image. As a 
confirmatory analysis, I used a function in the confocal microscope software to 
construct Maximal Image Projection images, where the all the images taken in the z-
stack are superimposed to give a single image. This leads to areas where the pixels 
in the images are saturated and potentially dampens any observed difference 
between positive and negative fluorescing cells. There are no published studies 
describing cell fluorescence measurements taking into account all sources of bias in 
this way. 
 
When analysing the results, I used both parametric and non-parametric statistical 
tests (Table 6.1). If cellular fluorescence was measured for every single cell on each 
slide, there is nothing to suggest the results would not be normally distributed so I 
feel a parametric test to compare means is appropriate (unpaired t-test). However, 
for completeness I also treated the data as non-parametric and used the Mann-
Whitney test to compare medians. The results of both statistical analyses and both 
types of image (single cell section and Maximal Image Projection) demonstrated a 
clear statistically significant difference in fluorescence between test and control 
antibodies in all three cell lines for nanoparticles conjugated to antibodies using 
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PAMAM dendrimers, suggesting that the type of statistical test used was not a key 
factor influencing the result.  
 
6.4.3 The relative merits of the chemical linkage strategies 
tested 
I evaluated four linking strategies, including established and novel techniques, which 
employed both whole and reduced anti-CEA antibodies. SMCC and PEG, both of 
which used reduced antibodies for targeting, failed to demonstrate any antibody-
dependent cell binding. Control SMCC-linked particles produced high levels of non-
specific fluorescence, whereas PEG-linked particles produced very little. I attempted 
to discover the cause of this by varying experimental conditions and using different 
control antibodies but this had no effect on the non-specific binding. I also 
hypothesised that a proportion of amine groups on the particle surface may not be 
bound to SMCC linkers and may be creating a positive surface charge leading to 
non-specificity. I used succunic anhydride, which converts free amine groups into 
negatively charged carboxylates (Singh, 1998) to test this but no difference in 
fluorescence was observed. I also used bovine serum albumin in excess instead of 
antibodies to ensure all maleimide groups on the SMCC linkers were bound but this 
also failed to reduce the non-specific binding. The lack of any fluorescent cell 
labelling with PEG-linked test or control nanoparticles suggests that either the SMCC 
linker itself or the inherent properties of the aminated basic nanparticle may have 
been the cause of the non-specificity. However it also suggests that using reduced 
antibodies in this context may inhibit antibody-antigen binding. I selected these novel 
linking strategies in an effort to control the orientation of the antigen binding sites and 
therefore increase sensitivity while reducing steric hindrance. The selective reduction 
of the hinge region of IgG antibodies is well known (Yoshitake et al., 1979) and 
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investigators have experimented with Fab and fc antibody fragments for nanoparticle 
targeting to try to control binding site orientation (Cheng and Allen, 2008, Kumar et 
al., 2008) but not with silica nanoparticles. The results failed to show a significant 
sensitivity advantage. 
 
EDC linking showed tumour-specific binding, although the effect was low (fold 
change 1.7) and observed in LoVo cells only. Of the limited work published exploring 
dye-doped silica nanoparticles for cell labelling applications, EDC seems to have 
been the most popular. However, none of the work used adequate controls. At the 
time of this work, only two papers described in vitro cancer cell targeting with this 
type of nanoparticle and neither described experiments that were adequately 
controlled - one used bare EDC-linked nanoparticles (Santra et al., 2001) and the 
other no controls at all (Huang et al., 2009). My data can be interpreted to suggest 
that the cell targeting potential of nanoparticles linked in this way has been over-
stated due to a lack of appreciation of the non-specific binding. 
 
PAMAM dendrimer linking allowed strong tumour-specific imaging. The fluorescence 
fold change between test and control particles was 12.3, 8.0 and 3.2 for LS174T, 
LoVo and HCT116 cells respectively. Although these figures correlate with the 
relative expression of CEA by the cell lines, they are dependent on the level of non-
specific fluorescence recorded for control nanoparticles, which varied considerably. It 
is difficult to draw any conclusions regarding the relationship between targeted-
nanoparticle-induced fluorescence and cell surface antigen density. The relative size 
of the particles means there are likely to be unbound antigen sites between adjacent 
bound particles. Steric hindrance, where the size of the nanoparticle-antibody 
complex, the location and orientation of the antibodies on the surface, and the 
relative density of the antigen on the cell membrane can all reduce immunoreactivity 
(Lu et al., 1996, Jie et al., 2011). 
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The successful targeting seen with PAMAM-linked particles and, to a much lesser 
extent, with EDC-linked particles, may explain the failure of SMCC and PEG. Both 
PAMAM and EDC linking methodologies required the aminated surface of the particle 
to be carboxylated. This has the effect of producing an overall negative surface 
charge prior to attaching the linker and then antibody. Cells have a slight negative 
charge and positively-charged, non-targeted nanoparticles have been shown to be 
taken up by cells more rapidly than negatively charged controls (Chen et al., 2011a). 
Although I tried to eliminate any positive surface charge on SMCC-linked particles 
with succinic anhydride, this may not have been effective due to the antibodies 
having already been attached; attempting this prior to antibody incubation would 
prevent their conjugation. The difference in targeting between PEG-linked and EDC-
linked particles might then be either due to the increase in available binding sites for 
the antibody molecules or the increase in distance between the antibody and 
nanoparticle surface. Having shown the difference in this pragmatic, proof-of-concept 
project, these questions now warrant future investigation. 
 
6.4.4 In vivo potential for PAMAM-linked antibody-directed 
nanoparticles 
Having developed a fluorescent nanoparticle with genuine specificity for a surface 
antigen that is over-expressed in colorectal cancer, I then examined the potential for 
this to be used to image tumours in vivo, using a murine xenograft model of 
colorectal cancer. The principle aim of this part of the project was to test whether the 
particles could reach the tumour cells following systemic delivery, and whether they 
showed tumour-specific binding. Only two other studies have investigated specific 
targeting of dye-doped silica nanoparticles to tumours via systemic delivery: Tivnan 
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et al (Tivnan et al., 2012) used dendrimer-conjugated particles targeted to 
neuroblastoma, whilst Soster et al (Soster et al., 2012) used PEG-conjugated 
particles targeted to colorectal cancer metastases, both in murine xenograft models. 
However, both studies used ‘bare’ nanoparticles as controls, which are potentially 
problematic in terms of demonstrating antigen-specific targeting, and both imaged 
fluorescence only on harvested organs ex vivo, which may relate to poor tissue 
penetration of fluorescence. 
 
My in vitro results suggested that non-specific binding could be a potential problem 
and this might have been compounded by the fact that normal cells also express 
CEA. I therefore injected non-tumour bearing mice with CEA-targeted particles to 
evaluate non-specific binding to normal tissues. Reassuringly the only significant 
fluorescence observed was hepatobiliary, which peaked at 24 hours and reduced by 
72 hours post-injection. This corroborates the only study to examine the 
biodistribution and excretion of mesoporous silica nanoparticles (Souris et al., 2010), 
which also found that a higher particle surface charge was associated with rapid 
excretion. I chose LS174T cells for my xenograft model because they showed the 
greatest fold difference between test and control (Table 6.1) and because they 
closely resemble colonic mucosal cells with numerous microvilli and intracytoplasmic 
mucin vaculoles (Tom et al., 1976). When the CEA-targeted and control-IgG targeted 
nanoparticles were injected into tumour-bearing mice, I observed significant time-
dependent accumulation within tumours that was entirely absent for control IgG-
targeted particles (p<0.0001). A similar pattern of hepatic excretion was observed as 
in my first mouse experiment and there was no difference in liver fluorescence of 
control or test mice at any time point (p=0.3 to 0.9). There was a wide variation in the 
tumour-specific fluorescence observed in the three test mice. This is probably due to 
two main factors: the quality of the tail vein injection and the blood supply to the 
xenograft tumour. The tail vein injections failed in a number of mice during the early 
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experiments in this work, despite appropriate needles and expertise. In Figure 6.19 a 
fluorescent signal persists in the tail of the second mouse injected with CEA-targeted 
particles throughout the experiment, suggesting that the entire dose was not 
effectively delivered. This mouse showed the least tumour-specific fluorescence of 
the three. On examining the tumours at the end of the experiment, the mouse with 
the greatest tumour-specific signal appeared to have a very vascularised, intra-
muscular tumour (Figure 6.22), potentially enabling greater nanoparticle penetration. 
This could have been due to a deeper subcutaneous injection of tumour cells, where 
it is difficult to precisely control the depth of the flank injection. Therefore, although 
the fluorescence measurements had a wide range, more accurate and consistent 
tumour and nanoparticle injections would probably reduce this. 
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Figure 6.22. Dissection of xenograft tumour with the greatest tumour-specific 
signal. 
The mouse with the greatest tumour-specific fluorescent signal had a highly 
vascularised, intra-muscular tumour. LS174T cell xenograft tumours were grown on 
the flank of six week old BALB/c nu/nu female mice and dye-doped silica 
nanoparticles were delivered systemically via the tail vein. 
 
 
This work is, at the time of writing and to the best of my knowledge, the first to use 
nanoparticles successfully to provide tumour-specific, live, in vivo fluorescent imaging 
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in a murine model of colorectal cancer. Although the in vivo study utilised just three 
animals in each arm, the lack of any detectable signal in the xenograft tumours when 
injected with control particles makes the result highly significant. Throughout this 
section of the project I have maintained a pragmatic approach, aware that proof of 
concept was required and therefore a balance was struck between optimising each 
individual variable exhaustively and making relatively rapid progress. I believe it has 
paid off and there is now a great deal of further work that can be carried out, 
including chemical optimisation of the nanoparticle and larger in vivo experiments 
with orthotopic primary and metastatic colorectal cancer murine models. Critically my 
work shows great promise for clinical translation in the context of intra-operative 
imaging since fluorescence is bright, the antibody is humanised and has been used 
in clinical trials previously, and silica nanoparticles appear to have favourable toxicity 
profiles. Furthermore, the technology is applicable to imaging any tissue or pathology 
using antibodies targeting appropriate specific biomarkers. 
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Chapter Seven 
 
 
Summary 
  
 212 
7 SUMMARY 
 
I aimed to develop a fluorescent, tumour-specific, molecular imaging probe for 
colorectal cancer that could potentially be used for laparoscopic intra-operative 
staging, locate impalpable tumours and allow stratification of resection radicality. To 
achieve this I divided the project into a number of distinct steps that followed a logical 
progression from the identification of an appropriate target for colorectal cancer to the 
development and in vivo testing of a tumour-specific, molecular probe for real-time 
fluorescent imaging. 
 
 
7.1 Future perspectives 
 
7.1.1 Biomarker targeting 
 
The biomarker component of this work was crucial. The performance of the system is 
completely dependent upon the ability to discriminate between normal colorectal 
tissue and tumour tissue, meaning that even the perfect fluorescent molecular bio-
imaging probe will fail if the biomarker is unable to achieve this. I showed that CEA 
has a high sensitivity and specificity as a biomarker for differentiating colorectal 
cancer. The large variation in treatment responses in targeted therapy for colorectal 
cancer has led to a greater appreciation of the heterogeneity of the disease, with 
specific epi-genetic and tumour micro-environment factors allowing a personalised 
approach to therapy (Linnekamp et al., 2015). The identification and classification of 
colorectal cancer subtypes could allow even more accurate tumour localisation - the 
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antibody component could be selected from a ‘catalogue’ of available options based 
on this information. 
 
Although I chose antibodies as the targeting mechanism for my project, there are 
other novel methods of targeting membrane-bound molecules. I made this decision in 
the interest of time and progress, particularly as anti-CEA antibodies are readily 
available. Antibody fragments can be synthesised from the variable region of an IgG 
molecule and have a number of theoretical advantages over whole antibodies 
including small size, lower immunogenicity and potentially increased sensitivity over 
whole antibodies (Holliger and Hudson, 2005). They were used in 
radioimmunoguided surgery (section 1.2.1), an application closely related to mine in 
that antibodies were used for intra-operative tumour detection. Roselli et al (Roselli et 
al., 1996) and Percivale et al (Percivale et al., 1998) produced F(ab’)2 anti-CEA 
antibodies, where the constant and variable portions of the antibody are split, and 
their result suggested a possible improvement in sensitivity. Biparatropic antibodies 
(BpAbs) were prepared by cross-linking reduced Fab fragments of two different anti-
CEA antibodies, so that they were able to bind to two different epitopes of CEA, in an 
attempt to further increase the sensitivity, with some success (Robert et al., 1999, 
Kim et al., 2002, Kim et al., 2005). These techniques could be applied to my chosen 
anti-CEA antibody. Other alternatives include various antibody mimetics, which target 
antigens but are structurally different and much smaller than antibodies (6-20 kDa 
versus 150 kDa) (Qiu et al., 2007), and aptamers (Farokhzad et al., 2006), which are 
less immunogenic and cheaper to produce for clinical applications than antibodies. 
 
It is conceivable that one of the above alternative targeting mechanisms could be 
chemically substituted for the antibody on my final nanoparticle, although this may 
behave differently and require full characterisation with in vitro and in vivo studies. 
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An alternative, non-targeted approach to intra-operative fluorescent imaging exploits 
the endogenous fluorescent properties of protoporphyrin IX, which tend to be 
increased in certain cancers. 5-aminolevulinic acid can be used as a photosensitiser 
to enhance this natural fluorescence and its potential is currently under investigation 
in colorectal cancer. 
 
7.1.2 Targeted indocyanine green 
 
I exploited a unique feature of protein-bound ICG, which allows it to produce 
cytoplasmic fluorescence if internalised, to produce a simple system that allowed 
CEA-specific fluorescent imaging in live colorectal cancer cells. The major advantage 
of this strategy is that both ICG and the anti-CEA antibody I used in my experiments 
are approved by the MHRA so translation into clinical trials could potentially be rapid. 
I would anticipate the next steps in this process as being: 
1. A small in vivo study to confirm my in vitro results. I would deliver the ICG-
anti-CEA and ICG-control antibodies systemically to a murine xenograft 
model of colorectal cancer. 
2. A proof of concept, first-in-human clinical trial. This would require ethical 
approval and manufacture of the conjugate to a satisfactory standard. Early 
correspondence with the appropriate regulatory bodies suggest that, based 
on our findings, authorisation for this would be granted. 
 
7.1.3 Targeted fluorescent nanoparticles 
 
I synthesised a fluorescent, CEA-targeted, silica nanoparticle that allowed tumour-
specific fluorescent labelling in three different cell lines in vitro and in a xenograft 
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mouse model of colorectal cancer using one of these cell lines. Although my in vivo 
study consisted of just six mice, the following three observations make the results 
very powerful. Firstly, tumour-specific fluorescence was observed in all of the mice 
injected with CEA-targeted nanoparticles and none of the mice injected with control 
nanoparticles, producing a highly significant result and suggesting a high sensitivity 
and adequate signal strength. Secondly, the only fluorescence observed in non-
tumour tissue was hepatic, consistent with nanoparticle excretion, meaning the 
particles are highly specific at least in a murine host. Thirdly, the nanoparticles and 
fluorescent signal persisted at 72 hours following delivery, suggesting stability in vivo. 
These three findings are perhaps the most important for translating this work into a 
clinical trial. Given my pragmatic approach to the synthesis of the nanoparticle, there 
is undoubtedly potential for further optimisation of the nanoparticle, with probable 
resultant improvements in in vivo diagnostic performance. Following this, a larger 
study using an orthotopic murine model of colorectal cancer, possibly with a 
metastatic model alongside, would provide the necessary information to inform a 
first-in-man study. However, rigorous toxicology studies would be required prior to 
this. 
 
7.1.3.1 Targeted nanoparticles versus targeted ICG 
The nanoparticles caused membranous fluorescence whereas the ICG caused 
cytoplasmic fluorescence. The fluorescence fold difference for CEA-targeted 
compared with control-targeted was similar for both strategies (3.2 - 12.3) but the 
intensity of the fluorescent signal was greater for the nanoparticles, which would be 
crucial for tissue penetration in laparoscopic surgery. The fold difference was similar 
for LoVo cells but for LS174T cells it was higher for the nanoparticles (12.3 vs 5.2) 
and for HCT116 cells it was higher for ICG (12.2 vs 3.2). The relationship between 
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fluorescent labelling and cellular CEA concentration is unclear: a number of factors 
may influence this, including steric hindrance, particle size and rate of internalisation.  
 
 
 
7.2 Limitations 
 
If I were to redesign the experiments in this project with the benefit of hindsight I 
would make a number of changes. If possible, I would test the sensitivity and 
specificity of my biomarkers in a large cohort of matched normal and malignant 
lymph nodes in addition to primary tumours, to confirm my findings in section 3.3. 
Whilst identifying the primary tumour is important for laparoscopic resection of small 
early tumours, the intra-operative lymph node status is arguably the single most 
important factor in determining the type of resection performed.  
 
The ideal model for testing the delivery and fate of anti-CEA antibodies would be to 
inject them intravenously prior to a patient undergoing colorectal cancer resection 
and ascertain whether they were present in the specimen post-operatively. This 
would be a more realistic model than the ex vivo study I conducted in 4.3.4 and more 
likely to produce conclusive results, but would require a full Clinical Trial of a 
Medicinal Product study. This would be costly, time-consuming and probably 
unnecessary given the successful use of anti-CEA and anti-TAG-72 for in vivo 
tumour targeting in the past (section 0). A simple animal study would have been a 
better compromise: a murine orthotopic colorectal cancer model could be injected 
with the antibodies and immunohistochemical analysis performed on the resected 
tumour. 
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7.3 Potential impact 
 
A strength of this work is that my findings can be applied to other scientific areas 
outside the remit of this project. I have identified CEA as the most appropriate 
biomarker for in vivo colorectal cancer targeting and this could be exploited for 
targeted non-invasive imaging and for targeted chemotherapeutics. Similarly, by 
substituting the conjugated antibody, my nanoparticle could be used for intra-
operative imaging in other cancers that express membrane-bound, tumour-specific 
biomarkers. 
 
It is my hope that the body of work presented will make a major contribution to the 
exciting and rapidly expanding field of intraoperative diagnostics and image-guided 
surgery. In particular, I hope that I have contributed to the clinical need for a platform 
to discriminate malignant and normal tissue in vivo, and therefore to the ambition to 
make stratified surgery for colorectal cancer a reality.  
  
 218 
 
 
 
 
 
 
References 
 
 
  
 219 
8 REFERENCES 
 
ABDOLAHI, M., SHAHBAZI-GAHROUEI, D., LAURENT, S., SERMEUS, C., 
FIROZIAN, F., ALLEN, B. J., BOUTRY, S. & MULLER, R. N. 2013. Synthesis and in 
vitro evaluation of MR molecular imaging probes using J591 mAb-conjugated 
SPIONs for specific detection of prostate cancer. Contrast Media Mol Imaging, 8, 
175-84. 
 
ABRAHAM, N. S., YOUNG, J. M. & SOLOMON, M. J. 2004. Meta-analysis of short-
term outcomes after laparoscopic resection for colorectal cancer. British Journal of 
Surgery, 91, 1111-1124. 
 
ACPGBI 2007. Guidelines for the management of colorectal cancer, 
Association of Surgeons of Great Britain and Ireland. 
 
ADAM, R., LUCIDI, V. & BISMUTH, H. 2004. Hepatic colorectal metastases: 
methods of improving resectability. Surg Clin North Am, 84, 659-71. 
 
ADAMS, E. J., GREEN, J. A., CLARK, A. H. & YOUNGSON, J. H. 1999. Comparison 
of different scoring systems for immunohistochemical staining. Journal of Clinical 
Pathology, 52, 75-77. 
 
AHLSKOG, J. K. J., SCHLIEMANN, C., MARLIND, J., QURESHI, U., AMMAR, A., 
PEDLEY, R. B. & NERI, D. 2009. Human monoclonal antibodies targeting carbonic 
anhydrase IX for the molecular imaging of hypoxic regions in solid tumours. Br J 
Cancer, 101, 645-657. 
 
AITKEN, D. R., HINKLE, G. H., THURSTON, M. O., TUTTLE, S. E., MARTIN, D. T., 
OLSEN, J., HAAGENSEN, D. E., JR., HOUCHENS, D. & MARTIN, E. W., JR. 1984. 
A gamma-detecting probe for radioimmune detection of CEA-producing tumors.  
Successful experimental use and clinical case report. Dis Colon Rectum, 27, 279-82. 
 
AJCC 2002. AJCC staging handbook, New York, Springer. 
 
ALANDER, J. T., KAARTINEN, I., LAAKSO, A., PATILA, T., SPILLMANN, T., 
TUCHIN, V. V., VENERMO, M. & VALISUO, P. 2012. A review of indocyanine green 
fluorescent imaging in surgery. International journal of biomedical imaging, 2012, 
940585-940585. 
 
ALEXIS, F., PRIDGEN, E., MOLNAR, L. K. & FAROKHZAD, O. C. 2008. Factors 
affecting the clearance and biodistribution of polymeric nanoparticles. Molecular 
Pharmaceutics, 5, 505-515. 
 
ALLRED, D. C., CLARK, G. M., ELLEDGE, R., FUQUA, S. A. W., BROWN, R. W., 
CHAMNESS, G. C., OSBORNE, C. K. & MCGUIRE, W. L. 1993. ASSOCIATION OF 
P53 PROTEIN EXPRESSION WITH TUMOR-CELL PROLIFERATION RATE AND 
CLINICAL OUTCOME IN NODE-NEGATIVE BREAST-CANCER. Journal of the 
National Cancer Institute, 85, 200-206. 
 
AMAYA, H., TANIGAWA, N., LU, C., MATSUMURA, M., SHIMOMATSUYA, T., 
HORIUCHI, T. & MURAOKA, R. 1997. Association of vascular endothelial growth 
factor expression with tumor angiogenesis, survival and thymidine 
 220 
phosphorylase/platelet-derived endothelial cell growth factor expression in human 
colorectal cancer. Cancer Lett, 119, 227-35. 
 
ANDRE, T., BONI, C., NAVARRO, M., TABERNERO, J., HICKISH, T., TOPHAM, C., 
BONETTI, A., CLINGAN, P., BRIDGEWATER, J., RIVERA, F. & DE GRAMONT, A. 
2009. Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As 
Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial. Journal of 
Clinical Oncology, 27, 3109-3116. 
 
ANDRESEN, T. L., THOMPSON, D. H. & KAASGAARD, T. 2010. Enzyme-triggered 
nanomedicine: Drug release strategies in cancer therapy (Invited Review). Molecular 
Membrane Biology, 27, 353-363. 
 
ARNOLD, M. W., SCHNEEBAUM, S., BERENS, A., PETTY, L., MOJZISIK, C., 
HINKLE, G. & MARTIN, E. W., JR. 1992. Intraoperative detection of colorectal 
cancer with radioimmunoguided surgery and CC49, a second-generation monoclonal 
antibody. Ann Surg, 216, 627-32. 
 
ASHITATE, Y., STOCKDALE, A., CHOI, H. S., LAURENCE, R. G. & FRANGIONI, J. 
V. 2012. Real-Time Simultaneous Near-Infrared Fluorescence Imaging of Bile Duct 
and Arterial Anatomy. Journal of Surgical Research, In Press, Corrected Proof. 
ASHRAF, S. Q., UMANA, P., MOESSNER, E., NTOUROUPI, T., BRUENKER, P., 
SCHMIDT, C., WILDING, J. L., MORTENSEN, N. J. & BODMER, W. F. 2009. 
Humanised IgG1 antibody variants targeting membrane-bound carcinoembryonic 
antigen by antibody-dependent cellular cytotoxicity and phagocytosis. British Journal 
of Cancer, 101, 1758-1768. 
 
ASSOCIATION OF BREAST SURGERY AT BASO 2009. Surgical guidelines for the 
management of breast cancer. Ejso, 35, S1-S22. 
 
ASTM 2012. E2456-06 Standard terminology relating to nanotechnology. 
 
BAGWE, R. P. & KHILAR, K. C. 2000. Effects of intermicellar exchange rate on the 
formation of silver nanoparticles in reverse microemulsions of AOT. Langmuir, 16, 
905-910. 
 
BAGWE, R. P., MISHRA, B. K. & KHLIAR, K. C. 1999. Effect of chain length of 
oxyethylene group on particle size and absorption spectra of silver nanoparticles 
prepared in non-ionic water-in-oil microemulsions. Journal of Dispersion Science and 
Technology, 20, 1569-1579. 
 
BAGWE, R. P., YANG, C., HILLIARD, L. R. & TAN, W. 2004. Optimization of dye-
doped silica nanoparticles prepared using a reverse microemulsion method. 
Langmuir, 20, 8336-42. 
 
BALLOU, B., LAGERHOLM, B. C., ERNST, L. A., BRUCHEZ, M. P. & WAGGONER, 
A. S. 2003. Noninvasive Imaging of Quantum Dots in Mice. Bioconjugate Chemistry, 
15, 79-86. 
BARBET, J., BARDIES, M., BOURGEOIS, M., CHATAL, J.-F., CHEREL, M., 
DAVODEAU, F., FAIVRE-CHAUVET, A., GESTIN, J.-F. & KRAEBER-BODERE, F. 
2012. Radiolabeled antibodies for cancer imaging and therapy. Methods in molecular 
biology (Clifton, N.J.), 907, 681-97. 
 
BEHR, T. M., BEHE, M., LOHR, M., SGOUROS, G., ANGERSTEIN, C., 
WEHRMANN, E., NEBENDAHL, K. & BECKER, W. 2000. Therapeutic advantages of 
 221 
Auger electron- over beta-emitting radiometals or radioiodine when conjugated to 
internalizing antibodies. European Journal of Nuclear Medicine, 27, 753-765. 
 
BELLONE, G., GRAMIGNI, C., VIZIO, B., MAURI, F. A., PRATI, A., SOLERIO, D., 
DUGHERA, L., RUFFINI, E., GASPARRI, G. & CAMANDONA, M. 2010. Abnormal 
expression of Endoglin and its receptor complex (TGF-beta 1 and TGF-beta receptor 
II) as early angiogenic switch indicator in premalignant lesions of the colon mucosa. 
International Journal of Oncology, 37, 1153-1165. 
 
BEMBENEK, A., SCHNEIDER, U., GRETSCHEL, S., FISCHER, J. & SCHLAG, P. M. 
2005. Detection of lymph node micrometastases and isolated tumor cells in sentinel 
and nonsentinel lymph nodes of colon cancer patients. World Journal of Surgery, 29, 
1172-1175. 
 
BEMBENEK, A., STRING, A., GRETSCHEL, S. & SCHLAG, P. M. 2008. Technique 
and clinical consequences of sentinel lymph node biopsy in colorectal cancer. Surg 
Oncol, 17, 183-93. 
 
BERTELSEN, C. A., BOLS, B., INGEHOLM, P., JANSEN, J. E., 
NEUENSCHWANDER, A. U. & VILANDT, J. 2011. Can the quality of colonic surgery 
be improved by standardization of surgical technique with complete mesocolic 
excision? Colorectal Disease, 13, 1123-1129. 
 
BHARGAVA, R., CHEN, B., KLIMSTRA, D. S., SALTZ, L. B., HEDVAT, C., TANG, L. 
H., GERALD, W., TERUYA-FELDSTEIN, J., PATY, P. B., QIN, J. & SHIA, J. 2006. 
Comparison of two antibodies for immunohistochemical evaluation of epidermal 
growth factor receptor expression in colorectal carcinomas, adenomas, and normal 
mucosa. Cancer, 106, 1857-1862. 
 
BILCHIK, A., NISSAN, A., WAINBERG, Z., SHEN, P., MCCARTER, M., PROTIC, M., 
HOWARD, R., ELASHOFF, D., TYLER, J., PEOPLES, G. E. & STOJADINOVIC, A. 
2010. Surgical Quality and Nodal Ultrastaging Is Associated With Long-Term 
Disease-Free Survival in Early Colorectal Cancer An Analysis of 2 International 
Multicenter Prospective Trials. Annals of Surgery, 252, 467-476. 
 
BILCHIK, A. J., HOON, D. S. B., SAHA, S., TURNER, R. R., WIESE, D., DINOME, 
M., KOYANAGI, K., MCCARTER, M., SHEN, P., IDDINGS, D., CHEN, S. L., 
GONZALEZ, M., ELASHOFF, D. & MORTON, D. L. 2007. Prognostic impact of 
micrometastases in colon cancer - Interim results of a prospective multicenter trial. 
Annals of Surgery, 246, 568-577. 
 
BILCHIK, A. J., NORA, D., TOLLENAAR, R. A. E. M., VAN DE VELDE, C. J. H., 
WOOD, T., TURNER, R., MORTON, D. L. & HOON, D. S. B. 2002. Ultrastaging of 
early colon cancer using lymphatic mapping and molecular analysis. European 
Journal of Cancer, 38, 977-985. 
 
BIPAT, S., GLAS, A. S., SLORS, F. J. M., ZWINDERMAN, A. H., BOSSUYT, P. M. 
M. & STOKER, J. 2004. Rectal cancer: Local staging and assessment of lymph node 
involvement with endoluminal US, CT, and MR imaging - A meta-analysis. Radiology, 
232, 773-783. 
 
BLECHINGER, J., BAUER, A. T., TORRANO, A. A., GORZELANNY, C., 
BRÄUCHLE, C. & SCHNEIDER, S. W. 2013. Uptake Kinetics and Nanotoxicity of 
Silica Nanoparticles Are Cell Type Dependent. Small, 9, 3970-3980. 
 
 222 
BOERMAN, O. C. & OYEN, W. J. G. 2011. Immuno-PET of Cancer: A Revival of 
Antibody Imaging. Journal of Nuclear Medicine, 52, 1171-1172. 
 
BOPPART, S. A., BOUMA, B. E., PITRIS, C., SOUTHERN, J. F., BREZINSKI, M. E. 
& FUJIMOTO, J. G. 1998. In vivo cellular optical coherence tomography imaging. 
Nature Medicine, 4, 861-865. 
 
BOPPART, S. A., DEUTSCH, T. F. & RATTNER, D. W. 1999. Optical imaging 
technology in minimally invasive surgery - Current status and future directions. 
Surgical Endoscopy-Ultrasound and Interventional Techniques, 13, 718-722. 
 
BOPPART, S. A., LUO, W., MARKS, D. L. & SINGLETARY, K. W. 2004. Optical 
coherence tomography: feasibility for basic research and image-guided surgery of 
breast cancer. Breast Cancer Research and Treatment, 84, 85-97. 
 
BRENNAN, D. J., O'CONNOR, D. P., REXHEPAJ, E., PONTEN, F. & GALLAGHER, 
W. M. 2010. Antibody-based proteomics: fast-tracking molecular diagnostics in 
oncology. Nat Rev Cancer, 10, 605-617. 
 
BROWN, G., RICHARDS, C. J., BOURNE, M. W., NEWCOMBE, R. G., RADCLIFFE, 
A. G., DALLIMORE, N. S. & WILLIAMS, G. T. 2003. Morphologic Predictors of 
Lymph Node Status in Rectal Cancer with Use of High-Spatial-Resolution MR 
Imaging with Histopathologic Comparison1. Radiology, 227, 371-377. 
 
BRYAN, J. N., JIA, F., MOHSIN, H., SIVAGUMA, G., MILLER, W. H., ANDERSON, 
C. J., HENRY, C. J. & LEWIS, M. R. 2005. Comparative uptakes and biodistributions 
of internalizing vs. noninternalizing copper-64 radioimmunoconjugates in cell and 
animal models of colon cancer. Nuclear Medicine and Biology, 32, 851-858. 
 
BU, X. D., LI, N., TIAN, X. Q. & HUANG, P. L. 2011. Caco-2 and LS174T cell lines 
provide different models for studying mucin expression in colon cancer. Tissue Cell, 
43, 201-6. 
 
BUCHSBAUM, D., LLOYD, R., JUNI, J., WOLLNER, I., BRUBAKER, P., HANNA, D., 
SPICKER, J., BURNS, F., STEPLEWSKI, Z., COLCHER, D. & ET AL. 1988. 
Localization and imaging of radiolabeled monoclonal antibodies against colorectal 
carcinoma in tumor-bearing nude mice. Cancer Res, 48, 4324-33. 
 
BUCKLEY, A. F. & KAKAR, S. 2007. Comparison of the dako EGFR pharmDx kit and 
zymed EGFR antibody for assessment of EGFR status in colorectal 
adenocarcinoma. Applied Immunohistochemistry & Molecular Morphology, 15, 305-
309. 
 
BURNS, A., OW, H. & WIESNER, U. 2006. Fluorescent core-shell silica 
nanoparticles: towards "Lab on a Particle" architectures for nanobiotechnology. 
Chemical Society Reviews, 35, 1028-1042. 
 
BURROWS, F. J., DERBYSHIRE, E. J., TAZZARI, P. L., AMLOT, P., GAZDAR, A. 
F., KING, S. W., LETARTE, M., VITETTA, E. S. & THORPE, P. E. 1995. Up-
regulation of endoglin on vascular endothelial cells in human solid tumors: 
implications for diagnosis and therapy. Clinical Cancer Research, 1, 1623-1634. 
 
CAHILL, R., ANDERSON, M., WANG, L., LINDSEY, I., CUNNINGHAM, C. & 
MORTENSEN, N. 2012. Near-infrared (NIR) laparoscopy for intraoperative lymphatic 
 223 
road-mapping and sentinel node identification during definitive surgical resection of 
early-stage colorectal neoplasia. Surgical Endoscopy, 1-8. 
 
CAHILL, R. A. 2010. Natural orifice transluminal endoscopic surgery--here and now. 
Surgeon, 8, 44-50. 
 
CAHILL, R. A., ASAKUMA, M., TRUNZO, J., SCHOMISCH, S., WIESE, D., SAHA, 
S., DALLEMAGNE, B., MARKS, J. & MARESCAUX, J. 2010. Intraperitoneal virtual 
biopsy by fibered optical coherence tomography (OCT) at natural orifice transluminal 
endoscopic surgery (NOTES). J Gastrointest Surg, 14, 732-8. 
 
CAHILL, R. A., LEROY, J. & MARESCAUX, J. 2009. Localized resection for colon 
cancer. Surgical Oncology-Oxford, 18, 334-342. 
 
CAHILL, R. A., RIS, F. & MORTENSEN, N. J. 2011. Near-infrared laparoscopy for 
real-time intra-operative arterial and lymphatic perfusion imaging. Colorectal Dis, 13 
Suppl 7, 12-7. 
 
CAMP, R. L., CHARETTE, L. A. & RIMM, D. L. 2000. Validation of tissue microarray 
technology in breast carcinoma. Laboratory Investigation, 80, 1943-1949. 
 
CARRASQUILLO, J. A., PANDIT-TASKAR, N., O'DONOGHUE, J. A., HUMM, J. L., 
ZANZONICO, P., SMITH-JONES, P. M., DIVGI, C. R., PRYMA, D. A., RUAN, S., 
KEMENY, N. E., FONG, Y., WONG, D., JAGGI, J. S., SCHEINBERG, D. A., 
GONEN, M., PANAGEAS, K. S., RITTER, G., JUNGBLUTH, A. A., OLD, L. J. & 
LARSON, S. M. 2011. 124I-huA33 Antibody PET of Colorectal Cancer. Journal of 
Nuclear Medicine, 52, 1173-1180. 
 
CHEN, L., MCCRATE, J. M., LEE, J. C. & LI, H. 2011a. The role of surface charge 
on the uptake and biocompatibility of hydroxyapatite nanoparticles with osteoblast 
cells. Nanotechnology, 22, 105708. 
 
CHEN, L., WANG, Y., CHENG, D., DOU, S., LIU, X., LIU, G., HNATOWICH, D. J. & 
RUSCKOWSKI, M. 2011b. Comparing two TAG-72 binding peptides previously 
identified by phage display as potential imaging agents. Nuclear Medicine 
Communications, 32, 920-924. 
 
CHEN, L., WANG, Y., LIU, X., DOU, S., LIU, G., HNATOWICH, D. J. & 
RUSCKOWSKI, M. 2008. A new TAG-72 cancer marker peptide identified by phage 
display. Cancer Letters, 272, 122-132. 
 
CHEN, S. L. & BILCHIK, A. J. 2006. More extensive nodal dissection improves 
survival for stages I to III of colon cancer - A population-based study. Annals of 
Surgery, 244, 602-610. 
 
CHEN, W.-T., KHAZAIE, K., ZHANG, G., WEISSLEDER, R. & TUNG, C.-H. 2005. 
Detection of dysplastic intestinal adenomas using a fluorescent folate imaging probe. 
Molecular imaging, 4, 67-74. 
 
CHEN, Y. & ZHANG, Y. 2011. Fluorescent quantification of amino groups on silica 
nanoparticle surfaces. Analytical and Bioanalytical Chemistry, 399, 2503-2509. 
 
CHEN, Z. Z., CAI, L., DONG, X. M., TANG, H. W. & PANG, D. W. 2012. Covalent 
conjugation of avidin with dye-doped silica nanopaticles and preparation of high 
 224 
density avidin nanoparticles as photostable bioprobes. Biosens Bioelectron, 37, 75-
81. 
 
CHENG, W. W. K. & ALLEN, T. M. 2008. Targeted delivery of anti-CD19 liposomal 
doxorubicin in B-cell lymphoma: A comparison of whole monoclonal antibody, Fab' 
fragments and single chain Fv. Journal of Controlled Release, 126, 50-58. 
 
CHERUKURI, P. & CURLEY, S. A. 2010. Use of Nanoparticles for Targeted, 
Noninvasive Thermal Destruction of Malignant Cells. In: GROBMYER, S. R. & 
MOUDGIL, B. M. (eds.) Cancer Nanotechnology: Methods and Protocols. 
 
CHESTER, K., PEDLEY, B., TOLNER, B., VIOLET, J., MAYER, A., SHARMA, S., 
BOXER, G., GREEN, A., NAGL, S. & BEGENT, R. 2004. Engineering antibodies for 
clinical applications in cancer. Tumor Biology, 25, 91-98. 
 
CHO, M., LIM, K. & WOO, K. 2010. Facile synthesis and optical properties of 
colloidal silica microspheres encapsulating a quantum dot layer. Chemical 
Communications, 46, 5584-5586. 
 
CHUNG, K. Y., SHIA, J., KEMENY, N. E., SHAH, M., SCHWARTZ, G. K., TSE, A., 
HAMILTON, A., PAN, D., SCHRAG, D., SCHWARTZ, L., KLIMSTRA, D. S., 
FRIDMAN, D., KELSEN, D. P. & SALTZ, L. B. 2005. Cetuximab shows activity in 
colorectal cancer patients with tumors that do not express the epidermal growth 
factor receptor by immunohistochemistry. J Clin Oncol, 23, 1803-10. 
 
CLASPER, S., ROYSTON, D., BABAN, D., CAO, Y., EWERS, S., BUTZ, S., 
VESTWEBER, D. & JACKSON, D. G. 2008. A Novel Gene Expression Profile in 
Lymphatics Associated with Tumor Growth and Nodal Metastasis. Cancer Research, 
68, 7293-7303. 
 
COHEN, A. M., MARTIN, E. W., JR., LAVERY, I., DALY, J., SARDI, A., AITKEN, D., 
BLAND, K., MOJZISIK, C. & HINKLE, G. 1991. Radioimmunoguided surgery using 
iodine 125 B72.3 in patients with colorectal cancer. Arch Surg, 126, 349-52. 
 
COLCHER, D., MILENIC, D., ROSELLI, M., RAUBITSCHEK, A., YARRANTON, G., 
KING, D., ADAIR, J., WHITTLE, N., BODMER, M. & SCHLOM, J. 1989. 
Characterization and Biodistribution of Recombinant and Recombinant/Chimeric 
Constructs of Monoclonal Antibody B72.3. Cancer Research, 49, 1738-1745. 
 
COLOR STUDY GROUP 2005. Laparoscopic surgery versus open surgery for colon 
cancer: short-term outcomes of a randomised trial. The Lancet Oncology, 6, 477-484. 
 
CONAGHAN, P. J., ASHRAF, S. Q., TYTHERLEIGH, M. G., WILDING, J. L., 
TCHILIAN, E., BICKNELL, D., MORTENSEN, N. J. & BODMER, W. F. 2008. 
Targeted killing of colorectal cancer cell lines by a humanised IgGl monoclonal 
antibody that binds to membrane-bound carcinoembryonic antigen. British Journal of 
Cancer, 98, 1217-1225. 
 
CONAGHAN, P. J., MAXWELL-ARMSTRONG, C. A., GARRIOCH, M. V., HONG, L. 
& ACHESON, A. G. 2010. Leaving a mark: the frequency and accuracy of tattooing 
prior to laparoscopic colorectal surgery. Colorectal Disease, no-no. 
 
CRUK. 2007. Bowel Cancer Statistics - Key Facts [Online]. Available: 
http://info.cancerresearchuk.org/cancerstats/types/bowel/. 
 
 225 
CRUK. 2010. Bowel Cancer Statistics - Key Facts [Online]. Available: 
http://info.cancerresearchuk.org/cancerstats/types/bowel//incidence. 
 
CUNNINGHAM, D., HUMBLET, Y., SIENA, S., KHAYAT, D., BLEIBERG, H., 
SANTORO, A., BETS, D., MUESER, M., HARSTRICK, A., VERSLYPE, C., CHAU, I. 
& VAN CUTSEM, E. 2004. Cetuximab monotherapy and cetuximab plus irinotecan in 
irinotecan-refractory metastatic colorectal cancer. N Engl J Med, 351, 337-45. 
 
DA PAZ, M. C., ALMEIDA SANTOS, M. D. F. M., SANTOS, C. M. B., DA SILVA, S. 
W., DE SOUZA, L. B., LIMA, E. C. D., SILVA, R. C., LUCCI, C. M., MORAIS, P. C., 
AZEVEDO, R. B. & LACAVA, Z. G. M. 2012. Anti-CEA loaded maghemite 
nanoparticles as a theragnostic device for colorectal cancer. International Journal of 
Nanomedicine, 7, 5271-5282. 
 
DARBANDI, M., URBAN, G. & KRÜGER, M. 2010. A facile synthesis method to silica 
coated CdSe/ZnS nanocomposites with tuneable size and optical properties. Journal 
of Colloid and Interface Science, 351, 30-34. 
 
DAVIDSON, E. M., BARENHOLZ, Y., COHEN, R., HAROUTIUNIAN, S., KAGAN, L. 
& GINOSAR, Y. 2010. High-Dose Bupivacaine Remotely Loaded into Multivesicular 
Liposomes Demonstrates Slow Drug Release Without Systemic Toxic Plasma 
Concentrations After Subcutaneous Administration in Humans. Anesthesia & 
Analgesia, 110, 1018-1023. 
 
DAWSON, P. M., BLAIR, S. D., BEGENT, R. H. J., KELLY, A. M. B., BOXER, G. M. 
& THEODOROU, N. A. 1991. THE VALUE OF RADIOIMMUNOGUIDED SURGERY 
IN 1ST AND 2ND LOOK LAPAROTOMY FOR COLORECTAL-CANCER. Diseases 
of the Colon & Rectum, 34, 217-222. 
 
DE HAAS, R. J., ADAM, R., WICHERTS, D. A., AZOULAY, D., BISMUTH, H., 
VIBERT, E., SALLOUM, C., PERDIGAO, F., BENKABBOU, A. & CASTAING, D. 
2010. Comparison of simultaneous or delayed liver surgery for limited synchronous 
colorectal metastases. Br J Surg, 97, 1279-89. 
 
DE JONG, G. M., BLEICHRODT, R. P., EEK, A., OYEN, W. J. G., BOERMAN, O. C. 
& HENDRIKS, T. 2011. Experimental study of radioimmunotherapy versus 
chemotherapy for colorectal cancer. British Journal of Surgery, 98, 436-441. 
 
DEARLING, J. L. J., FLYNN, A. A., QURESHI, U., WHITING, S., BOXER, G. M., 
GREEN, A., BEGENT, R. H. J. & PEDLEY, R. B. 2009. Localization of radiolabeled 
anti-CEA antibody in subcutaneous and intrahepatic colorectal xenografts: influence 
of tumor size and location within host organ on antibody uptake. Nuclear Medicine 
and Biology, 36, 883-894. 
 
DES GUETZ, G., UZZAN, B., NICOLAS, P., CUCHERAT, M., DE MESTIER, P., 
MORERE, J. F., BREAU, J. L. & PERRET, G. 2007. Is sentinel lymph node mapping 
in colorectal cancer a future prognostic factor? A meta-analysis. World Journal of 
Surgery, 31, 1304-1312. 
 
DIGHE, S., PURKAYASTHA, S., SWIFT, I., TEKKIS, P. P., DARZI, A., A'HERN, R. & 
BROWN, G. 2010. Diagnostic precision of CT in local staging of colon cancers: a 
meta-analysis. Clinical Radiology, 65, 708-719. 
 
DIPALMA, J. A., BRADY, C. E., STEWART, D. L., KARLIN, D. A., MCKINNEY, M. 
K., CLEMENT, D. J., COLEMAN, T. W. & PIERSON, W. P. 1984. COMPARISON OF 
 226 
COLON CLEANSING METHODS IN PREPARATION FOR COLONOSCOPY. 
Gastroenterology, 86, 856-860. 
 
DOEVENDANS, P. A., DAEMEN, M. J., DE MUINCK, E. D. & SMITS, J. F. 1998. 
Cardiovascular phenotyping in mice. Cardiovasc Res, 39, 34-49. 
 
DOORNEBOSCH, P. G., GOSSELINK, M. P., NEIJENHUIS, P. A., SCHOUTEN, W. 
R., TOLLENAAR, R. & DE GRAAF, E. J. R. 2008. Impact of transanal endoscopic 
microsurgery on functional outcome and quality of life. International Journal of 
Colorectal Disease, 23, 709-713. 
 
DOORNEBOSCH, P. G., TOLLENAAR, R., GOSSELINK, M. P., STASSEN, L. P., 
DIJKHUIS, C. M., SCHOUTEN, W. R., DE VELDE, C. J. V. & DE GRAAF, E. J. R. 
2007. Quality of life after transanal endoscopic microsurgery and total mesorectal 
excision in early rectal cancer. Colorectal Disease, 9, 553-558. 
 
DUFF, S. E., JEZIORSKA, M., ROSA, D. D., KUMAR, S., HABOUBI, N., 
SHERLOCK, D., O'DWYER, S. T. & JAYSON, G. C. 2006. Vascular endothelial 
growth factors and receptors in colorectal cancer: implications for anti-angiogenic 
therapy. Eur J Cancer, 42, 112-7. 
 
DUKES, C. 1932. The classification of cancer of the rectum. Journal of Pathological 
Bacteriology, 35, 323. 
 
ELIAS, J., MAUAD, F. M., MUGLIA, V. F., CAETANO, E., DOS SANTOS, J. S., 
KEMP, R., PAVAN, T. Z. & CARNEIRO, A. A. O. Intraoperative application of real-
time tissue elastography for the diagnosis and staging of pancreatic tumours.  Health 
Care Exchanges (PAHCE), 2011 Pan American, March 28 2011-April 1 2011 2011. 
179-181. 
 
ELIAS, J. M. 1990. Immunohistochemical methods. Immunohistopathology: A 
Practical Approach to Diagnosis. Chicago: ASCP Press. 
 
FAHLGREN, A., BARANOV, V., FRANGSMYR, L., ZOUBIR, F., HAMMARSTROM, 
M. L. & HAMMARSTROM, S. 2003. Interferon-gamma tempers the expression of 
carcinoembryonic antigen family molecules in human colon cells: A possible role in 
innate mucosal defence. Scandinavian Journal of Immunology, 58, 628-641. 
 
FAROKHZAD, O. C., KARP, J. M. & LANGER, R. 2006. Nanoparticle-aptamer 
bioconjugates for cancer targeting. Expert Opinion on Drug Delivery, 3, 311-324. 
 
FAWCETT, T. 2006. An introduction to ROC analysis. Pattern Recognition Letters, 
27, 861-874. 
 
FENG, Q. Y., WEI, Y., ZHU, D. X., YE, L. C., LIN, Q., LI, W. X., QIN, X. Y., LYU, M. 
Z. & XU, J. M. 2014. Timing of Hepatectomy for Resectable Synchronous Colorectal 
Liver Metastases: For Whom Simultaneous Resection Is More Suitable - A Meta-
Analysis. Plos One, 9. 
 
FOERSCH, S., KIESSLICH, R., WALDNER, M. J., DELANEY, P., GALLE, P. R., 
NEURATH, M. F. & GOETZ, M. 2010. Molecular imaging of VEGF in gastrointestinal 
cancer in vivo using confocal laser endomicroscopy. Gut, 59, 1046-1055. 
 
FOGH J, T. G. 1975. Human Tumour Cells In Vivo, New York, Plenum. 
 227 
FOX, I. J., BROOKER, L. G. S., HESELTINE, D. W. & ESSEX, H. E. 1957. A 
TRICARBOCYANINE DYE FOR CONTINUOUS RECORDING OF DILUTION 
CURVES IN WHOLE BLOOD INDEPENDENT OF VARIATIONS IN BLOOD 
OXYGEN SATURATION. Federation Proceedings, 16, 39-39. 
 
FU, C., LIU, T., LI, L., LIU, H., CHEN, D. & TANG, F. 2013. The absorption, 
distribution, excretion and toxicity of mesoporous silica nanoparticles in mice 
following different exposure routes. Biomaterials, 34, 2565-2575. 
 
GABIZON, A., SHMEEDA, H. & BARENHOLZ, Y. 2003. Pharmacokinetics of 
pegylated liposomal doxorubicin - Review of animal and human studies. Clinical 
Pharmacokinetics, 42, 419-436. 
 
GAO, X. H., CUI, Y. Y., LEVENSON, R. M., CHUNG, L. W. K. & NIE, S. M. 2004. In 
vivo cancer targeting and imaging with semiconductor quantum dots. Nature 
Biotechnology, 22, 969-976. 
 
GAUR, U., SAHOO, S. K., DE, T. K., GHOSH, P. C., MAITRA, A. & GHOSH, P. K. 
2000. Biodistribution of fluoresceinated dextran using novel nanoparticles evading 
reticuloendothelial system. International Journal of Pharmaceutics, 202, 1-10. 
 
GEORGE, S., PRIMROSE, J., TALBOT, R., SMITH, J., MULLEE, M., BAILEY, D., 
DU BOULAY, C., JORDAN, H. & WESSEX COLORECTAL CANC, A. 2006. Will 
Rogers revisited: prospective observational study of survival of 3592 patients with 
colorectal cancer according to number of nodes examined by pathologists. British 
Journal of Cancer, 95, 841-847. 
 
GIANTONIO, B. J., CATALANO, P. J., MEROPOL, N. J., O'DWYER, P. J., 
MITCHELL, E. P., ALBERTS, S. R., SCHWARTZ, M. A. & BENSON, A. B., 3RD 
2007. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin 
(FOLFOX4) for previously treated metastatic colorectal cancer: results from the 
Eastern Cooperative Oncology Group Study E3200. J Clin Oncol, 25, 1539-44. 
 
GOETZ, M., ZIEBART, A., FOERSCH, S., VIETH, M., WALDNER, M. J., DELANEY, 
P., GALLE, P. R., NEURATH, M. F. & KIESSLICH, R. 2010. In Vivo Molecular 
Imaging of Colorectal Cancer With Confocal Endomicroscopy by Targeting Epidermal 
Growth Factor Receptor. Gastroenterology, 138, 435-446. 
 
GOODWIN, J. F. & CHOI, S.-Y. 1970. Quantification of Protein Solutions with 
Trinitrobenzenesulfonic Acid. Clinical Chemistry, 16, 24-31. 
 
GRONE, J., DOEBLER, O., LODDENKEMPER, C., HOTZ, B., BUHR, H. J. & 
BHARGAVA, S. 2006. Robo1/Robo4: Differential expression of angiogenic markers 
in colorectal cancer. Oncology Reports, 15, 1437-1443. 
 
GUBALA, V., LE GUEVEL, X., NOONEY, R., WILLIAMS, D. E. & MACCRAITH, B. 
2010. A comparison of mono and multivalent linkers and their effect on the colloidal 
stability of nanoparticle and immunoassays performance. Talanta, 81, 1833-1839. 
 
GUILLOU, P. J., QUIRKE, P., THORPE, H., WALKER, J., JAYNE, D. G., SMITH, A. 
M. H., HEATH, R. M. & BROWN, J. M. 2005. Short-term endpoints of conventional 
versus laparoscopic-assisted surgery in patients with colorectal cancer (MRC 
CLASICC trial): multicentre, randomised controlled trial. The Lancet, 365, 1718-1726. 
 
 228 
HABEEB, A. F. 1966. Determination of free amino groups in proteins by 
trinitrobenzenesulfonic acid. Anal Biochem, 14, 328-36. 
 
HAMMARSTRÖM, S. 1999. The carcinoembryonic antigen (CEA) family: structures, 
suggested functions and expression in normal and malignant tissues. Seminars in 
Cancer Biology, 9, 67-81. 
 
HAMY, A., CURTET, C., PAINEAU, J., CHATAL, J. F. & VISSET, J. 1995. Feasibility 
of radioimmunoguided surgery of colorectal carcinoma using indium 111 CEA 
specific antibody and simulation with a phantom using 2 steps targetting with 
bispecific antibody. Tumori, 81, 103-6. 
 
HANRAHAN, V., CURRIE, M. J., GUNNINGHAM, S. P., MORRIN, H. R., SCOTT, P. 
A., ROBINSON, B. A. & FOX, S. B. 2003. The angiogenic switch for vascular 
endothelial growth factor (VEGF)-A, VEGF-B, VEGF-C, and VEGF-D in the 
adenoma-carcinoma sequence during colorectal cancer progression. J Pathol, 200, 
183-94. 
 
HARITOGLOU, C., GANDORFER, A., SCHAUMBERGER, M., TADAYONI, R. & 
KAMPIK, A. 2003. Light-absorbing properties and osmolarity of indocyanine-green 
depending on concentration and solvent medium. Investigative Ophthalmology & 
Visual Science, 44, 2722-2729. 
 
HASHIGUCHI, Y., HASE, K., UENO, H., MOCHIZUKI, H., SHINTO, E. & 
YAMAMOTO, J. 2011. Optimal margins and lymphadenectomy in colonic cancer 
surgery. British Journal of Surgery, 98, 1171-1178. 
 
HE, X., HU, C., GUO, Q., WANG, K., LI, Y. & SHANGGUAN, J. 2013. Rapid and 
ultrasensitive Salmonella Typhimurium quantification using positive dielectrophoresis 
driven on-line enrichment and fluorescent nanoparticleslabel. Biosens Bioelectron, 
42, 460-6. 
 
HE, X., NIE, H., WANG, K., TAN, W., WU, X. & ZHANG, P. 2008. In vivo study of 
biodistribution and urinary excretion of surface-modified silica nanoparticles. Anal 
Chem, 80, 9597-603. 
 
HE, X., WANG, Y., WANG, K., CHEN, M. & CHEN, S. 2012. Fluorescence 
resonance energy transfer mediated large Stokes shifting near-infrared fluorescent 
silica nanoparticles for in vivo small-animal imaging. Anal Chem, 84, 9056-64. 
 
HEATH, C. H., DEEP, N. L., SWEENY, L., ZINN, K. R. & ROSENTHAL, E. L. 2012. 
Use of Panitumumab-IRDye800 to Image Microscopic Head and Neck Cancer in an 
Orthotopic Surgical Model. Annals of Surgical Oncology, 19, 3879-3887. 
 
HEINE, M., NOLLAU, P., MASSLO, C., NIELSEN, P., FREUND, B., BRUNS, O. T., 
REIMER, R., HOHENBERG, H., PELDSCHUS, K., ITTRICH, H. & SCHUMACHER, 
U. 2011. Investigations on the Usefulness of CEACAMs as Potential Imaging Targets 
for Molecular Imaging Purposes. PLoS ONE, 6, e28030. 
 
HEITSCH, A. T., SMITH, D. K., PATEL, R. E., RESS, D. & KORGEL, B. A. 2008. 
Multifunctional Particles: Magnetic Nanocrystals and Gold Nanorods Coated with 
Fluorescent Dye-Doped Silica Shells. J Solid State Chem, 181, 1590-1599. 
 
HERMANEK, P., HUTTER, R. V. P., SOBIN, L. H. & WITTEKIND, C. 1999. 
Classification of isolated tumor cells and micrometastasis. Cancer, 86, 2668-2673. 
 229 
 
HILDERBRAND, S. A. & WEISSLEDER, R. 2010. Near-infrared fluorescence: 
application to in vivo molecular imaging. Current Opinion in Chemical Biology, 14, 71-
79. 
 
HOGAN, A. M. & WINTER, D. C. 2009. Complete mesocolic excision (CME): A 
“novel” concept? Journal of Surgical Oncology, 100, 182-183. 
 
HOHENBERGER, W., WEBER, K., MATZEL, K., PAPADOPOULOS, T. & MERKEL, 
S. 2009. Standardized surgery for colonic cancer: complete mesocolic excision and 
central ligation - technical notes and outcome. Colorectal Disease, 11, 354-364. 
 
HOLLIGER, P. & HUDSON, P. J. 2005. Engineered antibody fragments and the rise 
of single domains. Nature Biotechnology, 23, 1126-1136. 
 
HOLZ, F. G., BELLMANN, C., ROHRSCHNEIDER, K., BURK, R. O. W. & 
VOLCKER, H. E. 1998. Simultaneous confocal scanning laser fluorescein and 
indocyanine green angiography. American Journal of Ophthalmology, 125, 227-236. 
 
HUANG, D., SWANSON, E. A., LIN, C. P., SCHUMAN, J. S., STINSON, W. G., 
CHANG, W., HEE, M. R., FLOTTE, T., GREGORY, K., PULIAFITO, C. A. & 
FUJIMOTO, J. G. 1991. OPTICAL COHERENCE TOMOGRAPHY. Science, 254, 
1178-1181. 
 
HUANG, S., LI, R., QU, Y., SHEN, J. & LIU, J. 2009. Fluorescent Biological Label for 
Recognizing Human Ovarian Tumor Cells Based on Fluorescent Nanoparticles. 
Journal of Fluorescence, 19, 1095-1101. 
 
HUN, X. & ZHANG, Z. 2007. Fluoroimmunoassay for tumor necrosis factor-alpha in 
human serum using Ru(bpy)(3)Cl(2)-doped fluorescent silica nanoparticles as labels. 
Talanta, 73, 366-71. 
 
HUTTEMAN, M., CHOI, H. S., MIEOG, J. S., VAN DER VORST, J. R., ASHITATE, 
Y., KUPPEN, P. J., VAN GRONINGEN, M. C., LOWIK, C. W., SMIT, V. T., VAN DE 
VELDE, C. J., FRANGIONI, J. V. & VAHRMEIJER, A. L. 2010. Clinical Translation of 
Ex Vivo Sentinel Lymph Node Mapping for Colorectal Cancer Using Invisible Near-
Infrared Fluorescence Light. Ann Surg Oncol. 
 
HUTTEMAN, M., CHOI, H. S., MIEOG, J. S. D., VAN DER VORST, J. R., 
ASHITATE, Y., KUPPEN, P. J. K., VAN GRONINGEN, M. C., LOWIK, C. W. G. M., 
SMIT, V. T. H. B. M., VAN DE VELDE, C. J. H., FRANGIONI, J. V. & VAHRMEIJER, 
A. L. 2011. Clinical Translation of Ex Vivo Sentinel Lymph Node Mapping for 
Colorectal Cancer Using Invisible Near-Infrared Fluorescence Light. Annals of 
Surgical Oncology, 18, 1006-1014. 
 
IDDINGS, D., AHMAD, A., ELASHOFF, D. & BILCHIK, A. 2006. The prognostic 
effect of micrometastases in previously staged lymph node negative (N0) colorectal 
carcinoma: A meta-analysis. Annals of Surgical Oncology, 13, 1386-1392. 
 
 
ILIUM, L., HUNNEYBALL, I. M. & DAVIS, S. S. 1986. The effect of hydrophilic 
coatings on the uptake of colloidal particles by the liver and by peritoneal 
macrophages. International Journal of Pharmaceutics, 29, 53-65. 
INOUE, Y., TAKAHASHI, M., ARITA, J., AOKI, T., HASEGAWA, K., BECK, Y., 
MAKUUCHI, M. & KOKUDO, N. 2010. Intra-operative freehand real-time 
 230 
elastography for small focal liver lesions: “Visual palpation” for non-palpable tumors. 
Surgery, 148, 1000-1011. 
 
ISHIZAWA, T., TAMURA, S., MASUDA, K., AOKI, T., HASEGAWA, K., IMAMURA, 
H., BECK, Y. & KOKUDO, N. 2009. Intraoperative fluorescent cholangiography using 
indocyanine green: a biliary road map for safe surgery. Journal of the American 
College of Surgeons, 208, e1-4. 
 
ISO. 2008. ISO/TS 27687:2008 Nanotechnologies - Terminology and definitions for 
nano objects - nanoparticle, nanofibre and nanoplate. [Online]. Available: 
http://www.iso.org/iso/iso_catalogue.htm. 
 
ITO, S., MUGURUMA, N., KAKEHASHI, Y., HAYASHI, S., OKAMURA, S., SHIBATA, 
H., OKAHISA, T., KANAMORI, M., SHIBAMURA, S., TAKESAKO, K., NOZAWA, M., 
ISHIDA, K. & SHIGA, M. 1995. DEVELOPMENT OF FLUORESCENCE-EMITTING 
ANTIBODY LABELING SUBSTANCE BY NEAR-INFRARED RAY EXCITATION. 
Bioorganic & Medicinal Chemistry Letters, 5, 2689-2694. 
 
ITOH, A., UENO, E., TOHNO, E., KAMMA, H., TAKAHASHI, H., SHIINA, T., 
YAMAKAWA, M. & MATSUMURA, T. 2006. Breast disease: Clinical application of 
US elastography for diagnosis. Radiology, 239, 341-350. 
 
JACOBS, M., VERDEJA, J. C. & GOLDSTEIN, H. S. 1991. Minimally invasive colon 
resection (laparoscopic colectomy). Surgical laparoscopy & endoscopy, 1, 144-50. 
 
JAMIESON, J. K. & DOBSON, J. F. 1909. The lymphatics of the colon - With special 
reference to the operative treatment of cancer of the colon. Annals of Surgery, 50, 
1077-1090. 
 
JANTSCHEFF, P., TERRACCIANO, L., LOWY, A., GLATZ-KRIEGER, K., 
GRUNERT, F., MICHEEL, B., BRÜMMER, J., LAFFER, U., METZGER, U., 
HERRMANN, R. & ROCHLITZ, C. 2003. Expression of CEACAM6 in Resectable 
Colorectal Cancer: A Factor of Independent Prognostic Significance. Journal of 
Clinical Oncology, 21, 3638-3646. 
 
JAYNE, D. G., THORPE, H. C., COPELAND, J., QUIRKE, P., BROWN, J. M. & 
GUILLOU, P. J. 2010. Five-year follow-up of the Medical Research Council CLASICC 
trial of laparoscopically assisted versus open surgery for colorectal cancer. British 
Journal of Surgery, 97, 1638-1645. 
 
JEONG, M.-H., KIM, K., KIM, E.-M., CHEONG, S.-J., LEE, C.-M., JEONG, H.-J., 
KIM, D. W., LIM, S. T., SOHN, M.-H. & CHUNG, J. 2012. In vivo and in vitro 
evaluation of Cy5.5 conjugated epidermal growth factor receptor binding peptide. 
Nuclear Medicine and Biology, 39, 805-812. 
 
JIE, G. F., WANG, L. & ZHANG, S. S. 2011. Magnetic Electrochemiluminescent 
Fe3O4/CdSe-CdS Nanoparticle/Polyelectrolyte Nanocomposite for Highly Efficient 
Immunosensing of a Cancer Biomarker. Chemistry-a European Journal, 17, 641-648. 
JIWAJI, M., SANDISON, M. E., REBOUD, J., STEVENSON, R., DALY, R.,  
 
BARKESS, G., FAULDS, K., KOLCH, W., GRAHAM, D., GIROLAMI, M. A., 
COOPER, J. M. & PITT, A. R. 2014. Quantification of functionalised gold 
nanoparticle-targeted knockdown of gene expression in HeLa cells. PLoS One, 9, 
e99458. 
 
 231 
JOHNSON, V. G., SCHLOM, J., PATERSON, A. J., BENNETT, J., MAGNANI, J. L. & 
COLCHER, D. 1986. Analysis of a Human Tumor-associated Glycoprotein (TAG-72) 
Identified by Monoclonal Antibody B72.3. Cancer Research, 46, 850-857. 
 
JONKER, D. J., O'CALLAGHAN, C. J., KARAPETIS, C. S., ZALCBERG, J. R., TU, 
D., AU, H.-J., BERRY, S. R., KRAHN, M., PRICE, T., SIMES, R. J., TEBBUTT, N. C., 
VAN HAZEL, G., WIERZBICKI, R., LANGER, C. & MOORE, M. J. 2007. Cetuximab 
for the treatment of colorectal cancer. New England Journal of Medicine, 357, 2040-
2048. 
 
JONKMAN, J., BROWN, C. M. & COLE, R. W. 2014. Quantitative confocal 
microscopy: beyond a pretty picture. Methods Cell Biol, 123, 113-34. 
 
JOOSTEN, J. J. A., STROBBE, L. J. A., WAUTERS, C. A. P., PRUSZCZYNSKI, M., 
WOBBES, T. & RUERS, T. J. M. 1999. Intraoperative lymphatic mapping and the 
sentinel node concept in colorectal carcinoma. British Journal of Surgery, 86, 482-
486. 
 
KAASGAARD, T. & ANDRESEN, T. L. 2010. Liposomal cancer therapy: exploiting 
tumor characteristics. Expert Opinion on Drug Delivery, 7, 225-243. 
 
KALYANASUNDARAM, K. 1982. Photophysics, photochemistry and solar energy 
conversion with tris(bipyridyl)ruthenium(II) and its analogues. Coordination Chemistry 
Reviews, 46, 159-244. 
 
KAMPHUIS, M. M. J., JOHNSTON, A. P. R., SUCH, G. K., DAM, H. H., EVANS, R. 
A., SCOTT, A. M., NICE, E. C., HEATH, J. K. & CARUSO, F. 2010. Targeting of 
Cancer Cells Using Click-Functionalized Polymer Capsules. Journal of the American 
Chemical Society, 132, 15881-15883. 
 
KATO, K., SUGIMOTO, H., KANAZUMI, N., NOMOTO, S., TAKEDA, S. & NAKAO, 
A. 2008. Intra-operative application of real-time tissue elastography for the diagnosis 
of liver tumours. Liver International, 28, 1264-1271. 
 
KAUSHAL, S., MCELROY, M. K., LUIKEN, G. A., TALAMINI, M. A., MOOSSA, A. R., 
HOFFMAN, R. M. & BOUVET, M. 2008. Fluorophore-conjugated anti-CEA Antibody 
for the Intraoperative Imaging of Pancreatic and Colorectal Cancer. Journal of 
Gastrointestinal Surgery, 12, 1938-1950. 
 
KENT, S. P., RYAN, K. H. & SIEGEL, A. L. 1978. STERIC HINDRANCE AS A 
FACTOR IN REACTION OF LABELED ANTIBODY WITH CELL-SURFACE 
ANTIGENIC DETERMINANTS. Journal of Histochemistry & Cytochemistry, 26, 618-
621. 
 
KIM, J. C., ROH, S. A., KOO, K. H., CHO, Y. K., KIM, H. C., YU, C. S., OH, S. J., 
RYU, J. S., BICKNELL, D. C. & BODMER, W. F. 2005. Preclinical application of 
radioimmunoguided surgery using anti-carcinoembryonic antigen biparatopic 
antibody in the colon cancer. Eur Surg Res, 37, 36-44. 
 
KIM, J. C., ROH, S. A., KOO, K. H., RYU, J. H., HONG, H. K., OH, S. J., RYU, J. S., 
KIM, H. J. & BODMER, W. F. 2002. Enhancement of colorectal tumor targeting using 
a novel biparatopic monoclonal antibody against carcinoembryonic antigen in 
experimental radioimmunoguided surgery. Int J Cancer, 97, 542-7. 
 
 232 
KIM, N. K., KIM, M. J., PARK, J. K., PARK, S. I. & MIN, J. S. 2000. Preoperative 
staging of rectal cancer with MRI: Accuracy and clinical usefulness. Annals of 
Surgical Oncology, 7, 732-737. 
 
KING, D. S., FIELDS, C. G. & FIELDS, G. B. 1990. A CLEAVAGE METHOD WHICH 
MINIMIZES SIDE REACTIONS FOLLOWING FMOC SOLID-PHASE PEPTIDE-
SYNTHESIS. International Journal of Peptide and Protein Research, 36, 255-266. 
KOIVISTO, T. & SALASPURO, M. 1997. Effects of Acetaldehyde on Brush Border 
Enzyme Activities in Human Colon Adenocarcinoma Cell Line Caco-2. Alcoholism: 
Clinical and Experimental Research, 21, 1599-1605. 
 
KONIG, K., SCHEIPERS, U., PESAVENTO, A., LORENZ, A., ERMERT, H. & 
SENGE, T. 2005. Initial experiences with real-time elastography guided biopsies of 
the prostate. Journal of Urology, 174, 115-117. 
 
KOPANSKY, E., SHAMAY, Y. & DAVID, A. 2011. Peptide-directed HPMA 
copolymer-doxorubicin conjugates as targeted therapeutics for colorectal cancer. 
Journal of Drug Targeting, 19, 933-943. 
 
KOPPE, M. J., BLEICHRODT, R. P., OYEN, W. J. G. & BOERMAN, O. C. 2005. 
Radioimmunotherapy and colorectal cancer. British Journal of Surgery, 92, 264-276. 
 
KORETZ, K., SCHLAG, P. & MOLLER, P. 1990. EXPRESSION OF EPIDERMAL 
GROWTH-FACTOR RECEPTOR IN NORMAL COLORECTAL MUCOSA, 
ADENOMA, AND CARCINOMA. Virchows Archiv a-Pathological Anatomy and 
Histopathology, 416, 343-349. 
 
KUANG, Y., WANG, F., CORN, D. J., TIAN, H. & LEE, Z. 2014. In vitro 
characterization of uptake mechanism of L-[methyl-(3)H]-methionine in hepatocellular 
carcinoma. Mol Imaging Biol, 16, 459-68. 
 
KUMAR, S., AARON, J. & SOKOLOV, K. 2008. Directional conjugation of antibodies 
to nanoparticles for synthesis of multiplexed optical contrast agents with both delivery 
and targeting moieties. Nature Protocols, 3, 314-320. 
 
KUSANO, M., TAJIMA, Y., YAMAZAKI, K., KATO, M., WATANABE, M. & MIWA, M. 
2008. Sentinel node mapping guided by indocyanine green fluorescence imaging: A 
new method for sentinel node navigation surgery in gastrointestinal cancer. Digestive 
Surgery, 25, 103-108. 
 
LANDSMAN, M. L. J., KWANT, G., MOOK, G. A. & ZIJLSTRA, W. G. 1976. LIGHT-
ABSORBING PROPERTIES, STABILITY, AND SPECTRAL STABILIZATION OF 
INDOCYANINE GREEN. Journal of Applied Physiology, 40, 575-583. 
 
LANE, D. M., EAGLE, K. F., BEGENT, R. H. J., HOPESTONE, L. D., GREEN, A. J., 
CASEY, J. L., KEEP, P. A., KELLY, A. M. B., LEDERMANN, J. A., GLASER, M. G. & 
HILSON, A. J. W. 1994. RADIOIMMUNOTHERAPY OF METASTATIC 
COLORECTAL TUMORS WITH IODINE-131-LABELED ANTIBODY TO 
CARCINOEMBRYONIC ANTIGEN - PHASE I/II STUDY WITH COMPARATIVE 
BIODISTRIBUTION OF INTACT AND F(AB')(2) ANTIBODIES. British Journal of 
Cancer, 70, 521-525. 
 
LEE, J. C., WANG, S. T., CHOW, N. H. & YANG, H. B. 2002. Investigation of the 
prognostic value of coexpressed erbB family members for the survival of colorectal 
cancer patients after curative surgery. European Journal of Cancer, 38, 1065-1071. 
 233 
 
LEEMAN, M. F., MCKAY, J. A. & MURRAY, G. I. 2002. Matrix metalloproteinase 13 
activity is associated with poor prognosis in colorectal cancer. Journal of Clinical 
Pathology, 55, 758-762. 
 
LEWINSKI, N., COLVIN, V. & DREZEK, R. 2008. Cytotoxicity of nanoparticles. 
Small, 4, 26-49. 
 
LI, C. G., HAMPSON, I. N., HAMPSON, L., KUMAR, P., BERNABEU, C. & KUMAR, 
S. 2000. CD105 antagonizes the inhibitory signaling of transforming growth factor 
beta 1 on human vascular endothelial cells. Faseb Journal, 14, 55-64. 
 
LI, J. J. E., MURALIKRISHNAN, S., NG, C.-T., YUNG, L.-Y. L. & BAY, B.-H. 2010. 
Nanoparticle-induced pulmonary toxicity. Experimental Biology and Medicine, 235, 
1025-1033. 
 
LI, Z., BARNES, J. C., BOSOY, A., STODDART, J. F. & ZINK, J. I. 2012. 
Mesoporous silica nanoparticles in biomedical applications. Chemical Society 
Reviews, 41, 2590-2605. 
 
LIAN, T. & HO, R. J. Y. 2001. Trends and developments in liposome drug delivery 
systems. Journal of Pharmaceutical Sciences, 90, 667-680. 
 
LIAN, W., LITHERLAND, S. A., BADRANE, H., TAN, W. H., WU, D. H., BAKER, H. 
V., GULIG, P. A., LIM, D. V. & JIN, S. G. 2004. Ultrasensitive detection of 
biomolecules with fluorescent dye-doped nanoparticles. Analytical Biochemistry, 334, 
135-144. 
 
LINNEKAMP, J. F., WANG, X., MEDEMA, J. P. & VERMEULEN, L. 2015. Colorectal 
cancer heterogeneity and targeted therapy: a case for molecular disease subtypes. 
Cancer Res, 75, 245-9. 
 
LIU, S., ZHANG, H.-L., LIU, T.-C., LIU, B., CAO, Y.-C., HUANG, Z.-L., ZHAO, Y.-D. 
& LUO, Q.-M. 2007. Optimization of the methods for introduction of amine groups 
onto the silica nanoparticle surface. Journal of Biomedical Materials Research Part A, 
80A, 752-757. 
 
LOGAN, R. F. A., PATNICK, J., NICKERSON, C., COLEMAN, L., RUTTER, M. D. & 
VON WAGNER, C. 2011. Outcomes of the Bowel Cancer Screening Programme 
(BCSP) in England after the first 1 million tests. Gut. 
 
LOMBARDI, D. P., GERADTS, J., FOLEY, J. F., CHIAO, C., LAMB, P. W. & 
BARRETT, J. C. 1999. Loss of KAI1 Expression in the Progression of Colorectal 
Cancer. Cancer Research, 59, 5724-5731. 
 
LOWRY, O. H., ROSEBROUGH, N. J., FARR, A. L. & RANDALL, R. J. 1951. 
PROTEIN MEASUREMENT WITH THE FOLIN PHENOL REAGENT. Journal of 
Biological Chemistry, 193, 265-275. 
 
LU, B., SMYTH, M. R. & OKENNEDY, R. 1996. Oriented immobilization of antibodies 
and its applications in immunoassays and immunosensors. Analyst, 121, R29-R32. 
 
LYALL, M. S., DUNDAS, S. R., CURRAN, S. & MURRAY, G. I. 2006. Profiling 
markers of prognosis in colorectal cancer. Clinical Cancer Research, 12, 1184-1191. 
 
 234 
LYSHCHIK, A., HIGASHI, T., ASATO, R., TANAKA, S., ITO, J., MAI, J. J., PELLOT-
BARAKAT, C., INSANA, M. F., BRILL, A. B., SAGA, T., HIRAOKA, M. & TOGASHI, 
K. 2005. Thyroid gland tumor diagnosis at US elastography. Radiology, 237, 202-
211. 
 
MALIK, R., QIAN, S. & LAW, B. 2011. Design and synthesis of a near-infrared 
fluorescent nanofiber precursor for detecting cell-secreted urokinase activity. Anal 
Biochem, 412, 26-33. 
 
MANK, A. J. G. & YEUNG, E. S. 1995. DIODE LASER-INDUCED FLUORESCENCE 
DETECTION IN CAPILLARY ELECTROPHORESIS AFTER PRECOLUMN 
DERIVATIZATION OF AMINO-ACIDS AND SMALL PEPTIDES. Journal of 
Chromatography A, 708, 309-321. 
 
MARAQA, L., CUMMINGS, M., PETER, M. B., SHAABAN, A. M., HORGAN, K., 
HANBY, A. M. & SPEIRS, V. 2008. Carcinoembryonic Antigen Cell Adhesion 
Molecule 6 Predicts Breast Cancer Recurrence following Adjuvant Tamoxifen. 
Clinical Cancer Research, 14, 405-411. 
 
MARIANICOSTANTINI, R., MURARO, R., FICARI, F., VALLI, C., BEI, R., TONELLI, 
F., CARAMIA, F. & FRATI, L. 1991. IMMUNOHISTOCHEMICAL EVIDENCE OF 
IMMUNE-RESPONSES TO TUMOR-ASSOCIATED ANTIGENS IN LYMPH-NODES 
OF COLON-CARCINOMA PATIENTS. Cancer, 67, 2880-2886. 
 
MARQUIS, B. J., LOVE, S. A., BRAUN, K. L. & HAYNES, C. L. 2009. Analytical 
methods to assess nanoparticle toxicity. Analyst, 134, 425-439. 
 
MARSDEN, J. R., NEWTON-BISHOP, J. A., BURROWS, L., COOK, M., CORRIE, P. 
G., COX, N. H., GORE, M. E., LORIGAN, P., MACKIE, R., NATHAN, P., PEACH, H., 
POWELL, B. & WALKER, C. 2010. Revised UK guidelines for the management of 
cutaneous melanoma 2010. British Journal of Dermatology, 163, 238-256. 
 
MATSUI, A., WINER, J. H., LAURENCE, R. G. & FRANGIONI, J. V. 2011. Predicting 
the survival of experimental ischaemic small bowel using intraoperative near-infrared 
fluorescence angiography. British Journal of Surgery, 98, 1725-1734. 
 
MATSUMURA, Y. & MAEDA, H. 1986. A New Concept for Macromolecular 
Therapeutics in Cancer Chemotherapy: Mechanism of Tumoritropic Accumulation of 
Proteins and the Antitumor Agent Smancs. Cancer Research, 46, 6387-6392. 
 
MAYER, A., TSIOMPANOU, E., O’MALLEY, D., BOXER, G. M., BHATIA, J., FLYNN, 
A. A., CHESTER, K. A., DAVIDSON, B. R., LEWIS, A. A. M., WINSLET, M. C., 
DHILLON, A. P., HILSON, A. J. W. & BEGENT, R. H. J. 2000. Radioimmunoguided 
Surgery in Colorectal Cancer Using a Genetically Engineered Anti-CEA Single-Chain 
Fv Antibody. Clinical Cancer Research, 6, 1711-1719. 
 
MAYER-KUCKUK, P., GADE, T. P. F., BUCHANAN, I. M., DOUBROVIN, M., 
AGEYEVA, L., BERTINO, J. R., BOSKEY, A. L., BLASBERG, R. G., KOUTCHER, J. 
A. & BANERJEE, D. 2005. High-Resolution Imaging of Bone Precursor Cells Within 
the Intact Bone Marrow Cavity of Living Mice. Mol Ther, 12, 33-41. 
 
MCCARTY, K. S. J., SZABO, E., FLOWERS, J. L., COX, E. B., LEIGHT, G. S., 
MILLER, L., KONRATH, J., SOPER, J. T., BUDWIT, D. A. & ET AL. 1986. USE OF A 
MONOCLONAL ANTI-ESTROGEN RECEPTOR ANTIBODY IN THE 
 235 
IMMUNOHISTOCHEMICAL EVALUATION OF HUMAN TUMORS. Cancer 
Research, 46, 4244S-4248S. 
 
MCCORMACK, D., AL-SHAER, M., GOLDSCHMIDT, B. S., DALE, P. S., HENRY, 
C., PAPAGEORGIO, C., BHATTACHARYYA, K. & VIATOR, J. A. 2009. 
Photoacoustic detection of melanoma micrometastasis in sentinel lymph nodes. 
Journal of biomechanical engineering, 131, 074519. 
 
MCLAUGHLIN, R. A., SCOLARO, L., ROBBINS, P., HAMZA, S., SAUNDERS, C. & 
SAMPSON, D. D. 2010. Imaging of human lymph nodes using optical coherence 
tomography: potential for staging cancer. Cancer Res, 70, 2579-84. 
 
MELLA, J., BIFFIN, A., RADCLIFFE, A. G., STAMATAKIS, J. D. & STEELE, R. J. C. 
1997. Population-based audit of colorectal cancer management in two UK health 
regions. British Journal of Surgery, 84, 1731-1736. 
 
MELLER, B., RAVE-FRAENCK, M., BREUNIG, C., SCHIRMER, M., BAEHRE, M., 
NADROWITZ, R., LIERSCH, T. & MELLER, J. 2011. Novel Carcinoembryonic-
Antigen-(CEA)-Specific Pretargeting System to Assess Tumor Cell Viability after 
Irradiation of Colorectal Cancer Cells. Strahlentherapie Und Onkologie, 187, 120-
126. 
 
MENG, H., XUE, M., XIA, T., JI, Z., TARN, D. Y., ZINK, J. I. & NEL, A. E. 2011. Use 
of size and a copolymer design feature to improve the biodistribution and the 
enhanced permeability and retention effect of doxorubicin-loaded mesoporous silica 
nanoparticles in a murine xenograft tumor model. ACS Nano, 5, 4131-44. 
 
MEREDITH, R. F., KHAZAELI, M. B., PLOTT, W. E., GRIZZLE, W. E., LIU, T., 
SCHLOM, J., RUSSELL, C. D., WHEELER, R. H. & LOBUGLIO, A. F. 1996. Phase II 
study of dual 131I-labeled monoclonal antibody therapy with interferon in patients 
with metastatic colorectal cancer. Clinical Cancer Research, 2, 1811-1818. 
 
MEYER, T., GAYA, A. M., DANCEY, G., STRATFORD, M. R. L., OTHMAN, S., 
SHARMA, S. K., WELLSTED, D., TAYLOR, N. J., STIRLING, J. J., POUPARD, L., 
FOLKES, L. K., CHAN, P.-S., PEDLEY, R. B., CHESTER, K. A., OWEN, K., VIOLET, 
J. A., MALARODA, A., GREEN, A. J., BUSCOMBE, J., PADHANI, A. R., RUSTIN, G. 
J. & BEGENT, R. H. 2009. A Phase I Trial of Radioimmunotherapy with 131I-A5B7 
Anti-CEA Antibody in Combination with Combretastatin-A4-Phosphate in Advanced 
Gastrointestinal Carcinomas. Clinical Cancer Research, 15, 4484-4492. 
 
MICHALET, X., PINAUD, F. F., BENTOLILA, L. A., TSAY, J. M., DOOSE, S., LI, J. 
J., SUNDARESAN, G., WU, A. M., GAMBHIR, S. S. & WEISS, S. 2005. Quantum 
dots for live cells, in vivo imaging, and diagnostics. Science, 307, 538-544. 
 
MICHIELSEN, A. J., O'SULLIVAN, J. N. & RYAN, E. J. 2012. Tumor conditioned 
media from colorectal cancer patients inhibits dendritic cell maturation. 
Oncoimmunology, 1, 751-753. 
 
MILLER, C. R., BONDURANT, B., MCLEAN, S. D., MCGOVERN, K. A. & O'BRIEN, 
D. F. 1998. Liposome-cell interactions in vitro: Effect of liposome surface charge on 
the binding and endocytosis of conventional and sterically stabilized liposomes. 
Biochemistry, 37, 12875-12883. 
 
 236 
MOGHIMI, S. M., HUNTER, A. C. & ANDRESEN, T. L. 2012. Factors Controlling 
Nanoparticle Pharmacokinetics: An Integrated Analysis and Perspective. Annual 
Review of Pharmacology and Toxicology, Vol 52, 52, 481-503. 
 
MONICI, M. 2005. Cell and tissue autofluorescence research and diagnostic 
applications. In: EL-GEWELY, M. R. (ed.) Biotechnology Annual Review. Elsevier. 
 
MUGURUMA, N., ITO, S., BANDO, T., TAOKA, S., KUSAKA, Y., HAYASHI, S., 
ICHIKAWA, S., MATSUNAGA, Y., TADA, Y., OKAMURA, S., II, K., IMAIZUMI, K., 
NAKAMURA, K., TAKESAKO, K. & SHIBAMURA, S. 1999. Labeled 
carcinoembryonic antigen antibodies excitable by infrared rays: A novel diagnostic 
method for micro cancers in the digestive tract. Internal Medicine, 38, 537-542. 
 
MUGURUMA, N., ITO, S., HAYASHI, S., TAOKA, S., KAKEHASHI, H., II, K., 
SHIBAMURA, S. & TAKESAKO, K. 1998. Antibodies labeled with fluorescence-agent 
excitable by infrared rays. Journal of Gastroenterology, 33, 467-471. 
 
MULLER, M. G., GEORGAKOUDI, I., ZHANG, Q. G., WU, J. & FELD, M. S. 2001. 
Intrinsic fluorescence spectroscopy in turbid media: disentangling effects of 
scattering and absorption. Applied Optics, 40, 4633-4646. 
 
MULSOW, J., WINTER, D. C., O'KEANE, J. C. & O'CONNELL, P. R. 2003. Sentinel 
lymph node mapping in colorectal cancer. British Journal of Surgery, 90, 659-667. 
 
NAGATA, K., ENDO, S., HIDAKA, E., TANAKA, J., KUDO, S. & SHIOKAWA, A. 
2006. Laparoscopic sentinel node mapping for colorectal cancer using infrared ray 
laparoscopy. Anticancer Research, 26, 2307-2311. 
 
NAKAJIMA, T., MITSUNAGA, M., BANDER, N. H., HESTON, W. D., CHOYKE, P. L. 
& KOBAYASHI, H. 2011. Targeted, Activatable, In Vivo Fluorescence Imaging of 
Prostate-Specific Membrane Antigen (PSMA) Positive Tumors Using the Quenched 
Humanized J591 Antibody-Indocyanine Green (ICG) Conjugate. Bioconjugate 
Chemistry, 22, 1700-1705. 
 
NATIONAL CANCER INTELLIGENCE NETWORK (NCIN) 2009. Colorectal Cancer 
Survival by Stage. London: ONS. 
 
NOONEY, R. I., MCCAHEY, C. M. N., STRANIK, O., GUEVEL, X. L., MCDONAGH, 
C. & MACCRAITH, B. D. 2009. Experimental and theoretical studies of the 
optimisation of fluorescence from near-infrared dye-doped silica nanoparticles. 
Analytical and Bioanalytical Chemistry, 393, 1143-1149. 
 
O'DONOGHUE, J. A., SMITH-JONES, P. M., HUMM, J. L., RUAN, S., PRYMA, D. 
A., JUNGBLUTH, A. A., DIVGI, C. R., CARRASQUILLO, J. A., PANDIT-TASKAR, N., 
FONG, Y., STRONG, V. E., KEMENY, N. E., OLD, L. J. & LARSON, S. M. 2011. 
124I-huA33 Antibody Uptake Is Driven by A33 Antigen Concentration in Tissues from 
Colorectal Cancer Patients Imaged by Immuno-PET. Journal of Nuclear Medicine, 
52, 1878-1885. 
 
OFFICE FOR NATIONAL STATISTICS 2010. Colorectal incidence and mortality, 
1972 - 2007. Office for National Statistics. 
 
OGAWA, M., KOSAKA, N., CHOYKE, P. L. & KOBAYASHI, H. 2009. In vivo 
Molecular Imaging of Cancer with a Quenching Near-Infrared Fluorescent Probe 
 237 
Using Conjugates of Monoclonal Antibodies and Indocyanine Green. Cancer 
Research, 69, 1268-1272. 
 
OHANNESIAN, D. W., LOTAN, D., THOMAS, P., JESSUP, J. M., FUKUDA, M., 
GABIUS, H. J. & LOTAN, R. 1995. CARCINOEMBRYONIC ANTIGEN AND OTHER 
GLYCOCONJUGATES ACT AS LIGANDS FOR GALECTIN-3 IN HUMAN COLON-
CARCINOMA CELLS. Cancer Research, 55, 2191-2199. 
 
OSIAC, E., SAFTOIU, A., GHEONEA, D. I., MANDRILA, I. & ANGELESCU, R. 2011. 
Optical coherence tomography and Doppler optical coherence tomography in the 
gastrointestinal tract. World Journal of Gastroenterology, 17, 15-20. 
 
OW, H., LARSON, D. R., SRIVASTAVA, M., BAIRD, B. A., WEBB, W. W. & 
WIESNER, U. 2005. Bright and stable core-shell fluorescent silica nanoparticles. 
Nano Lett, 5, 113-7. 
 
OWENS III, D. E. & PEPPAS, N. A. 2006. Opsonization, biodistribution, and 
pharmacokinetics of polymeric nanoparticles. International Journal of Pharmaceutics, 
307, 93-102. 
 
PARK, I. J., CHOI, G. S., KANG, B. M., LIM, K. H. & JUN, S. H. 2009. Lymph node 
metastasis patterns in right-sided colon cancers: is segmental resection of these 
tumors oncologically safe? Ann Surg Oncol, 16, 1501-6. 
 
PEDLEY, R. B., BODEN, J. A., BODEN, R. W., GREEN, A., BOXER, G. M. & 
BAGSHAWE, K. D. 1989. THE EFFECT OF SERUM CEA ON THE DISTRIBUTION 
AND CLEARANCE OF ANTI-CEA ANTIBODY IN A PANCREATIC TUMOR 
XENOGRAFT MODEL. British Journal of Cancer, 60, 549-554. 
 
PEER, D., KARP, J. M., HONG, S., FAROKHZAD, O. C., MARGALIT, R. & 
LANGER, R. 2007. Nanocarriers as an emerging platform for cancer therapy. Nat 
Nano, 2, 751-760. 
 
PELLEY, J. L., DAAR, A. S. & SANER, M. A. 2009. State of Academic Knowledge on 
Toxicity and Biological Fate of Quantum Dots. Toxicological Sciences, 112, 276-296. 
PENZKOFER, A. & LU, Y. 1986. FLUORESCENCE QUENCHING OF RHODAMINE 
6G IN METHANOL AT HIGH-CONCENTRATION. Chemical Physics, 103, 399-405. 
 
PERACCHIA, M. T., FATTAL, E., DESMAËLE, D., BESNARD, M., NOËL, J. P., 
GOMIS, J. M., APPEL, M., D'ANGELO, J. & COUVREUR, P. 1999. Stealth® 
PEGylated polycyanoacrylate nanoparticles for intravenous administration and 
splenic targeting. Journal of Controlled Release, 60, 121-128. 
 
PERCIVALE, P., BERTOGLIO, S., MESZAROS, P., SCHENONE, F., GIPPONI, M., 
MORESCO, L., COSSO, M. & BADELLINO, F. 1998. Radioimmunoguided surgery 
with different iodine-125 radiolabeled monoclonal antibodies in recurrent colorectal 
cancer. Semin Surg Oncol, 15, 231-4. 
 
PERRAULT, S. D., WALKEY, C., JENNINGS, T., FISCHER, H. C. & CHAN, W. C. 
W. 2009. Mediating Tumor Targeting Efficiency of Nanoparticles Through Design. 
Nano Letters, 9, 1909-1915. 
 
PETROS, R. A. & DESIMONE, J. M. 2010. Strategies in the design of nanoparticles 
for therapeutic applications. Nature Reviews Drug Discovery, 9, 615-627. 
 
 238 
POTOMSKI, J., HARLOZINSKA, A., STARZYK, H., RICHTER, R. & WOZNIEWSKI, 
A. 1979. CORRELATION BETWEEN IMMUNOHISTOCHEMICAL LOCALIZATION 
OF CARCINOEMBRYONIC ANTIGEN (CEA) AND HISTOLOGICAL ESTIMATION 
OF CARCINOMAS, NORMAL MUCOSAE AND LYMPH-NODES OF THE 
DIGESTIVE-TRACT IN HUMANS. Archivum Immunologiae Et Therapiae 
Experimentalis, 27, 177-186. 
 
POVOSKI, S., HATZARAS, I., MOJZISIK, C., ARNOLD, M., HINKLE, G., 
HITCHCOCK, C., YOUNG, D. & MARTIN, E. 2012. Antigen-Directed Cancer Surgery 
for Primary Colorectal Cancer: 15-Year Survival Analysis. Annals of Surgical 
Oncology, 19, 131-138. 
 
PRATS-MATEU, B., ERTL, P. & TOCA-HERRERA, J. L. 2014. Influence of HepG2 
cell shape on nanoparticle uptake. Microsc Res Tech, 77, 560-5. 
 
PUCHTLER, H. & MELOAN, S. N. 1985. ON THE CHEMISTRY OF 
FORMALDEHYDE FIXATION AND ITS EFFECTS ON IMMUNOHISTOCHEMICAL 
REACTIONS. Histochemistry, 82, 201-204. 
 
QHOBOSHEANE, M., SANTRA, S., ZHANG, P. & TAN, W. 2001. Biochemically 
functionalized silica nanoparticles. Analyst, 126, 1274-8. 
 
QI, S., MIAO, Z., LIU, H., XU, Y., FENG, Y. & CHENG, Z. 2012. Evaluation of Four 
Affibody based Near-infrared Fluorescent Probes for Optical Imaging of Epidermal 
Growth Factor Receptor Positive Tumors. Bioconjugate Chemistry. 
 
QIU, X.-Q., WANG, H., CAI, B., WANG, L.-L. & YUE, S.-T. 2007. Small antibody 
mimetics comprising two complementarity-determining regions and a framework 
region for tumor targeting. Nature Biotechnology, 25, 921-929. 
 
RAHBARI, N. N., BORK, U., MOTSCHALL, E., THORLUND, K., BÜCHLER, M. W., 
KOCH, M. & WEITZ, J. 2012. Molecular Detection of Tumor Cells in Regional Lymph 
Nodes Is Associated With Disease Recurrence and Poor Survival in Node-Negative 
Colorectal Cancer: A Systematic Review and Meta-Analysis. Journal of Clinical 
Oncology, 30, 60-70. 
 
RAJKUMAR, V., BOXER, G., ROBSON, M., MUDDLE, J., PAPASTAVROU, Y. & 
PEDLEY, R. B. 2012. A comparative study of PDGFR inhibition with imatinib on 
radiolabeled antibody targeting and clearance in two pathologically distinct models of 
colon adenocarcinoma. Tumor Biology, 33, 2019-2029. 
REDDY, J. A. & LOW, P. S. 1998. Folate-mediated targeting of therapeutic and 
imaging agents to cancers. Critical Reviews in Therapeutic Drug Carrier Systems, 
15, 587-627. 
REITHMEIER, R., BRUCKMEIER, C. & RIEGER, B. 2012. Conversion of CO2 via 
Visible Light Promoted Homogeneous Redox Catalysis. Catalysts, 2, 544-571. 
 
RIS, F., HOMPES, R., CUNNINGHAM, C., LINDSEY, I., GUY, R., JONES, O., 
GEORGE, B., CAHILL, R. & MORTENSEN, N. 2014. Near-infrared (NIR) perfusion 
angiography in minimally invasive colorectal surgery. Surgical Endoscopy, 1-6. 
 
RIVAROLA, C. R., BERTOLOTTI, S. G. & PREVITALI, C. M. 2006. Photoreduction of 
Ru(bpy)(3)2+ by amines in aqueous solution. Kinetics characterization of a long-lived 
nonemitting excited state. Photochem Photobiol, 82, 213-8. 
 
 239 
RIZZARDI, A. E., JOHNSON, A. T., VOGEL, R. I., PAMBUCCIAN, S. E., 
HENRIKSEN, J., SKUBITZ, A. P. N., METZGER, G. J. & SCHMECHEL, S. C. 2012. 
Quantitative comparison of immunohistochemical staining measured by digital image 
analysis versus pathologist visual scoring. Diagnostic Pathology, 7. 
 
ROBERT, B., DORVILLIUS, M., BUCHEGGER, F., GARAMBOIS, V., MANI, J. C., 
PUGNIERES, M., MACH, J. P. & PELEGRIN, A. 1999. Tumor targeting with newly 
designed biparatopic antibodies directed against two different epitopes of the 
carcinoembryonic antigen (CEA). International Journal of Cancer, 81, 285-291. 
 
ROSELLI, M., GUADAGNI, F., BUONOMO, O., BELARDI, A., VITTORINI, V., 
CAVAZZANA, A., SPAGNOLI, L. G., CIPRIANI, C. & CASCIANI, C. U. 1996. 
Intraoperative radioimmunolocalization of an anti-CEA MAb F(Ab')(2) (F023C5) in 
CEA serum-negative colorectal cancer patients. Anticancer Research, 16, 883-889. 
 
SĂFTOIU, A., VILMANN, P., CIUREA, T., POPESCU, G. L., IORDACHE, A., 
HASSAN, H., GORUNESCU, F. & IORDACHE, S. 2007. Dynamic analysis of EUS 
used for the differentiation of benign and malignant lymph nodes. Gastrointestinal 
Endoscopy, 66, 291-300. 
 
SÁNCHEZ-ELSNER, T., BOTELLA, L. M., VELASCO, B., LANGA, C. & BERNABÉU, 
C. 2002. Endoglin Expression Is Regulated by Transcriptional Cooperation between 
the Hypoxia and Transforming Growth Factor-β Pathways. Journal of Biological 
Chemistry, 277, 43799-43808. 
 
SANTRA, S., ZHANG, P., WANG, K. M., TAPEC, R. & TAN, W. H. 2001. 
Conjugation of biomolecules with luminophore-doped silica nanoparticles for 
photostable biomarkers. Analytical Chemistry, 73, 4988-4993. 
 
SCARTOZZI, M., BEARZI, I., BERARDI, R., MANDOLESI, A., FABRIS, G. & 
CASCINU, S. 2004. Epidermal Growth Factor Receptor (EGFR) Status in Primary 
Colorectal Tumors Does Not Correlate With EGFR Expression in Related Metastatic 
Sites: Implications for Treatment With EGFR-Targeted Monoclonal Antibodies. 
Journal of Clinical Oncology, 22, 4772-4778. 
 
SCHIMANSKI, C., ZIMMERMANN, T., SCHMIDTMANN, I., GOCKEL, I., LANG, H., 
GALLE, P., MOEHLER, M. & BERGER, M. 2010a. K-&lt;i&gt;ras&lt;/i&gt; mutation 
status correlates with the expression of &lt;i&gt;VEGFR1&lt;/i&gt;, 
&lt;i&gt;VEGFR2&lt;/i&gt;, and &lt;i&gt;PDGFRα&lt;/i&gt; in colorectal cancer. 
International Journal of Colorectal Disease, 25, 181-186. 
 
SCHIMANSKI, C., ZIMMERMANN, T., SCHMIDTMANN, I., GOCKEL, I., LANG, H., 
GALLE, P., MOEHLER, M. & BERGER, M. 2010b. K-ras mutation status correlates 
with the expression of VEGFR1, VEGFR2, and PDGFRalpha in colorectal cancer. 
International Journal of Colorectal Disease, 25, 181-186. 
 
SCHMIDT, M. M., THURBER, G. M. & WITTRUP, K. D. 2008. Kinetics of anti-
carcinoembryonic antigen antibody internalization: effects of affinity, bivalency, and 
stability. Cancer Immunology Immunotherapy, 57, 1879-1890. 
 
SCHOFFELEN, R., SHARKEY, R. M., GOLDENBERG, D. M., FRANSSEN, G., 
MCBRIDE, W. J., ROSSI, E. A., CHANG, C.-H., LAVERMAN, P., DISSELHORST, J. 
A., EEK, A., VAN DER GRAAF, W. T. A., OYEN, W. J. G. & BOERMAN, O. C. 2010. 
Pretargeted Immuno-Positron Emission Tomography Imaging of Carcinoembryonic 
Antigen-Expressing Tumors with a Bispecific Antibody and a Ga-68- and F-18-
 240 
Labeled Hapten Peptide in Mice with Human Tumor Xenografts. Molecular Cancer 
Therapeutics, 9, 1019-1027. 
 
SCHOFFELEN, R., VAN DER GRAAF, W. T., SHARKEY, R. M., FRANSSEN, G. M., 
MCBRIDE, W. J., CHANG, C.-H., LAVERMAN, P., GOLDENBERG, D. M., OYEN, 
W. J. & BOERMAN, O. C. 2012. Pretargeted immuno-PET of CEA-expressing 
intraperitoneal human colonic tumor xenografts: a new sensitive detection method. 
EJNMMI research, 2, 5-5. 
 
SCHWENK, W., BOHM, B., WITT, C., JUNGHANS, T., GRUNDEL, K. & MULLER, J. 
M. 1999. Pulmonary function following laparoscopic or conventional colorectal 
resection: a randomized controlled evaluation. Arch Surg, 134, 6-12; discussion 13. 
 
SEDLAK, J. & LINDSAY, R. H. 1968. ESTIMATION OF TOTAL PROTEIN-BOUND 
AND NONPROTEIN SULFHYDRYL GROUPS IN TISSUE WITH ELLMANS 
REAGENT. Analytical Biochemistry, 25, 192-&. 
 
SHARKEY, R. M., CARDILLO, T. M., ROSSI, E. A., CHANG, C. H., KARACAY, H., 
MCBRIDE, W. J., HANSEN, H. J., HORAK, I. D. & GOLDENBERG, D. M. 2005. 
Signal amplification in molecular imaging by pretargeting a multivalent, bispecific 
antibody. Nature Medicine, 11, 1250-1255. 
 
SHIA, J., KLIMSTRA, D. S., NITZKORSKI, J. R., LOW, P. S., GONEN, M., 
LANDMANN, R., WEISER, M. R., FRANKLIN, W. A., PRENDERGAST, F. G., 
MURPHY, L., TANG, L. H., TEMPLE, L., GUILLEM, J. G., WONG, W. D. & PATY, P. 
B. 2008. Immunohistochemical expression of folate receptor [alpha] in colorectal 
carcinoma: patterns and biological significance. Human Pathology, 39, 498-505. 
 
SINGH, P. 1998. Terminal groups in Starburst dendrimers: activation and reactions 
with proteins. Bioconjug Chem, 9, 54-63. 
 
SIRIWARDENA, A. K., MASON, J. M., MULLAMITHA, S., HANCOCK, H. C. & 
JEGATHEESWARAN, S. 2014. Management of colorectal cancer presenting with 
synchronous liver metastases. Nature Reviews Clinical Oncology, 11, 446-459. 
 
SLOWING, I. I., VIVERO-ESCOTO, J. L., WU, C.-W. & LIN, V. S. Y. 2008. 
Mesoporous silica nanoparticles as controlled release drug delivery and gene 
transfection carriers. Advanced Drug Delivery Reviews, 60, 1278-1288. 
 
SMITH, A. E., PINKNEY, M., PIGGOTT, N. H., CALVERT, H., MILTON, I. D. & 
LUNEC, J. 2007. Novel monoclonal antibody for detection of folate receptor alpha in 
paraffin-embedded tissues. Hybridoma, 26, 281-288. 
 
SOENEN, S. J. H. & DE CUYPER, M. 2010. Assessing iron oxide nanoparticle 
toxicity in vitro: current status and future prospects. Nanomedicine, 5, 1261-1275. 
 
SOLTESZ, E. G., KIM, S., KIM, S. W., LAURENCE, R. G., DE GRAND, A. M., 
PARUNGO, C. P., COHN, L. H., BAWENDI, M. G. & FRANGIONI, J. V. 2006. 
Sentinel lymph node mapping of the gastrointestinal tract by using invisible light. 
Annals of Surgical Oncology, 13, 386-396. 
 
SOPPIMATH, K. S., AMINABHAVI, T. M., KULKARNI, A. R. & RUDZINSKI, W. E. 
2001. Biodegradable polymeric nanoparticles as drug delivery devices. Journal of 
Controlled Release, 70, 1-20. 
 
 241 
SOSLOW, R. A., DANNENBERG, A. J., RUSH, D., WOERNER, B. M., KHAN, K. N., 
MASFERRER, J. & KOKI, A. T. 2000. COX-2 is expressed in human pulmonary, 
colonic, and mammary tumors. Cancer, 89, 2637-2645. 
 
SOSTER, M., JURIS, R., BONACCHI, S., GENOVESE, D., MONTALTI, M., 
RAMPAZZO, E., ZACCHERONI, N., GARAGNANI, P., BUSSOLINO, F., PRODI, L. & 
MARCHIO, S. 2012. Targeted dual-color silica nanoparticles provide univocal 
identification of micrometastases in preclinical models of colorectal cancer. 
International Journal of Nanomedicine, 7, 4797-4807. 
 
SOURIS, J. S., LEE, C.-H., CHENG, S.-H., CHEN, C.-T., YANG, C.-S., HO, J.-A. A., 
MOU, C.-Y. & LO, L.-W. 2010. Surface charge-mediated rapid hepatobiliary excretion 
of mesoporous silica nanoparticles. Biomaterials, 31, 5564-5574. 
 
SPANO, J.-P., LAGORCE, C., ATLAN, D., MILANO, G., DOMONT, J., 
BENAMOUZIG, R., ATTAR, A., BENICHOU, J., MARTIN, A., MORERE, J.-F., 
RAPHAEL, M., PENAULT-LLORCA, F., BREAU, J.-L., FAGARD, R., KHAYAT, D. & 
WIND, P. 2005. Impact of EGFR expression on colorectal cancer patient prognosis 
and survival. Annals of Oncology, 16, 102-108. 
 
STEAD, M. L., BROWN, J. M., BOSANQUET, N., FRANKS, P. J., GUILLOU, P. J., 
QUIRKE, P., JAYNE, D., MONSON, J. R. T. & WEBB, A. V. 2000. Assessing the 
relative costs of standard open surgery and laparoscopic surgery in colorectal cancer 
in a randomised controlled trial in the United Kingdom. Critical Reviews in Oncology 
Hematology, 33, 99-103. 
 
SUN, D., BLOOMSTON, M., HINKLE, G., AL-SAIF, O. H., HALL, N. C., POVOSKI, S. 
P., ARNOLD, M. W. & MARTIN, E. W. 2007. Radioimmunoguided surgery (RIGS), 
PET/CT image-guided surgery, and fluorescence image-guided surgery: Past, 
present, and future. Journal of Surgical Oncology, 96, 297-308. 
 
SUN, L., WU, H. & GUAN, Y. S. 2008. Colonography by CT, MRI and PET/CT 
combined with conventional colonoscopy in colorectal cancer screening and staging. 
World Journal of Gastroenterology, 14, 853-863. 
 
SUPPIAH, A., MASLEKAR, S., ALABI, A., HARTLEY, J. E. & MONSON, J. R. T. 
2008. Transanal endoscopic microsurgery in early rectal cancer: time for a trial? 
Colorectal Disease, 10, 314-327. 
 
SWEDLOW, J. R., HU, K., ANDREWS, P. D., ROOS, D. S. & MURRAY, J. M. 2002. 
Measuring tubulin content in Toxoplasma gondii: a comparison of laser-scanning 
confocal and wide-field fluorescence microscopy. Proc Natl Acad Sci U S A, 99, 
2014-9. 
 
TAN, C., XIE, Y., HE, X., WANG, K. & JIANG, Y. 2010a. Hyper-efficient quenching of 
a conjugated polyelectrolyte by dye-doped silica nanoparticles: better quenching in 
the nonaggregated state. Langmuir, 26, 1528-32. 
 
TAN, K. Y., KAWAMURA, Y. J., MIZOKAMI, K., SASAKI, J., TSUJINAKA, S., 
MAEDA, T., NOBUKI, M. & KONISHI, F. 2010b. Distribution of the first metastatic 
lymph node in colon cancer and its clinical significance. Colorectal Disease, 12, 44-
47. 
 
TANG, F., LI, L. & CHEN, D. 2012. Mesoporous Silica Nanoparticles: Synthesis, 
Biocompatibility and Drug Delivery. Advanced Materials, 24, 1504-1534. 
 242 
 
TANG, Y., YANG, S., GARIÉPY, J., SCOLLARD, D. A. & REILLY, R. M. 2007. 
Construction and Evaluation of the Tumor Imaging Properties of 123I-Labeled 
Recombinant and Enzymatically Generated Fab Fragments of the TAG-72 
Monoclonal Antibody CC49. Bioconjugate Chemistry, 18, 677-684. 
 
TAO, L., SONG, C., SUN, Y., LI, X., LI, Y., JIN, B., ZHANG, Z. & YANG, K. 2013. A 
fluorescent and chemiluminescent difunctional mesoporous silica nanoparticle as a 
label for the ultrasensitive detection of cancer cells. Anal Chim Acta, 761, 194-200. 
 
TAYLOR, E. F., THOMAS, J. D., WHITEHOUSE, L. E., QUIRKE, P., JAYNE, D., 
FINAN, P. J., FORMAN, D., WILKINSON, J. R. & MORRIS, E. J. A. 2013. 
Population-based study of laparoscopic colorectal cancer surgery 2006-2008. British 
Journal of Surgery, 100, 553-560. 
 
TEEGUARDEN, J. G., HINDERLITER, P. M., ORR, G., THRALL, B. D. & POUNDS, 
J. G. 2007. Particokinetics in vitro: Dosimetry considerations for in vitro nanoparticle 
toxicity assessments. Toxicological Sciences, 95, 300-312. 
 
TIVNAN, A., ORR, W. S., GUBALA, V., NOONEY, R., WILLIAMS, D. E., 
MCDONAGH, C., PRENTER, S., HARVEY, H., DOMINGO-FERNANDEZ, R., BRAY, 
I. M., PISKAREVA, O., NG, C. Y., LODE, H. N., DAVIDOFF, A. M. & STALLINGS, R. 
L. 2012. Inhibition of Neuroblastoma Tumor Growth by Targeted Delivery of 
MicroRNA-34a Using Anti-Disialoganglioside GD(2) Coated Nanoparticles. Plos One, 
7. 
 
TIWARI, D. K., TANAKA, S., INOUYE, Y., YOSHIZAWA, K., WATANABE, T. M. & 
JIN, T. 2009. Synthesis and Characterization of Anti-HER2 Antibody Conjugated 
CdSe/CdZnS Quantum Dots for Fluorescence Imaging of Breast Cancer Cells. 
Sensors (Basel), 9, 9332-64. 
 
TOM, B. H., RUTZKY, L. P., JAKSTYS, M. M., OYASU, R., KAYE, C. I. & KAHAN, B. 
D. 1976. HUMAN COLONIC ADENOCARCINOMA CELLS .1. ESTABLISHMENT 
AND DESCRIPTION OF A NEW LINE. In Vitro-Journal of the Tissue Culture 
Association, 12, 180-191. 
 
TOMPKINS, W. A., WATRACH, A. M., SCHMALE, J. D., SCHULTZ, R. M. & 
HARRIS, J. A. 1974. CULTURAL AND ANTIGENIC PROPERTIES OF NEWLY 
ESTABLISHED CELL STRAINS DERIVED FROM ADENOCARCINOMAS OF 
HUMAN COLON AND RECTUM. Journal of the National Cancer Institute, 52, 1101-
1110. 
 
TONRA, J. R., DEEVI, D. S., CORCORAN, E., LI, H. L., WANG, S., CARRICK, F. E. 
& HICKLIN, D. J. 2006. Synergistic antitumor effects of combined epidermal growth 
factor receptor and vascular endothelial growth factor receptor-2 targeted therapy. 
Clinical Cancer Research, 12, 2197-2207. 
 
TORHORST, J., BUCHER, C., KONONEN, J., HAAS, P., ZUBER, M., KOCHLI, O. 
R., MROSS, F., DIETERICH, H., MOCH, H., MIHATSCH, M., KALLIONIEMI, O. P. & 
SAUTER, G. 2001. Tissue microarrays for rapid linking of molecular changes to 
clinical endpoints. American Journal of Pathology, 159, 2249-2256. 
 
TORRANO, A. A. & BRAUCHLE, C. 2014. Precise quantification of silica and ceria 
nanoparticle uptake revealed by 3D fluorescence microscopy. Beilstein J 
Nanotechnol, 5, 1616-24. 
 243 
 
UUSARO, A., RUOKONEN, E. & TAKALA, J. 1995. ESTIMATION OF SPLANCHNIC 
BLOOD-FLOW BY THE FICK PRINCIPLE IN MAN AND PROBLEMS IN THE USE 
OF INDOCYANINE GREEN. Cardiovascular Research, 30, 106-112. 
 
VAHRMEIJER, A. L., HUTTEMAN, M., VAN DER VORST, J. R., VAN DE VELDE, C. 
J. H. & FRANGIONI, J. V. 2013. Image-guided cancer surgery using near-infrared 
fluorescence. Nature Reviews Clinical Oncology, 10, 507-518. 
 
VAKUROV, A., PCHELINTSEV, N. A., FORDE, J., FAGAIN, C. O., GIBSON, T. & 
MILLNER, P. 2009. The preparation of size-controlled functionalized polymeric 
nanoparticles in micelles. Nanotechnology, 20. 
 
VAN CUTSEM, E., KOHNE, C. H., HITRE, E., ZALUSKI, J., CHIEN, C. R. C., 
MAKHSON, A., D'HAENS, G., PINTER, T., LIM, R., BODOKY, G., ROH, J. K., 
FOLPRECHT, G., RUFF, P., STROH, C., TEJPAR, S., SCHLICHTING, M., 
NIPPGEN, J. & ROUGIER, P. 2009. Cetuximab and Chemotherapy as Initial 
Treatment for Metastatic Colorectal Cancer. New England Journal of Medicine, 360, 
1408-1417. 
 
VAN DER PAS, M. H. G. M., HAGLIND, E., CUESTA, M. A., FÜRST, A., LACY, A. 
M., HOP, W. C. J. & BONJER, H. J. 2013. Laparoscopic versus open surgery for 
rectal cancer (COLOR II): short-term outcomes of a randomised, phase 3 trial. The 
Lancet Oncology, 14, 210-218. 
 
VAN DER PAS, M. H. G. M., MEIJER, S., HOEKSTRA, O. S., RIPHAGEN, I. I., DE 
VET, H. C. W., KNOL, D. L., VAN GRIEKEN, N. C. T. & MEIJERINK, W. J. H. J. 
2011. Sentinel lymph node procedure in colon and rectal cancer: a systematic review 
and meta-analysis. Lancet Oncology, 12, 540-550. 
 
VAN DIEST, P. J., VAN DAM, P., HENZEN-LOGMANS, S. C., BERNS, E., VAN DER 
BURG, M. E., GREEN, J. & VERGOTE, I. 1997. A scoring system for 
immunohistochemical staining: consensus report of the task force for basic research 
of the EORTC-GCCG. European Organization for Research and Treatment of 
Cancer-Gynaecological Cancer Cooperative Group. J Clin Pathol, 50, 801-4. 
 
VAN SCHELTINGA, A. G. T. T., VAN DAM, G. M., NAGENGAST, W. B., 
NTZIACHRISTOS, V., HOLLEMA, H., HEREK, J. L., SCHRODER, C. P., 
KOSTERINK, J. G. W., LUB-DE HOOG, M. N. & DE VRIES, E. G. E. 2011. 
Intraoperative Near-Infrared Fluorescence Tumor Imaging with Vascular Endothelial 
Growth Factor and Human Epidermal Growth Factor Receptor 2 Targeting 
Antibodies. Journal of Nuclear Medicine, 52, 1778-1785. 
 
VEIT-HAIBACH, P., KUEHLE, C. A., BEYER, T., STERGAR, H., KUEHL, H., 
SCHMIDT, J., BORSCH, G., DAHMEN, G., BARKHAUSEN, J., BOCKISCH, A. & 
ANTOCH, G. 2006. Diagnostic accuracy of colorectal cancer staging with whole-body 
PET/CT colonography. Jama-Journal of the American Medical Association, 296, 
2590-2600. 
VIGOR, K. L., KYRTATOS, P. G., MINOGUE, S., AL-JAMAL, K. T., KOGELBERG, 
H., TOLNER, B., KOSTARELOS, K., BEGENT, R. H., PANKHURST, Q. A., 
LYTHGOE, M. F. & CHESTER, K. A. 2010. Nanoparticles functionalised with 
recombinant single chain Fv antibody fragments (scFv) for the magnetic resonance 
imaging of cancer cells. Biomaterials, 31, 1307-1315. 
 
 244 
WANG, B., XIAO, Y., DING, B.-B., ZHANG, N., YUAN, X.-B., GUI, L., QIAN, K.-X., 
DUAN, S., CHEN, Z., RAO, Y. & GENG, J.-G. 2003. Induction of tumor angiogenesis 
by Slit-Robo signaling and inhibition of cancer growth by blocking Robo activity. 
Cancer Cell, 4, 19-29. 
 
WANG, H., RAJAGOPAL, S., REYNOLDS, S., CEDERBERG, H. & CHAKRABARTY, 
S. 1999. Differentiation-promoting effect of 1-O (2 methoxy) hexadecyl glycerol in 
human colon cancer cells. Journal of Cellular Physiology, 178, 173-178. 
 
WANG, L., YANG, C. Y. & TAN, W. H. 2005. Dual-luminophore-doped silica 
nanoparticles for multiplexed signaling. Nano Letters, 5, 37-43. 
 
WATSON, A., WU, X. Y. & BRUCHEZ, M. 2003. Lighting up cells with quantum dots. 
Biotechniques, 34, 296-+. 
 
WEEKS, J. C., NELSON, H., GELBER, S., SARGENT, D., SCHROEDER, G. & GRP, 
C. S. 2002. Short-term quality-of-life outcomes following laparoscopic-assisted 
colectomy vs open colectomy for colon cancer - A randomized trial. Jama-Journal of 
the American Medical Association, 287, 321-328. 
 
WEISSLEDER, R. & NTZIACHRISTOS, V. 2003. Shedding light onto live molecular 
targets. Nat Med, 9, 123-128. 
 
WEITZ, J., KOCH, M., DEBUS, J., HÖHLER, T., GALLE, P. R. & BÜCHLER, M. W. 
2005. Colorectal cancer. The Lancet, 365, 153-165. 
 
WEST, N. P., MORRIS, E. J. A., ROTIMI, O., CAIRNS, A., FINAN, P. J. & QUIRKE, 
P. 2008. Pathology grading of colon cancer surgical resection and its association with 
survival: a retrospective observational study. Lancet Oncology, 9, 857-865. 
 
WEST, N. P., SUTTON, K. M., INGEHOLM, P., HAGEMANN-MADSEN, R. H., 
HOHENBERGER, W. & QUIRKE, P. 2010. Improving the Quality of Colon Cancer 
Surgery Through a Surgical Education Program. Diseases of the Colon & Rectum, 
53, 1594-1603. 
 
WIESE, D., SIROP, S., YESTREPSKY, B., GHANEM, M., BASSILY, N., NG, P., LIU, 
W. M., QUIACHON, E., AHSAN, A., BADIN, J. & SAHA, S. 2010. Ultrastaging of 
sentinel lymph nodes (SLNs) vs. non-SLNs in colorectal cancer-do we need both? 
American Journal of Surgery, 199, 354-358. 
 
WINDER, T. & LENZ, H.-J. 2010. Vascular Endothelial Growth Factor and Epidermal 
Growth Factor Signaling Pathways as Therapeutic Targets for Colorectal Cancer. 
Gastroenterology, 138, 2163-2176. 
 
WOLF, D. E., SAMARASEKERA, C. & SWEDLOW, J. R. 2007. Quantitative analysis 
of digital microscope images. Methods Cell Biol, 81, 365-96. 
 
WU, H., HUO, Q., VARNUM, S., WANG, J., LIU, G., NIE, Z., LIU, J. & LIN, Y. 2008. 
Dye-doped silica nanoparticle labels/protein microarray for detection of protein 
biomarkers. Analyst, 133, 1550-1555. 
 
WU, J., MA, R., CAO, H., WANG, Z., JING, C., SUN, Y., ZHANG, Y., YANG, Z., 
HOFFMAN, R. M. & TANG, J. 2013. Intraoperative Imaging of Metastatic Lymph 
Nodes Using a Fluorophore-conjugated Antibody in a HER2/neu-expressing 
Orthotopic Breast Cancer Mouse Model. Anticancer Research, 33, 419-424. 
 245 
 
WU, X. Y., LIU, H. J., LIU, J. Q., HALEY, K. N., TREADWAY, J. A., LARSON, J. P., 
GE, N. F., PEALE, F. & BRUCHEZ, M. P. 2003. Immunofluorescent labeling of 
cancer marker Her2 and other cellular targets with semiconductor quantum dots. 
Nature Biotechnology, 21, 41-46. 
 
XIAO, B., LAROUI, H., VIENNOIS, E., AYYADURAI, S., CHARANIA, M. A., ZHANG, 
Y., ZHANG, Z., BAKER, M. T., ZHANG, B., GEWIRTZ, A. T. & MERLIN, D. 2014. 
Nanoparticles with surface antibody against CD98 and carrying CD98 small 
interfering RNA reduce colitis in mice. Gastroenterology, 146, 1289-300 e1-19. 
 
YANG, L., MAO, H., WANG, Y. A., CAO, Z., PENG, X., WANG, X., DUAN, H., NI, C., 
YUAN, Q., ADAMS, G., SMITH, M. Q., WOOD, W. C., GAO, X. & NIE, S. 2009. 
Single Chain Epidermal Growth Factor Receptor Antibody Conjugated Nanoparticles 
for in vivo Tumor Targeting and Imaging. Small, 5, 235-243. 
 
YANG, S.-J., LIN, F.-H., TSAI, K.-C., WEI, M.-F., TSAI, H.-M., WONG, J.-M. & 
SHIEH, M.-J. 2010a. Folic Acid-Conjugated Chitosan Nanoparticles Enhanced 
Protoporphyrin IX Accumulation in Colorectal Cancer Cells. Bioconjugate Chemistry, 
21, 679-689. 
 
YANG, Z., LIU, Z. W., ALLAKER, R. P., REIP, P., OXFORD, J., AHMAD, Z. & REN, 
G. 2010b. A review of nanoparticle functionality and toxicity on the central nervous 
system. Journal of the Royal Society Interface, 7, S411-S422. 
 
YAZAKI, P. J., KASSA, T., CHEUNG, C.-W., CROW, D. M., SHERMAN, M. A., 
BADING, J. R., ANDERSON, A.-L. J., COLCHER, D. & RAUBITSCHEK, A. 2008. 
Biodistribution and tumor imaging of an anti-CEA single-chain antibody–albumin 
fusion protein. Nuclear Medicine and Biology, 35, 151-158. 
 
YOSHITAKE, S., YAMADA, Y., ISHIKAWA, E. & MASSEYEFF, R. 1979. Conjugation 
of glucose oxidase from Aspergillus niger and rabbit antibodies using N-
hydroxysuccinimide ester of N-(4-carboxycyclohexylmethyl)-maleimide. Eur J 
Biochem, 101, 395-9. 
 
ZHANG, L., ZHU, W., YANG, C., GUO, H., YU, A., JI, J., GAO, Y., SUN, M. & ZHAI, 
G. 2012. A novel folate-modified self-microemulsifying drug delivery system of 
curcumin for colon targeting. International Journal of Nanomedicine, 7, 151-162. 
 
ZHAO, X. J., BAGWE, R. P. & TAN, W. H. 2004a. Development of organic-dye-
doped silica nanoparticles in a reverse microemulsion. Advanced Materials, 16, 173-
+. 
 
ZHAO, X. J., HILLIARD, L. R., MECHERY, S. J., WANG, Y. P., BAGWE, R. P., JIN, 
S. G. & TAN, W. H. 2004b. A rapid bioassay for single bacterial cell quantitation 
using bioconjugated nanoparticles. Proceedings of the National Academy of 
Sciences of the United States of America, 101, 15027-15032. 
 
ZOU, P., XU, S., POVOSKI, S. P., WANG, A., JOHNSON, M. A., MARTIN, E. W., 
SUBRAMANIAM, V., XU, R. & SUN, D. 2009. Near-Infrared Fluorescence Labeled 
Anti-TAG-72 Monoclonal Antibodies for Tumor Imaging in Colorectal Cancer 
Xenograft Mice. Molecular Pharmaceutics, 6, 428-440. 
 
ZOUBIR, F., ZEROMSKI, J., SIKORA, J., SZMEJA, J., HEDIN, A. & 
HAMMARSTROM, S. 1990. TUMOR SPECIFICITY OF MONOCLONAL-
 246 
ANTIBODIES TO CARCINOEMBRYONIC ANTIGEN - IMMUNOHISTOCHEMICAL 
ANALYSIS. Tumor Biology, 11, 5-19. 
 
ZWEIG, M. H. & CAMPBELL, G. 1993. RECEIVER-OPERATING 
CHARACTERISTIC (ROC) PLOTS - A FUNDAMENTAL EVALUATION TOOL IN 
CLINICAL MEDICINE. Clinical Chemistry, 39, 561-577. 
 
ZYSK, A. M., NGUYEN, F. T., OLDENBURG, A. L., MARKS, D. L. & BOPPART, S. 
A. 2007. Optical coherence tomography: a review of clinical development from bench 
to bedside. Journal of Biomedical Optics, 12. 
 
 
 
